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Abstract 
Rationale: Elevated asymmetric dimethylarginine (ADMA) levels contribute to the 
pathogenesis of hypoxia-induced pulmonary hypertension. Chronic hypoxia decreases the 
activity of the enzymes metabolising ADMA, dimethylarginine dimethylaminohydrolases 
(DDAH1 and DDAH2) but the mechanisms responsible are not understood.  
 
Objective: To elucidate the physiological significance and the mechanism of hypoxia-
induced downregulation of ADMA metabolism. 
 
Methods and Results: Exposure of human pulmonary artery endothelial cells (HPAECs) to 
hypoxia inhibited both DDAH1 and DDAH2 gene and protein expression, reduced DDAH 
activity and increased ADMA levels. In contrast, in human pulmonary artery smooth muscle 
cells (HPASMCs) only DDAH2 was reduced while ADMA levels remained unchanged. This 
endothelium-specific regulation of DDAH1 and ADMA resulted from NFκB-dependent, 
microRNA-21 (miR-21)-mediated degradation of DDAH1 mRNA. Down regulation of DDAH1 
activity contributed to hypoxia-induced endothelial barrier dysfunction and HPASMC 
proliferation and was prevented by overexpression of DDAH1 and miR-21 blockade. 
Conversely, overexpression of miR-21 mimicked the effects of hypoxia. DDAH1 
overexpressing transgenic mice exposed to 2 weeks hypoxia, showed attenuated pulmonary 
hypertension and vascular remodelling, compared with wildtype controls.  Importantly, 
inhibition of miR21 in vivo prevented the hypoxia-induced reduction in pulmonary DDAH1 
expression and attenuated the development of pulmonary hypertension. Lung tissue 
samples from hypoxic mice and treatment-naïve IPAH patients also showed reduced DDAH1 
expression and increased miR-21 levels, compared with controls. 
 
Conclusion: Down regulation of DDAH1 expression by miR-21 in the pulmonary vascular 
endothelium has a key role in the pathogenesis of hypoxia-induced pulmonary hypertension 
and may be of broader significance in pulmonary hypertension. 
 
9 
  
 
Acknowledgments 
Dedicated to Daniel, the best thing I have ever done. 
 
I would like to express my immense gratitude to my supervisors Beata Wojciak-Stothard, 
James Leiper and Lan Zhao, who have been inspiring, and providing excellent guidance 
throughout these 3 years. I am especially thankful to Beata, who’s patience and support 
have made an important impact on me to accomplish this project, and James for his 
passionate approach, for his ability to stimulate my curiosity and especially for the capability 
to make me work until late just to answer his scientific questions. 
 
I would like to show special gratitude to Prof. Martin Wilkins for providing important 
support and advice throughout this project (and also for the Monday morning football 
chats). Special thanks should go also to other PH group members for the great time both in 
the lab and at the pub during the last 3 years. 
 
As for anything I have achieved in life, I am immensely indebted to my family who have 
always supported me and for their positive influence. 
  
Finally, to Morena my wife, whom I married during the last year of this project. She had a 
real experience of the natural drama of a PhD student with all of its highs and lows… and did 
not run away. Despite many ruined weekends and evenings, she has always provided moral 
support, encouragement, food, laughs and jokes throughout. I would not have done this 
without you. 
 
 
 
 
 
 
 
 
10 
  
 
Abbreviations 
ADMA Asymmetric dimethylarginine 
AGT- II Angiotensin-II  
ANP 
ATP 
Atrial natriuretic peptide 
Adenosine triphosphate  
BH4 Tetrahydrobiopterin 
BMP Bone morphogenetic protein  
BMPR2 Bone morphogenetic protein receptor 2 
bp Base pair 
BrdU Bromodeoxyuridine 
BSA Bovine specific albumin 
BSA Bovine specific albumin 
cAMP Cyclic adenosine monophosphate  
cDNA Complementary deoxyribose nucleic acid 
cGMP Cyclic guanosine monophosphate 
CPE Cytopathic Cytopathic effect 
Ct qPCR fluorescence threshold 
CTEPH Chronic thromboembolic pulmonary hypertension  
D7-ADMA 2,3,3,4,4,5,5-D7-asymmetric dimethylarginine  
DAPI 4',6-diamidino-2-phenylindole 
DDAH Dimethylarginine dimethylaminohydrolase 
DEPC Diethylpyrocarbonate 
DMEM Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleoside triphosphates 
DTT Dithiothreitol 
ECM Extracellular matrix  
EDCF Endothelium-derived constriction factor  
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme linked immunosorbent assay 
eNOS Endothelial NOS/NOSIII 
ET-1 Endothelin-1 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum  
FGF Fibroblast growth factors  
FITC Fluorescein isothiocyanate  
FPH Familial pulmonary hypertension 
FXR Farnesoid X receptor 
GDF Growth and differentiation factors  
GDP Guanosine diphosphate  
GFP Green fluorescent protein 
GTP Guanosine triphosphate 
HEK 293 Human embryonic kidney cells  
11 
  
 
HIF-1 Hypoxia-inducible factor 1  
HPAECs Human pulmonary arterial endothelial cells 
HPASMCs Human pulmonary arterial smooth muscle cells 
HPLC High performance liquid chromatography 
HPLC High performance liquid chromatography 
HPV Hypoxic pulmonary vasoconstriction  
HRP Horseradish peroxidase  
HUVECs Human umbilical vein endothelial cells 
IL- Interleukins  
iNOS Inducible NOS 
IPH 
IP3 
Idiopathic pulmonary hypertension 
Inositol 1,4,5-trisphosphate 
IV Intravenous 
LC-MS Liquid chromatography-mass spectrometry  
LNA Locked nucleic acid 
L-NMMA N(G)-monomethyl-L-arginine 
MCT Monocrotaline 
miR/miRNA MicroRNA 
MLC Myosin light chain  
MRE MicroRNA Recognition Element 
mRNA Messenger RNA 
NF-kb Nuclear factor kB 
NK Natural killer 
nm Nanometers 
nNOS Neuronal NOS 
NO Nitric oxide 
NOS Nitric oxide synthase 
OD Optical density  
PAGE Polyacrylamide gel electrophoresis 
PAH Pulmonary arterial hypertension 
PAP Pulmonary arterial pressure  
PBS Phosphate buffered saline 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction  
PDE-5 Phosphodiesterase-5  
PDEGF Platelet-derived endothelial cell growth factor  
pGC Particulate guanylyl cyclase  
PH Pulmonary hypertension 
PI Propidium Iodide 
PKA Protein kinase A  
PKG Protein kinase G  
PRMT Protein methyl transferase 
PVDF Polyvinylidene difluoride  
12 
  
 
PVR Pulmonary vascular remodelling   
qPCR Quantitative PCR 
Rho Ras homologous 
RNA Ribonucleic acid  
ROCK Rho Kinase  
ROS Reactive oxygen species  
RT-PCR Reverse transcription-PCR 
RV Right ventricle 
RVH Right ventricular hypertrophy 
RVSP Right ventricular systolic pressure  
SAH 
SAM 
SDS 
S-adenosylhomocysteine 
S-adenosylmethionine 
Sodium dodecyl sulphate 
SERC 
Ser188 
SR Ca2+-ATPase 
Serine 188 
sGC Soluble guanylyl cyclase  
t1/2 Half-life 
TBP Tata binding protein 
TGF-β Transforming growth factor β 
TNF-α Tumor necrosis factor alpha 
T-reg  Regulatory T cell 
UTR Untranslated region 
VASP Vasodilator-stimulated phosphor-protein  
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
α-SMC Alpha-smooth muscle actin 
 
 
 
 
 
 
 
 
 
13 
  
 
Figures  
FIGURE 1: DIAGRAMS OF POSSIBLE MECHANISMS THAT EXPLAIN HOW HYPOXIA CAUSES 
CONSTRICTION IN PULMONARY ARTERIAL SMOOTH MUSCLE. ................................................................................... 22 
FIGURE 2:  HISTOLOGICAL FEATURE OF SEVERE PAH ...................................................................................................... 23 
FIGURE 3: PATHWAYS INVOLVED IN PULMONARY ARTERY ENDOTHELIAL CELL DYSFUNCTION ............ 25 
FIGURE 4: PROPOSED MODEL OF THE EFFECT OF CGMP ON ENDOTHELIAL CELL PERMEABILITY. ......... 27 
FIGURE 5: NITRIC OXIDE PATHWAY AND CYCLIC GUANOSINE MONOPHOSPHATE PATHWAYS.. ............... 34 
FIGURE 6: INCREASE CGMP PRODUCTION. ............................................................................................................................. 35 
FIGURE 7: SYNTHESIS AND DEGRADATION OF ADMA. ..................................................................................................... 39 
FIGURE 8: PATHWAYS AFFECTING RHOA ACTIVITY IN PULMONARY VASCULATURE...................................... 43 
FIGURE 9: SIMPLIFIED CANONICAL AND NONCANONICAL BMP PATHWAYS ....................................................... 45 
FIGURE 10: THE MIRNA PROCESSING PATHWAY ................................................................................................................ 51 
FIGURE 11: THE EFFECT OF HYPOXIA ON DDAH1 AND DDAH2 MRNA EXPRESSION ........................................ 80 
FIGURE 12: THE EFFECTS OF HYPOXIA ON DDAH1 AND DDAH2 PROTEIN EXPRESSION................................ 81 
FIGURE 13: METHYLARGININE LEVELS IN HPAECS AND HPASMCS........................................................................... 83 
FIGURE 14: HYPOXIA-INDUCED CHANGES IN DDAH ACTIVITY .................................................................................... 84 
FIGURE 15: ADMA LEVELS IN CULTURE MEDIA ................................................................................................................... 86 
FIGURE 16: HYPOXIA PLAYS A KEY ROLE IN THE REGULATION OF DDAH MRNA STABILITY. ...................... 88 
FIGURE 17: LUCIFERASE REPORTER ASSAY SYSTEM WITH 3′UTR OF DDAH1 MRNA. ..................................... 94 
FIGURE 18: THE DDAH1 3′-UTR IS REGULATED BY HYPOXIA. ...................................................................................... 96 
FIGURE 19: PREDICTED MICRORNA TARGET SITES ON THE 400 NT FRAGMENT OF 3′UTR OF DDAH1 
MRNA. ........................................................................................................................................................................................................ 97 
FIGURE 20: THE EFFECT OF MIR-21 AND MIR-128 OVEREXPRESSION ON DDAH1 AND DDAH2 MRNA 
LEVELS. ..................................................................................................................................................................................................... 99 
FIGURE 21: THE ROLE OF MIR21 AND MIR128 IN THE REGULATION OF DDAH1 EXPRESSION IN HPAECS.
 .................................................................................................................................................................................................................... 100 
FIGURE 22: THE EFFECTS OF HYPOXIA ON HPAECS AND HPASMCS CELL DEATH. .......................................... 105 
FIGURE 23: THE EFFECTS OF HYPOXIA AND DDAH ON CELL PROLIFERATION. ................................................ 107 
FIGURE 24: DDAH1 ENDOTHELIUM-DEPENDENT MODULATION OF HPASMC PROLIFERATION .............. 108 
FIGURE 25: DDAH1 PREVENTS HYPOXIA-INDUCED DISPERSION OF INTER-CELLULAR ADHERENS 
JUNCTIONS IN HPAECS. ................................................................................................................................................................... 110 
FIGURE 26: THE EFFECTS OF HYPOXIA AND DDAH ON ENDOTHELIAL BARRIER FUNCTION. .................... 112 
FIGURE 27: DDAH1 ACTIVITY REGULATES ANGIOGENESIS IN HPAECS. ................................................................ 114 
FIGURE 28: NF-ΚB INHIBITION PREVENTS HYPOXIA-INDUCED CHANGES IN MIR-21.................................... 116 
FIGURE 29: INCREASED EXPRESSION OF DDAH1 ATTENUATES DEVELOPMENT OF CHRONIC HYPOXIA-
INDUCED PULMONARY HYPERTENSION ............................................................................................................................... 122 
FIGURE 30: EXPRESSION OF DDAH1, DDAH2, RHOA, PSER188RHOA IN TRANSGENIC MICE.. .................... 124 
FIGURE 31: TREATMENT OF HYPOXIA-INDUCED PULMONARY HYPERTENSION WITH LNA21 ................ 125 
14 
  
 
FIGURE 32: LNA21 TREATMENT INCREASED EXPRESSION OF DDAH1 AND ATTENUATES 
DEVELOPMENT OF CHRONIC HYPOXIA-INDUCED PH IN MICE. .................................................................................. 127 
FIGURE 33: ADMA, MIR-21 AND DDAH1 LEVELS IN NORMOXIC OR HYPOXIC MICE ........................................ 128 
FIGURE 34: DDAH1, DDAH2 AND MIR-21 LEVELS IN IPAH PATIENTS. ................................................................... 129 
 
Tables 
TABLE 1: UPDATE CLINICAL CLASSIFICATION OF PULMONARY HYPERTENSION (DANA POINT, 2008) ................ 18 
TABLE 2: PRIMARY AND SECONDARY ANTIBODIES USED IN WESTERN BLOTTING.. ............................................ 58 
TABLE 3: PATIENT CHARACTERISTICS ................................................................................................................... 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
  
 
1. Introduction 
1.1 Pulmonary Circulation 
The main function of the pulmonary circulation is to deliver oxygen to the blood and free it 
of carbon dioxide.  Cardiovascular function is essential to the survival of higher organisms 
since every cell requires nutrition and gas exchange. The circuit starts with the pulmonary 
artery, which extends from the right ventricle and carries blood with low oxygen content to 
the lungs,  where it branches into two arteries, one for each lung, and then into arterioles 
and capillaries. The primary site of gas exchange is the vascular/alveolar interface in the 
pulmonary capillaries, located deep within the lung. Once blood is oxygenated in the lung, it 
is pumped by the heart throughout the body, where exchange of gas within the tissue 
occurs via capillary beds.  Then, carbon dioxide-rich blood is returned to the lungs via the 
vena cava for the respiratory/circulatory cycle to begin again. The walls of pulmonary 
arteries and veins are significantly thinner than the walls of corresponding vessels in the rest 
of the body. Therefore, the pressure in this part of the system is only one sixth of that in the 
systemic circulation. In the pulmonary circulation, the roles of arteries and veins are the 
contrary of what they are in the systemic circulation.  The blood in the arteries is less 
oxygenated; meanwhile blood in the veins is oxygen-rich. Carbon dioxide is removed from 
the blood in the pulmonary arteries across capillary walls and leaves the body through the 
mouth and nose (Young 1940). 
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1.1.1. Anatomy and Function of Pulmonary Vasculature 
Anatomically the post-capillary blood vessels are composed of three layers – the tunica 
intima, the tunica media and the tunica adventitia. The tunica intima forms the innermost 
layer and contains a monolayer of endothelial cells (ECs).  The tunica media forms the 
middle layer of the vessel and comprises smooth muscle cells (SMCs) organized in a 
circumferentially-arranged manner. The tunica adventitia comprises primarily fibroblasts 
and connective tissue, which have the role of providing a structural support and holding the 
vessel in position. These layers are separated by the internal and external elastic laminae, 
while the internal lamina consists in a fenestrated layer of elastic tissue that is the 
outermost part of the intima of an artery, the external lamina beneath the smooth muscle 
delimits the tunica media from the tunica adventitia(Hatabu, Gefter et al. 1991).  
The pulmonary circulation has a large surface area (~120m2) with the essential function of 
gas exchange and important roles in host defence and maintenance of blood homeostasis. 
The pulmonary vascular bed is unique as it receives all cardiac output, maintains a low blood 
pressure, and is exposed to high mechanical stress and the highest oxygen tension of all 
vascular beds. The airways branch to form bronchi, bronchioli, terminal bronchioli and 
respiratory bronchioli leading to the alveolar ducts, which incorporate the majority of the 
vast surface area of the lung. The pulmonary vessels also branch to form smaller and less 
muscularised arteries leading to the capillary bed, where the lung gas exchange occurs (Stan 
2009). Consistent with vessel formation in other tissues, angiogenesis and vasculogenesis 
are considered to work together to form the pulmonary vascular system. Growth factors 
such as the platelet-derived endothelial cell growth factor (PDEGF), vascular endothelial 
growth factor (VEGF) and fibroblast growth factors (FGF) stimulate the growth of the new 
endothelium in a bed of extracellular matrix (ECM) (Stenmark and Mecham 1997). In 
addition, the various components of ECM, including collagen, elastin, fibronectin, and 
proteoglycans are involved in a number of functions, such as tensile strength, tissue 
architecture, elasticity, proliferation and cell migration. Larger vessels are supported by the 
development of a smooth muscle layer whereas more distal vessels remain completely non-
muscularised (Hislop and Pierce 2000) and while layers of elastin provide vessels with 
elasticity, the collagen complex provides rigidity.    
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1.1.2. Hypoxia and the pulmonary circulation 
The cellular responses to oxygen are essential for physiological mediator release, cellular 
metabolism, proliferation and survival.  The lung has three sources of oxygen: inspired gas, 
bronchial circulation and venous blood returning to the lung via the right ventricle. 
Generally, hypoxia is defined as a condition in which the body is deprived of adequate 
oxygen supply. In the lung, hypoxia is a pathologic condition caused by a deficiency of 
oxygen in the atmosphere, where the blood oxygen saturation becomes less than 90% 
(based on the oxyhemoglobin desaturation curve).  
Acute hypoxia is defined as a rapid (minutes-hours) decrease in tissue oxygen, while chronic 
hypoxia is usually a slow (hours-days) reduction in tissue oxygenation. In the lung, the 
endothelium of large pulmonary arteries is exposed to mixed alveolar and venous oxygen. 
Thus, it is normal to find heterogeneity in the response of the endothelium to hypoxia, 
depending on the type of blood vessel.  In general, acute hypoxia causes acute hypoxic 
pulmonary vasoconstriction crucially required to assure optimized adaptation of the 
perfusion to ventilation, while chronic hypoxia causes sustained pulmonary vasoconstriction 
and pulmonary vascular remodelling, leading to development of pulmonary hypertension 
(Ghofrani, Voswinckel et al. 2006). Several lines in the literature implicate hypoxia as a 
stimulus for altered pulmonary vascular functions; each of the resident vascular cell types 
can face alterations in proliferation, expression of growth factors, matrix protein 
production, cytokines and receptors, and each resident cell type plays a specific role in the 
remodelling response (Stenmark, Fagan et al. 2006).  
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1.2. Pulmonary Hypertension (PH) 
In healthy adults, mean pulmonary arterial pressure (mPAP) is approximately 15 mmHg at 
rest, while in pulmonary hypertension (PH) there is an elevation of the resting mean 
pulmonary artery pressure (PAP) above 25mmHg. Increased pulmonary vascular resistance 
(PVR) that requires the right ventricle to raise PAP to maintain cardiac output causes the 
failure of the afterload-intolerant right ventricle, ultimately leading to death (Simonneau, 
Robbins et al. 2009). PH is a multifactorial, progressive disease, with a significant mortality 
and morbidity rate. It is characterised by increased pulmonary vasoconstriction and 
structural remodelling of the pulmonary vasculature, which vary in degree of importance in 
individual patients. Thrombotic lesions and inflammation are frequently involved in the 
pathology of PH (Tuder and Voelkel 1998) 
The structural remodelling seen in the pulmonary vessels in PH comprise medial thickening 
due to smooth muscle cell hyperplasia and hypertrophy (Hislop and Reid 1976), formation 
of a neointima composed of smooth muscle cells and the occurrence of plexiform and other 
obstructive lesions due to endothelial and smooth muscle cell proliferation (Yi, Kim et al. 
2000). Increased recruitment, proliferation and differentiation of pericytes and fibroblasts 
has also been implicated in muscularization of distal pulmonary arteries (Chan, Currie et al. 
1987) 
The vasoconstriction of the pulmonary arteries in PH has been attributed to reduced 
expression/activity of voltage-gated potassium channels on vascular smooth muscle cells 
and endothelial dysfunction characterised by reduced production of  vasodilators such as 
nitric oxide (NO) and prostacyclin and increased production of vasoconstrictors such as 
endothelin-1 (ET-1) and serotonin (5-HT) (Humbert, Morrell et al. 2004).  
 
1.2.1. Classification of PH 
The PH classification has gone through a series of changes since the 1st classification 
proposed in 1973 that identified only two categories, primary and secondary PH, depending 
on the presence or absence of risk factors (Hatano and Strasser 1975). During the 2nd world 
symposium on PH in France (Evian, 1998), a new classification was suggested to create 
categories of PH that shared similar pathogenesis, clinical futures and therapeutic options. 
The 3rd PH conference in Italy (Venice, 2003) proposed only minor changes, with the 
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exception of the introduction of the idiopathic (IPH), familial (FPH) and associate PH. In 2008 
the 4th world symposium on PH held in California (Dana Point), suggested a new 
classification in order to accurately reflect the literature over the past 5 years and clarify 
some areas that were ambiguous (Simonneau, Robbins et al. 2009). The current Dana Point 
classification is presented in Table 1.  
 
 
 
 
The pathogenesis of group 1, pulmonary arterial hypertension (PAH), includes a variety of 
diseases that share numerous pathophysiological and prognostic features. Although rare, 
idiopathic PAH (IPAH; group 1.1) is a disease in which there is not a family history or 
recognised risk factor for PAH. In heritable PAH (group 1.2; known as familial PAH), loss-of-
function mutations in the transforming growth factor β/bone morphogenetic protein (TGF-
β/BMP) receptor superfamily have been identified as a principal mechanism. Drug-induced 
and toxin-induced forms of PAH are included in group 1.3, while group 1.4 contains PAH 
associated with identified diseases, for example, HIV infections. Persistent pulmonary 
GROUP TYPE  
1 Pulmonary arterial hypertension (PAH) 
 
1.1 Idiopathic pulmonary arterial hypertension 
1.2 Heritable pulmonary arterial hypertension ( known as familial pulmonary arterial hypertension) 
1.3 Drug-induced and toxin-induced forms of pulmonary arterial hypertension 
1.4 Pulmonary arterial hypertension associated with identified diseases (HIV, schistosomiasis 
infections) 
1.5 Persistent pulmonary hypertension of the newborn 
2 Pulmonary hypertension resulting from left heart disease 
3 All forms of pulmonary hypertension associated with alveolar hypoxia and/or disorders of the 
respiratory system 
4 All thrombo-embolic diseases leading to pulmonary hypertension 
5 Pulmonary hypertension with unclear multifactorial mechanisms (diseases affecting directly the 
pulmonary vessels) 
Table 1: Update clinical classification of pulmonary hypertension (Dana Point, 2008) 
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hypertension of the newborn is incorporated in group 1.5, while patients with pulmonary 
veno-occlusive disease and/or pulmonary capillary hemangiomatosis are classified as being 
in group 1.3. PH resulting from left heart disease probably represents the most frequent 
cause of PH (Simonneau, Robbins et al. 2009). Left-sided ventricular diseases might produce 
an increase in the left atrial pressure, with passive retrograde transmission of the pressure 
leading to increase in pulmonary arterial pressure (PAP). The Group 3 includes all forms of 
PH associated with hypoxia condition or respiratory disorders. Predominantly, the cause of 
group 3 PH is alveolar hypoxia secondary to lung disease, impaired control of breathing, or 
residence at high altitude. The group 4 includes PH caused by obstruction of pulmonary 
arterial vessels due to thromboembolism or tumours. Chronic thromboembolic pulmonary 
hypertension (CTEPH) represents a common cause of PH. The group 5 consists of several 
forms of PH in which the multifactorial mechanisms are unclear (Simonneau, Robbins et al. 
2009).   
Overall, PH affects less than 5/100,000 people in Europe and has a prevalence of 15-50 
patients/million of the population. The prognosis of PH remains poor with high mortality 
rate. The estimated median survival for untreated PH patients is around 2.8 years (National 
Audit for Pulmonary Hypertension, 2013). Despite the advances in understanding and 
improved treatment options for PH in recent years, a recent multi-centre report showed 1 
and 3 year survival rates of approximately 83% and 58% respectively in PH populations 
(Humbert, Sitbon et al. 2010). However, for end-stage PH patients who failed to respond to 
the current therapeutics and interventions, there is no choice but to consider 
cardiopulmonary transplantation as the final option (Keogh, Mayer et al. 2009). 
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1.2.2. Responses of Pulmonary Circulation to Hypoxia  
In most tissues of the human body, the response to hypoxia is vasodilation. By widening the 
blood vessels, the tissue allows a greater perfusion. By contrast, in the lungs, the response 
to alveolar hypoxia is vasoconstriction, diverting pulmonary blood flow from areas of low 
oxygen to areas of high oxygen availability (Motley, Cournand et al. 1947). This response 
consists of 2 phases. The phase 1 of hypoxic pulmonary vasoconstriction (HPV) is transient 
(seconds), endothelium-independent and it is triggered by inhibition of voltage-dependent 
potassium channels in pulmonary artery SMCs (PASMCs) that leads to membrane 
depolarization and opening of voltage-dependent calcium channels (Aaronson, Robertson et 
al. 2006). The increase in intracellular calcium concentration initiates the contraction by 
stimulating phosphorylation of the myosin light chain.  
Phase 2 of HPV is endothelium-dependent and may last from hours to days, depending on 
the duration of hypoxia. The phase 2 of HPV is sustained by the activation of Rho-kinase in 
PASMC, which inhibits the de-phosphorylation of the myosin light chain by myosin light 
chain phosphatase, thereby allowing the contraction to proceed even when the calcium 
(Ca2+) concentration remains constant, in a process known as calcium sensitization of 
arterial smooth muscle contraction (Hilgers and Webb 2005).  During phase 2, the 
endothelium modulates HPV by releasing vasorelaxants such as nitric oxide (NO) or 
prostacyclin, or vasoconstrictors such as endothelin-1 (ET-1) or angiotensin-II (AGT- II). 
Increased release of endothelium-derived constriction factor (EDCF) from hypoxic lung, 
different from ET-1 has also been postulated (Robertson, Ward et al. 2001).  
Although the exact mechanism by which hypoxia is sensed and translated into 
vasoconstriction in the pulmonary circulation is not well understood, the involvement of 
reactive oxygen species (ROS) has been suggested (figure 1).  
Briefly, hypoxia can inhibit mitochondrial oxidative phosphorylation and increase ROS 
formation, which in turn, leads to increased intracellular Ca2+ levels and Rho kinase-
mediated Ca2+ sensitization followed by vasoconstriction (Sylvester, Shimoda et al. 2012) 
(figure 1). 
The pulmonary vascular response depends on the duration of the stimulus. Indeed, acute 
(intermittent) hypoxia was shown to increase oxidative stress, inflammation and expression 
of genes involved in ion transport and homeostasis (Giordano 2005; Rojas, Figueroa et al. 
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2006; Elahi, Kong et al. 2009). Chronic (or sustained) hypoxia was shown to increase 
proliferation of medial vascular smooth muscle cells and excessive deposition of ECM 
components by adventitial fibroblasts (Meyrick and Reid 1983). Furthermore, chronic 
hypoxia induces pulmonary hypertension in humans and animals (Zhao, Mason et al. 2001).  
 
 
Figure 1: Proposed signalling pathways contributing to hypoxia-induced pulmonary vasoconstriction. Main 
and alternative pathways are indicated by black and gray arrows, respectively. SOCC, store-operated Ca2+, 
NSCC nonselective cation channels; cADPR, cyclic ADP ribose; AMPK, AMP kinase; SR, sarcoplasmic 
reticulum. Adapted from (Sylvester, Shimoda et al. 2012). 
 
 
1.3. Cellular mechanisms leading to Pulmonary Vascular Remodelling in 
PH 
In physiological conditions, the thickness of the vascular wall is maintained at an optimal 
level by a balance between proliferation and apoptosis of the resident cell types. If this 
balance is disturbed in favour of proliferation, the vascular wall thickens, leading to the 
increased vascular resistance (Pak, Aldashev et al. 2007). This structural change is termed 
vascular remodelling (Kato and Staub 1966) .  
Pulmonary vascular remodelling affects all three layers of the arterial wall and involves 
increased proliferation and migration of ECs, SMCs, fibroblasts, inflammatory cells, platelet 
aggregation and increased deposition of ECM components such as collagen, elastin and 
fibronectin (Savale, Tu et al. 2009; Tuder, Abman et al. 2009) In severe human PAH, 
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increased proliferation of endothelial and smooth muscle cells leads to the formation of 
plexiform lesions. The endothelial cells within these lesions show disorganised angiogenesis 
accompanied by increased expression of pro-angiogenic mediators such as α and β subunits 
of hypoxia-inducible factor 1 (HIF-1), vascular endothelial growth factor (VEGF) and VEGF 
receptors (VEGFR)(Hirose, Hosoda et al. 2000; Tuder, Chacon et al. 2001).  
 
 
Figure 2: The most prominent histological feature of severe PAH is thickening of the three cellular layers of 
pulmonary arteries, due to increased cell proliferation and cell enlargement (hypertrophy). Other changes 
include development of plexiform lesions and in situ thrombosis. Adapted from (Galie, Hoeper et al. 2009)  
 
 
1.3.1. Endothelial Dysfunction in Pulmonary Hypertension 
It is widely considered that pulmonary endothelial damage is an early event in PH and a 
critical step that induces adverse structural changes in the vascular wall. The dysfunctional 
endothelium produces higher levels of vasoconstrictors, such as endothelin-1 and 
thromboxane and lower levels of vasorelaxants such as NO and prostacyclin (Budhiraja, 
Tuder et al. 2004). In addition to the imbalance in the production of vasodilators and 
vasoconstrictors, damage to the endothelium compromises endothelial barrier function and 
allows proliferative mediators to permeate into the underlying vascular tissues, resulting in 
enhanced proliferation and migration of vascular SMCs and fibroblasts (Budhiraja, Tuder et 
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al. 2004). Endothelial damage may be induced by hypoxia, inflammation, genetic 
susceptibility or response to drugs.  
 
1.3.1.1. Imbalanced Production of Vasoconstrictors and Vasorelaxants 
In a normal physiological state, the pulmonary endothelium helps maintain lung 
homeostasis by controlling vascular tone, barrier function, leukocyte trafficking, platelet 
aggregation and production of cytokines and growth factors. In PH, the pulmonary 
endothelium produces low levels of vasorelaxants, such as NO or prostacyclin and high 
levels of vasoconstrictors, such as endothelin-1 (ET-1), serotonin, or thromboxane 
(Budhiraja, Tuder et al. 2004). An imbalance between the levels of vasorelaxants and 
vasoconstrictors leads to an increase in the vascular tone and increased proliferation of 
vascular smooth muscle cells and fibroblasts.  As showed in figure 3, nitric oxide (NO) 
produced by endothelial nitric oxide synthase (eNOS) protects against hypoxia-induced 
vasoconstriction (Perrella, Edell et al. 1992), inhibits smooth muscle proliferation (Tsihlis, 
Oustwani et al. 2011), leukocyte adhesion and platelet aggregation (Nong, Hoylaerts et al. 
1997; Wang, Zhu et al. 1998).  Another potent vasodilator, prostacyclin, synthesized from 
cyclooxygenase by the enzyme prostacyclin synthase in the vascular endothelium, reduces 
vascular tone by increasing the levels of cAMP and reducing endothelin-1 levels (Langleben, 
Barst et al. 1999). Apart from acting as a vasodilator, prostacyclin also inhibits platelet 
aggregation and smooth muscle cell proliferation (Moncada, Higgs et al. 1977; Newby, 
Southgate et al. 1992). Endothelin-1 is a potent endothelium-derived vasoconstrictor 
implicated in pulmonary vascular remodelling in PH (Stenmark, Fagan et al. 2006). 
Another potent vasoconstrictor, thromboxane, has been found elevated in patient with PH 
(Christman, Mcpherson et al. 1992). However, the inhibition of thromboxane showed 
moderate effects on pulmonary haemodynamics in patients with PH (Langleben, Christman 
et al. 2002).  
More information regarding the role of NO, endothelin-1, serotonin and other 
vasoconstrictors and vasorelaxants is provided in chapters 1.4 and 1.5. 
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Figure 3: Pathways involved in pulmonary artery endothelial cell dysfunction. NO: nitric oxide; cAMP: cyclic 
3', 5'-adenosine monophosphate; cGMP: cyclic 3', 5'-guanosine monophosphate; PDE5: phosphodiesterase 
type 5; ET: endothelin; ETA: endothelin A receptor; ETB: endothelin B receptor. From (Humbert, Morrell et 
al. 2004) with modifications. 
 
 
1.3.1.2.  Lung Endothelial Permeability 
The endothelium regulates the exchange of fluids, nutrients, growth factors and cells 
between the blood and the underlying tissues.  Endothelial barrier function depends on the 
formation of endothelial cell-cell contacts (adherens and tight junctions) and cell-matrix 
adhesions. Under basal conditions, the lung vascular permeability is regulated by two 
different pathways: the transcellular pathway and the paracellular pathway. The 
transcellular pathway mediates the transport of plasma macromolecules (such as albumin) 
by caveolae via the receptor-mediated or fluid-phase mechanism (Mehta and Malik 2006). 
The paracellular pathway, regulates the passage of small molecules (such as urea and 
glucose) through the gaps formed between the cells formed as a result of a direct 
interaction of adherens/tight junctions and focal adhesions with the actin cytoskeleton 
(Mehta and Malik 2006).  The lung endothelial permeability can be increased by 
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inflammatory mediators, cytokines, oxidants or mechanical stress (McQuaid and Keenan 
1997; van Wetering, van Buul et al. 2002). It has been shown that hypoxia-induced increase 
in endothelial permeability is accompanied by Rho GTPases-mediated actin polymerization 
and the formation of stress fibers (Wojciak-Stothard, Tsang et al. 2005). Increased levels of 
intracellular Ca2+ ions are also known to contribute to the formation of stress fibres and 
increased endothelial paracellular permeability (ref) 
Furthermore, natriuretic peptides have been associated with endothelial permeability and 
PH. Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are respectively 
synthesized and released from cardiac atrial and ventricular tissue, in response to stretch, 
falls in blood volume and blood pressure. A third member of the family, C-type natriuretic 
peptide, is released from the vascular endothelium and can regulate local blood flow in a 
paracrine fashion (Scotland, Foster et al. 2004). Each natriuretic peptide acts on specific 
receptors in the vasculature, which can trigger guanylate cyclase activities. ANP can increase 
endothelial cell permeability in vitro (Scotland, Ahluwalia et al. 2005). Hovewer, ANP can 
also attenuate endothelial barrier dysfunction caused by inflammatory agents such as 
thrombin or histamine (Kuhn 2012).  
Nitric oxide and natriuretic peptides increase cGMP levels in endothelial cells. However, 
while Nitric oxide acts via the activation of soluble guanylate cyclase, natriuretic peptides 
activate particulate guanylate cyclase. Both NO and natriuretic peptides have barrier-
protective effects. Recent data suggest a role of cGMP in the regulation of endothelial cell 
permeability (figure 4). It has been shown that cGMP at lower concentrations can inhibit 
phosphodiesterase 3 (PDE3) and thereby increase a local pool of cAMP, while at higher 
concentrations cGMP can activate PDE2, reversing the effect. Furthermore, the PDE3 
inhibitors mimic the effect of low-dose ANP on permeability, while inhibitors of PDE2 
prevent the increase in endothelial permeability induced by higher doses of ANP (figure 4). 
Although the regulation of endothelial barrier function in the lung is not completely 
understood, it seems clear that a loss of endothelial barrier integrity would allow 
proliferative mediators to come in direct contact with smooth muscle cells and fibroblasts, 
leading to increased cell proliferation in the medial and adventitial vascular layers, a key 
feature in the pathophysiology of pulmonary hypertension (Dejana, Tournier-Lasserve et al. 
2009). 
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Figure 4: Proposed model of the 
effect of cGMP on endothelial cell 
permeability. cGMP generated by 
NO or ANP stimulation can affect 
endothelial permeability in two 
ways. cGMP can inhibit PDE3, 
leading to increased cAMP in the 
endothelial cell and decreased 
permeability. cGMP can also 
activate PDE2, leading to 
decreased cAMP and increased 
permeability. The concentration 
of cGMP within the cell plays a 
central role in whether PDE3 is 
inhibited (low cGMP) or PDE2 is 
activated (high cGMP). Adapted 
from (Mohamed, Oceandy et al. 
2009). 
 
 
 
 
 
1.3.1.3. Endothelial Cell Proliferation and Angiogenesis 
Severe pulmonary arterial hypertension is characterised by increased proliferation of 
endothelial cells in the medium-sized pre-capillary arteries, leading to the formation of 
obliterative plexiform lesions (Tuder, Groves et al. 1994; Lee, Shroyer et al. 1998).  Due to 
the increased levels of pro-angiogenic vascular endothelial growth factor (VEGF) and its 
receptor, VEGF receptor 2 (VEGFR-2), it has been postulated that plexiform lesions are 
formed as a result of dysregulated angiogenesis. Interestingly, plexiform lesions are absent 
in rodent models of mild and moderate pulmonary hypertension (Meyrick and Reid 1980).  
Only animal models using chronic hypoxia combined with VEGFR blocker, SU5416, have 
produced lesions that structurally resemble plexiform lesions seen in human PAH (Abe, Toba 
et al. 2010). However, these lesions develop early after treatment with SU5416 combined 
with hypoxia, a situation that does not fully reflect the human condition, in which a much 
longer period is needed (Jonigk, Golpon et al. 2011).  
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Although the mechanism of the abnormal endothelial proliferation is not well understood, 
reduced levels of vasodilatory and antiproliferative mediators such as nitric oxide (Giaid and 
Saleh 1995) and increased levels of pro-proliferative and vasoconstrictive mediators such as 
endothelin-1 (Giaid, Yanagisawa et al. 1993), may play a role.  
Furthermore, mutations in growth- suppressive genes, such as transforming growth factor-
beta (TGF-β), have been reported in plexiform lesions of patients with PH.  Indeed, in almost 
30% of plexiform lesions stop codon mutations have been shown in the transforming 
growth factor-beta type-2 receptor (TGF-βR2) gene (Taraseviciene-Stewart, Kasahara et al. 
2001).  
 
1.3.1.4. Endothelial Apoptosis 
Apoptosis is a form of cell death characterized by cell contraction, membrane blebbing, and 
chromatin condensation (Kerr, Wyllie et al. 1972). When completed, apoptotic cell debris is 
removed by phagocytic cells present in the immediate area (Granville, Carthy et al. 1998). 
Dysregulation of apoptosis is associated with a number of diseases, including pulmonary 
hypertension, cancer, ischaemia-reperfusion lung injury, heart failure, and sepsis.  
Endothelial apoptosis resulting from endothelial injury is thought to play a major role in the 
pathogenesis of PH (Sakao, Tatsumi et al. 2009). Lungs from animals with monocrotaline 
and chronic hypoxia-induced  pulmonary hypertension show reduced levels of VEGF (Arcot, 
Lipke et al. 1993). VEGF is not only a potent pro-angiogenic factor, but also acts as a potent 
inhibitor of apoptosis (Alavi, Hood et al. 2003). In vitro studies have shown that VEGFR 
blockade induces endothelial apoptosis followed by selection of proliferating, apoptosis- 
resistant endothelial cells (Sakao, Taraseviciene-Stewart et al. 2005). The absence of 
apoptotic endothelial cells in mature plexiform lesions (Yeager, Halley et al. 2001) may 
suggest that apoptosis is an early event in the lesion formation, followed by a clonal 
selection of apoptosis-resistant, highly proliferative endothelial cells (Jurasz, Courtman et al. 
2010).  The development and significance of these lesions in the pathogenesis of PAH have 
been debated and are not yet fully understood (Jonigk, Golpon et al. 2011).  
Additionally, the link between cell apoptosis and pulmonary hypertension has been 
strengthened by the finding that overexpression of VEGF and angiopoietin-1 reduces 
endothelial cell apoptosis and prevents the development of monocrotaline-induced PH 
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(Campbell, Zhao et al. 2001; Zhao, Campbell et al. 2003). Moreover, it has been shown that 
lungs from patients with pulmonary hypertension show increased levels of anti-apoptotic 
protein Bcl-2 (Levy, Maurey et al. 2007).  
 
1.3.2. Role of Inflammation  
Accumulating data show the involvement of inflammation in the regulation of vascular 
remodelling in PH (Rabinovitch, Guignabert et al. 2014). Pulmonary vascular lesions in 
human PH as well as in animal models of PH are characterized by perivascular inflammatory 
infiltrates comprising T- and B-lymphocytes, macrophages, dendritic cells, and mast cells 
(Cool, Kennedy et al. 1997; Pinto, Higuchi et al. 2004; Hall, Brogan et al. 2009).  
Inflammatory cell numbers correlate with the thickness of pulmonary arterial wall and mean 
pulmonary arterial pressure, suggesting an important role of perivascular inflammation in 
pulmonary vascular remodelling (Stacher, Graham et al. 2012). The fact that inflammation 
precedes vascular remodeling in experimental PH suggests that altered immunity is a cause 
rather than a consequence of vascular disease (Tamosiuniene, Tian et al. 2011). 
Cytokines and chemokines, which act as chemoattractants for circulating inflammatory cells, 
have been implicated in the pathophysiology of pulmonary hypertension. Abnormally 
elevated levels of tumour necrosis factor (TNF)-α, chemokine RANTES and interleukins (IL-
1β, IL-2, IL-6, IL-8, IL-10 and IL-12) have been observed in PH (Humbert, Monti et al. 1995; 
Dorfmuller, Zarka et al. 2002; Soon, Holmes et al. 2010) with some cytokines showing an 
inverse correlation with patient survival (Soon, Holmes et al. 2010). IL-1β and TNF-α, have 
been shown to increase expression of extracellular matrix proteins such as fibronectin in the 
remodelled vessels, while IL-6 has been shown to increase proliferation of smooth muscle 
cells (Humbert, Morrell et al. 2004; Rabinovitch 2008). In fact, overexpression of IL-6 
combined with hypoxia, was shown to trigger the development of PH in mice, whereas mice 
deficient of IL-6, showed ameliorated phenotype (Miyata, Sakuma et al. 1995)  
The accumulation of perivascular macrophages in the lung was shown to be essential for the 
development of hypoxia-induced pulmonary hypertension, suggesting an important role of 
macrophage infiltrates in human IPAH lung (Vergadi, Chang et al. 2011). In addition, it has 
been postulated that compromised function of T-reg (regulatory T cell) population and 
30 
  
 
natural killer (NK) cells may predispose individuals to PAH, as it does in animal models of PH 
(Humbert, Morrell et al. 2004; Rabinovitch 2008).  
 
1.3.3. Smooth Muscle Cells 
In pulmonary hypertension, an entire pulmonary vascular tree undergoes histological 
alterations with smaller vessels (such as arterioles) primarily affected. These alterations 
include medial cell hypertrophy, hyperplasia and arteriolar muscularization. Hypertrophy 
(enlargement) of SMC cells can be seen predominantly in larger, proximal arteries, while 
hyperplasia (increase in cell numbers) affects mainly smaller arteries (Meyrick and Reid 
1980). Increased SMC proliferation is associated with upregulation of growth factor 
expression, ion channel activity, and altered balance of vasoactive mediators (Rich, Dantzker 
et al. 1987). During development of PH, SMC phenotype changes from a contractile to a 
proliferative, migratory and synthetic phenotype (Thyberg, Blomgren et al. 1995; Louis and 
Zahradka 2010). This conversion depends, at least in part,  on the release of active forms of 
growth factors such as transforming growth factor beta (TGF-β) or fibroblast growth factors 
(FGF) from the extracellular matrix (Boudreau, Turley et al. 1991).  
Increase in endothelial permeability and an imbalance in endothelium-derived 
vasoconstrictors and vasorelaxants such as ET-1 and NO are also thought to contribute to 
SMC migration and proliferation (Di Luozzo, Bhargava et al. 2000; Napoli, Paolisso et al. 
2013). In addition, aberrations in the TGF-β signalling are thought to contribute to SMC 
dysfunction in PH (Morrell, Yang et al. 2001).  
The role of BMPR2 mutations and receptor signaling in pulmonary hypertension will be 
discussed further in chapter 1.5.4. 
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1.3.4. Fibroblasts 
Several studies support an active role of adventitial fibroblasts in pulmonary vascular 
remodeling in PH (Sartore, Chiavegato et al. 2001; Jeffery and Morrell 2002; Stenmark, 
Davie et al. 2006) In response to vascular stress,  fibroblasts show phenotypic changes 
characterised by increased proliferation, migration, differentiation and increased release of 
extracellular matrix components and growth factors that stimulate smooth muscle growth 
and recruitment of inflammatory and progenitor cells to the vessel wall. The key role of 
fibroblasts in vascular remodelling is supported by data showing that phenotypic changes in 
adventitial cells precede the intimal and medial remodeling (Siow, Mallawaarachchi et al. 
2003; Herrmann, Samee et al. 2005). Hypoxia and  other cellular stresses can increase the 
release of endothelial adenosine triphosphate (ATP) that acts synergistically with other 
growth factors released by smooth muscle cells  or endothelial cells (Gerasimovskaya, 
Ahmad et al. 2002). Hypoxia-induced release of angiotensin II is also thought to facilitate 
fibroblast proliferation (Krick, Hanze et al. 2005).  
Adventitial fibroblasts can differentiate into myofibroblasts expressing α-SMC actin 
(Zalewski, Shi et al. 2002) and this differentiation is regulated by several factors such as 
growth factors, cytokines, adhesion molecules and ECM molecules (Stenmark, Davie et al. 
2006).  Myofibroblasts trigger significant changes in the function and structure of the vessel 
wall by enhancing production of ECM proteins such as fibronectin and elastin (Gabbiani 
2003). Among others, TGF-β is capable of inducing fibroblast-myofibroblast transition by 
stimulating α-SMC-actin expression and collagen production (Gebb and Jones 2003).  
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1.4. Key signalling mediators in PH 
1.4.1. Nitric Oxide 
Decrease in nitric oxide (NO) bioavailability is one of the key manifestations of pulmonary 
endothelial dysfunction in PH. NO is required for the maintenance of pulmonary endothelial 
barrier function and has vasodilatory and anti-inflammatory effects in the vasculature 
(Predescu, Predescu et al. 2005).  
NO is synthesized in a series of biochemical reactions that transfer electrons from molecular 
oxygen through a number of cofactors, such as reduced nicotinamide adenine dinucleotide 
phosphate (NADPH), 6(R)-5,6,7,8-tetrahydrobiopterin (BH4), flavin, calmodulin and iron. 
These reactions are catalysed by a  family of enzymes termed nitric oxide synthases (NOS), 
which through the oxidation of L-arginine lead to the formation of NO and L-citrulline 
(Palmer, Ferrige et al. 1987). Three isoforms of NOS have been found in mammals with 
different tissue distribution and regulation: neuronal NOS (nNOS; NOS1), which acts as 
neurotransmitter in the central nervous system, inducible (iNOS; NOS2) that takes part in 
inflammatory responses, and endothelial NOS (eNOS; NOS3), important in the regulation of 
vascular tone.  
Synthesis of NO via NOS is dependent on the availability of substrates and cofactors such as 
L-arginine and tetrahydrobiopterin (BH4). NO synthesis can be enhanced by increasing 
nutritional intake of arginine, even though the intracellular concentrations of L-arginine 
greatly exceed the Km of NOS (Flam, Eichler et al. 2007). One explanation for this “arginine 
paradox” is that the intake of L-arginine can antagonise asymmetric dimethylarginine 
(ADMA), the endogenous NOS inhibitor (Albsmeier, Tsikas et al. 2002). In fact, all NOS 
isoforms can be competitively inhibited by the naturally occurring arginine analogues ADMA 
and L-NG-monomethyl arginine (L-NMMA). Apart from competing with L-arginine, ADMA 
and L-NMMA can also “uncouple” NOS, leading to reactive oxygen species (ROS) generation, 
implicated in pathogenesis of PH (Wilcox 2012). ADMA metabolism is further described in 
chapter 1.5. 
Pulmonary eNOS expression increases during fetal life and then declines during progression 
to adulthood. This temporal increase is crucial for the dilation of the pulmonary vascular 
bed after birth. In fact, disruption of NO synthesis has been implicated in animal model of 
foetal PH and human congenital pulmonary hypertension (North, Moya et al. 1995; 
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Villamor, LeCras et al. 1997).  In the adult, eNOS-derived NO acts as a vasodilator, stabilises 
endothelial barrier function, inhibits platelet aggregation and leukocyte adhesion and 
inhibits vascular smooth muscle cell proliferation (Shaul 2002).  
The NO/cGMP signalling cascade plays an essential role in the vascular smooth muscle 
relaxation (figure 5).  In vitro and in vivo studies show that NO and atrial natriuretic peptide 
(ANP) decrease blood pressure by causing relaxation of small arteries and arterioles 
(Sausbier, Schubert et al. 2000). Both NO and ANP stimulate guanylate cyclase (GC) (soluble 
or particulate respectively) and increase intracellular levels of cyclic guanosine 
monophosphate (cGMP).  
cGMP activates protein kinase G (PKG) which in turn activates potassium (K+) channels and 
allows K+ to flux out of the cell, causing plasma membrane hyperpolarization. This leads to 
inhibition of voltage-dependent Ca2+ channels (VOC), reduced Ca2+ influx and 
vasorelaxation.  cGMP can also lower intracellular Ca2+ levels by inhibition of receptor-
operated Ca2+ (ROC) channels (Lincoln, Dey et al. 2001). ROC channels are activated via 
receptor-mediated stimulation of G-protein coupled receptors (GPCRs) directly or via the 
second messenger, inositol 1,4,5-trisphosphate (IP3) (Qiao, He et al. 2014).  PKG can also 
lower intracellular Ca2+ levels by encouraging sequestration of Ca2+ and inhibiting its release 
from sarcoplasmic reticulum (SR). PKG increases Ca2+ sequestration by phosphorylation of 
the SR protein, phospholamban (Qiao, He et al. 2014) and by  activation of the SR Ca2+-
ATPase (SERCA) (Lincoln, Dey et al. 2001). Ca2+ release from the SR is decreased by PKG-
mediated phosphorylation of IP3 receptor (Xu, Kong et al. 2007).   
Lowering of intracellular Ca2+ levels reduce Ca2+/calmodulin-dependent phosphorylation of 
myosin light chain (MLC), leading to inhibition of actomyosin contractility and 
vasorelaxation.  In addition, PKG can decrease MLC phosphorylation by activating myosin 
light chain phosphatase (MLCP). This happens via the PKG-mediated phosphorylation of 
RhoA which in turn inhibits phosphorylation of MLCP by RhoA effector, Rho kinase (Patel 
and Rattan 2007). 
eNOS expression and activity show inverse correlation with the severity of morphological 
changes in PH lungs (Giaid and Saleh 1995). eNOS knockout mice show increased right 
ventricular hypertrophy (RVH) under normoxic and hypoxic conditions (Steudel, Ichinose et 
al. 1997). Conversely, inhaled NO reduces right ventricular hypertrophy in animal models of 
34 
  
 
pulmonary hypertension (Roberts, Roberts et al. 1995).  NO is a downstream effector of 
vascular endothelial growth factor (VEGF) and is required for the VEGF-induced effects on 
endothelial proliferation and angiogenesis (Bernatchez, Soker et al. 1999). In a regulatory 
feedback response, NO can also up-regulate VEGF expression in cells (Ziche, Morbidelli et al. 
1997). The pro-angiogenic effects of endothelial NO can be beneficial during lung 
development and endothelial wound repair but increase in eNOS expression has also been 
implicated in plexiform lesion formation (Budhiraja, Tuder et al. 2004).  
 
 
Figure 5: Nitric oxide pathway and cyclic guanosine monophosphate pathways in smooth muscle cell 
vasorelaxation. NO synthesized by endothelial nitric oxide synthase (eNOS) stimulates soluble guanylate 
cyclase (sGC) in smooth muscle cells and increases the levels of intracellular cyclic guanosine 
monophosphate (cGMP). The particulate form of guanylyl cyclase (GC-A) is stimulated by atrial natriuretic 
peptide (ANP). cGMP targets  include: phosphodiesterases 2 and 3 (PDE2 and 3), and protein kinase G (PKG).  
PKG induces vasorelaxation by interacting with Ca2+ modulating proteins in plasma membrane and 
sarcoplasmic reticulum and lowering intracellular Ca2+ levels (for further details please see text page 32). In 
addition, PKG can phosphorylate and inactivate RhoA leading to activation of myosin light chain 
phosphatase (MLCP), reduction in myosin light chain phosphorylation and vasorelaxation. 
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1.4.2. Guanylate Cyclase 
The guanylyl cyclase activity can be found in both particulate (pGC) and soluble (sGC) 
fractions of all mammalian cells (Lucas, Pitari et al. 2000). Soluble guanylate cyclase (sGC) is 
the main downstream effector of NO, which synthesises the second messenger, cyclic 
guanosine monophosphate (cGMP) (figure 6).  
Alterations in cGMP synthesis and metabolism have been implicated in a number of 
cardiovascular diseases, including systemic arterial hypertension and PH, coronary artery 
disease, peripheral vascular disease and atherosclerosis (Tsai and Kass 2009; Stasch, Pacher 
et al. 2011). 
sGC is a heterodimer composed of α1β1 and α2β2 isoforms. The α1β1 isoform is recognised 
as the most abundant in the vasculature and responsible for smooth muscle relaxation 
(Hobbs 1997; Russwurm and Koesling 2004), while α2β2 is thought to play a key role in 
synaptic transmission (Russwurm, Wittau et al. 2001). sGC is widely expressed in all 
mammalian cells  and mediates several physiological functions, such as inhibition of platelet 
aggregation,  immunomodulation and vasodilation/smooth muscle relaxation (Collier and 
Vallance 1989). In particular, sGC-α1 is essential for the pulmonary vasodilator response to 
inhaled NO in chronic hypoxia-induced pulmonary hypertension (Vermeersch, Buys et al. 
2007).  
Pharmacological agents that could target sGC-cGMP signaling directly can be divided into 
two main categories: sGC stimulators and sGC activators.  As shown in figure 6 stimulators 
(such as Bay41-2272), can sensitise sGC to low levels of NO, maintaining the enzyme in its 
active configuration. Their action is dependent on the presence of the ferrous heme (Fe II); 
in addition they can increase sGC activity in the absence of NO (Evgenov, Pacher et al. 2006). 
In contrast, sGC activators (Bay58-2667) preferentially activate sGC in the oxidized state (Fe 
III) (Dumitrascu, Weissmann et al. 2006; Tamargo, Duarte et al. 2010). Both types of 
compounds have been shown to attenuate structural remodelling of pulmonary arteries in 
experimental models of hypoxia-induced pulmonary hypertension (Li, Zhou et al. 1999; Li, 
Laubach et al. 2001).  
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Figure 6: The sGC stimulator Bay41-2272 and the activator Bay58-2667 increase 
cGMP production. Bay41-2272 is a NO-dependent stimulator acting on the 
physiological form of sGC containing the Fe (II) heme of sGC (left). Conversely, 
Bay58-2667 is a NO-independent activator acting on the Fe (III) heme of sGC (right). 
Increased levels of cGMP start vasodilatation and anti-aggregation resulting in anti-
remodeling of the vascular wall and unloading of the right ventricle. GTP (guanosine 
triphosphate), ox. Stress, (oxidative stress), RV (right ventricle).  Adapted from 
(Baliga, MacAllister et al. 2011) 
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1.5. The DDAH/ADMA pathway 
1.5.1. Methylarginines 
Methylation of the amino acids histidine, arginine and lysine in proteins is an essential form 
of post-translational modification used by cells to expand their functional set of proteins 
(Teerlink 2005).  
Methylarginines, asymmetric dimethylarginine (ADMA) and its isoforms NG-monomethyl-L-
arginine (L-NMMA or MMA) and symmetric dimethyl-L-arginine (SDMA), are endogenous 
amino acids that circulate in plasma (0.4-1 µM) (Lajer, Tarnow et al. 2008). Methylarginines 
are generated by proteolytic degradation of proteins methylated by protein arginine N-
methyltransferase enzymes (PRMTs) (figure 7). PRMTs are broadly distributed in the body 
and mainly two types of PRMTs (Type 1 and 2) catalyse the methylation of arginine residues. 
Type 1, which catalyses the formation of ADMA by adding a single methyl group, and type 2 
that can methylate both of the guanosine-nitrogen on the arginine residues (Bedford and 
Richard 2005). As showed in figure 7, PRMTs methylate protein arginine residues. PRMTs 
use S-adenosylmethionine (SAM), which is synthesised from methionine and ATP, as the 
methyl group donor. Subsequently, the transfer of its methyl group converts SAM into S-
adenosylhomocysteine (SAH). When methylated proteins are hydrolysed, free 
methylarginines ADMA, L-NMMA and SDMA are released (Wada, Inoue et al. 2002). L-
arginine and methylarginines are transported into the cell through the same y+ cationic 
amino acid transporter and so the excess of methylarginines can limit the pool of substrate 
available to NOS (Pope, Karuppiah et al. 2009). Only ADMA and L-NMMA can compete with 
L-arginine for NOS binding and inhibit NO production, while SDMA does not act as NOS 
inhibitor (Teerlink 2005). ADMA and L-NMMA are metabolised to L-citrulline and 
dimethylamine by enzymes dimethylarginine dimethylaminohydrolases 1 and 2 (DDAH 1 
and DDAH 2) (Vallance and Leiper 2004), while SDMA is usually removed by renal excretion 
(figure 7)(Cooke and Ghebremariam 2011).  
Interestingly, in vitro experiments have shown that exposure of endothelial cells to 
pathological concentrations of ADMA can drastically reduce NO synthesis and increase 
superoxide generation (Boger, Bode-Boger et al. 2000). 
Therefore, by inhibiting eNOS, ADMA can indirectly increase blood pressure and cause 
vasoconstriction. Other studies showed that a long-term exposure to ADMA can enhance 
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atherogenesis and produce sustained hypertensive damage to the vessels and kidneys in 
animal models of pulmonary hypertension (Naruse, Shimizu et al. 1994). 
The human body generates nearly 300 μmol/day of ADMA but only around 50 μmol/day is 
excreted in urine (Achan, Broadhead et al. 2003). Accordingly, data from humans studies 
showed that the local intra-arterial infusion of ADMA can significantly reduce forearm blood 
flow (Calver, Collier et al. 1993), while the intravenous infusion of ADMA can increase the 
mean blood pressure by 6% and systemic vascular resistance by 24%  reducing the heart 
rate and vascular responsiveness (Achan, Broadhead et al. 2003). ADMA plasma levels are 
raised in a number of pathologies including pulmonary hypertension, hypercholesterolemia, 
type II diabetes, hypertension, congestive heart failure, renal disease and cancer (Cooke 
2004). 
In addition, it has been shown that ADMA inhibits VEGF-induced endothelial angiogenesis 
and chemotaxis in vitro and in vivo as a result of reduced NO/cGMP signalling, inhibition of 
vasodilator-stimulated phosphoprotein (VASP) phosphorylation and Rac1 activity, important 
players in cell polarization and focal adhesion turnover (Wojciak-Stothard, Torondel et al. 
2009). Due to the correlation with adverse cardiovascular outcomes, ADMA has been 
recognized as an independent cardiovascular risk factor.  
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Figure 7: Synthesis and degradation of methylarginines. Protein arginine N-methyltransferase enzymes 
(PRMTs) transfer a methyl group from S-adenosyl-L-methionine (SAM) to each guanidino nitrogen of an 
arginine residue. This reaction produces a protein with methylarginines residue and S-adenosyl-L-
homocysteine (SAH). Hydrolysis of the methylated proteins releases SDMA, MMA or NMMA and ADMA. 
MMA and ADMA are competitive inhibitors of endothelial NOS. Approximately 20% of all methylarginines 
are removed by urine excretion, while the remaining 80% is metabolised by DDAH. SDMA: symmetric 
dimethyl-L-arginine, ADMA: asymmetric dimethylarginine L-NMMA or MMA:  NG-monomethyl-L-arginine. 
Adapted from (Cooke and Ghebremariam 2011). 
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1.5.2. DDAH enzymes 
In PH, increased plasma and lung tissue levels of ADMA are associated with reduced 
expression and activity of DDAH (Leiper, Murray-Rust et al. 2002). Two isoforms of DDAH 
enzymes, DDAH1 and DDAH2, are respectively encoded by genes on chromosome 1p22 and 
6p21.3. 38.  Structurally, the two cytosolic proteins display 62% homology at the amino acid 
level and 63% at the nucleotide level; DDAH1 is widely expressed in the lung, liver and 
kidney (major sites for methylarginines metabolism) at sites of NOS expression (Nijveldt, 
Teerlink et al. 2003). DDAH-1 expression has also been detected in the pancreas, aorta, 
peritoneal neutrophils and macrophages in fetal and adult tissues (Tran, Fox et al. 2000). 
Mouse homozygous gene deletion of DDAH1 is lethal in utero and DDAH1 +/− mice show 
increased right ventricular and pulmonary pressure (Leiper, Nandi et al. 2007).  
The DDAH-2 enzyme is abundant in fetal tissues, vascular endothelium, and tissues that play 
a role in immune responses (spleen, thymus, peripheral leukocytes, lymph nodes, and bone 
marrow) (Palm, Onozato et al. 2007). Both DDAH1 and DDAH2 have been implicated in the 
regulation of NO production in the vascular endothelium. Furthermore, the fact that DDAH2 
is highly expressed in immune cells and DDAH-2 gene is located near the MHC III region of 
the chromosome 6p21.3, suggests a potential role of DDAH2 in development of 
autoimmune diseases.  
While both DDAH1 and DDAH2 have been implicated in the pathogenesis of PH, their 
individual contributions are not well understood. Studies of DDAH gene silencing/deletion in 
rodents lead to the conclusion that plasma levels of ADMA are predominantly regulated by 
DDAH1, while DDAH-2 plays a lesser role (Palm, Onozato et al. 2007). For example, in 
transgenic mice overexpressing the human DDAH1 (hDDAH1), circulating levels of ADMA 
were 30–50% lower compared to wild-type (WT) mice. The hDDAH1 transgenic mice also 
exhibited a reduction in systolic blood pressure and systemic vascular resistance 
(Schwedhelm, von Leitner et al. 2009). Under pathophysiological conditions, DDAH1 
overexpression reduces development of graft coronary artery disease (Tanaka, Sydow et al. 
2005), improves endothelial regeneration (Konishi, Sydow et al. 2007) and reduces 
myocardial reperfusion injury (Stuhlinger, Conci et al. 2007), supporting the hypothesis that 
circulating ADMA concentrations are directly influenced by DDAH activity in cardiovascular 
tissues. In addition, studies reported that the ADMA/DDAH pathway is also implicated in the 
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regulation of the activity of Rho GTPases, which can be controlled by 
phosphorylation/dephosphorylation cycle, dependent upon the level of NO (Loirand, Guilluy 
et al. 2006).  
Although many of the effects of DDAH appear to be mediated by NO signalling, recent data 
show that DDAH enzymes can also activate important processes in a NO-independent way 
(Zhang, Hu et al. 2011). Indeed, this study found evidence of DDAH1/Ras interaction, 
suggesting a novel pathway where Ras acts as a downstream effector of DDAH1 and 
regulates endothelial function via Akt phosphorylation (protein kinase B) (Zhang, Hu et al. 
2011).  
1.5.3. Rho signalling 
Rho GTPases are Ras homologues proteins (hence the name ‘‘Ras homologous’’) that 
regulate organisation of the actin cytoskeleton via the cell surface receptors; in humans, 
more than 25 Rho GTPases have been identified with 80-90% homology among them (Hall 
1998). Apart from the actin cytoskeleton organisation, Rho proteins have several cellular 
functions such as regulation of cell motility, cell survival, cell cycle progression, membrane 
trafficking and transcriptional regulation (Etienne-Manneville and Hall 2002). Rho GTPases 
can be activated by several stimuli including vasoactive molecules (ET-1, VEGF, histamine) or 
by mechanical stimuli such as shear stress, pressure and hypoxia (figure 8) (Wojciak-
Stothard, Tsang et al. 2005). Rho proteins can switch between an active, guanosine 5c-
triphosphate (GTP) bound, and an inactive, guanosine 5c diphosphate (GDP) bound 
conformation (Jaffe and Hall 2005). In their active conformation, Rho proteins interact with 
downstream effectors, such as Rho Kinase (ROCK), to stimulate cellular responses.  
Several studies established the importance of RhoA and its downstream mediator, ROCK, in 
pulmonary arterial contractility and remodelling (Loirand and Pacaud 2010; Connolly and 
Aaronson 2011). The importance of RhoA/ROCK pathway has been highlighted in smooth 
muscle cells, where both contractile and proliferative phenotypes may depend on 
RhoA/ROCK signalling (Mack, Somlyo et al. 2001). In addition, due its ability to increase 
phosphorylation of myosin light chain (MLC), the RhoA/ROCK pathway is crucial in the 
regulation of actomyosin contractility and cell motility (Connolly and Aaronson 2011). 
In endothelial cells, well characterised members of the Rho GTPases family, RhoA, and Rac1 
play opposing roles in the regulation of endothelial barrier function. Activation of RhoA in 
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vascular endothelial cells increases actomyosin contractility that pulls the intercellular 
junctions apart, compromising endothelial barrier function while Rac1 can neutralize the 
actions of RhoA by increasing cell-to-cell adhesion (Wojciak-Stothard, Torondel et al. 2009). 
A coordinated activation of Rho GTPases RhoA, Rac1 and Cdc42 is required for cell 
movement. In particular, Rac1 and Cdc42 control the formation of membrane protrusions at 
the cell front, lamellipodia and filopodia respectively, while RhoA is required for retraction 
of the rear end of the cell (Ridley 2001).  
Studies have demonstrated that protein kinase G (PKG)-mediated phosphorylation of RhoA 
on serine 188 can inhibit its activation at the cell membrane (Ellerbroek, Wennerberg et al. 
2003). ADMA can activate RhoA by preventing NO/PKG-mediated phosphorylation, leading 
to a firm cell-substratum adhesion and inhibition of endothelial cell motility (Ridley 2001). 
ADMA has also been shown to abrogate VEGF-induced endothelial angiogenesis by 
inhibiting the activity of Rac1 in a NO/cGMP/PKG-dependent way (Wojciak-Stothard, 
Torondel et al. 2009).  
Recently, it has been shown that RhoB, a protein homologous to RhoA, is required for the 
hypoxia-induced changes in endothelial barrier function and pulmonary vascular smooth 
muscle cell migration and proliferation (Wojciak-Stothard and Wilkins 2012). Indeed, RhoB 
gene knockout attenuated development of chronic hypoxia-induced PH in mice, probably 
due the inhibition of Hypoxia-Inducible Factor-1 (HIF-1) and platelet-derived growth factor 
(PDGF) signalling (Wojciak-Stothard and Wilkins 2012). Interestingly, while RhoA can be 
phosphorylated and inactivated by PKG, RhoB lacks of Ser188 phosphorylation site and 
therefore cannot be directly modified by NO/PKG signaling. 
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Figure 8: Pathways affecting RhoA activity in pulmonary vasculature. RhoA can switch between an active 
guanosine triphosphate (GTP) bound state, and an inactive guanosine diphosphate (GDP) bound state. To 
exert its effects, RhoA has to be anchored to the cell membrane by an isoprenoid tail. Phosphorylation of 
RhoA by protein kinase A (PKA) or protein kinase G (PKG) stimulates the association of RhoA with guanine 
dissociation inhibitor (GDI), which renders the protein inactive. The inhibition of Rho kinase can prevent 
endothelial dysfunction, smooth muscle cell (SMC) contractility, growth and differentiation. ADMA, 
asymmetric methylarginine; DDAH, dimethylarginine dimethylaminohydrolases; GAPs, GTPase activating 
proteins; GEFs, guanosine nucleotide exchange factors; VSMC, vascular smooth muscle cells. Adapted from 
(Wojciak-Stothard 2008) 
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1.5.4. BMP signaling   
BMPs are the largest group of cytokines within the TGF-β superfamily. They were originally 
identified as molecules regulating growth and differentiation of bone and cartilage (Reddi 
1994). The TGF-β superfamily is composed of mediators such as TGF-β isoforms (TGF-β3), 
BMPs, activins and growth and differentiation factors (GDF). Genetic studies have shown 
that 10%–20% of patients with IPAH, and 70% of patients with hereditary PH, are 
heterozygous for a mutation in BMPR2 (Lane, Machado et al. 2000).  
The TGF-β superfamily has several roles in a variety of cellular processes such as cell 
proliferation, immunity, differentiation and inflammation. Fifteen BMPs have been 
identified so far. BMPs act via transmembrane serine/threonine kinase receptors and the 
binding to complexes containing type I and type II receptors. Type I receptors (50-55 kD) 
require type II receptors for the ligand binding, while type II receptors (70-80 kD) can bind 
ligands in the absence of type I receptors, but they require type I receptors for their 
signaling (Gilboa, Nohe et al. 2000). The ligand/receptor interaction results in signaling 
through SMAD-dependent or -independent pathway (Sieber, Kopf et al. 2009) (figure 9). 
Meanwhile in the SMAD-dependent pathway, BMP/type I receptor interaction activate 
SMAD 1/5/8 protein complex and induce the translocation of this signaling complex to the 
nucleus via the interaction with SMAD4, in the SMAD-independent pathway, MAP kinase 
(MAPKs), phosphatidylinositol 3-kinase/AKT, and protein kinase C  are involved (Lowery and 
de Caestecker 2010).  
The type II receptor (BMPR2) is expressed ubiquitously and after the ligand binding, BMPR2 
phosphorylates the intracellular glycine-serine rich domain on of the co-receptor BMPR1 
(figure 9. The phosphorylation allows the conformational changes that are essential for the 
subsequent signal transduction (Morrell 2006). BMPR2 seems to play a critical role in PH; for 
example, mutation in BMPR2 can have different effects depending on the cell type. For 
example, in PASMCs from PH patients BMPR2 mutations promote cell proliferation (Davies 
and Morrell 2008). In endothelial cells, loss of BMPR2 function results in increased apoptosis 
(Teichert-Kuliszewska, Kutryk et al. 2006); an early event in the pathogenesis of PH. 
Furthermore, activation of endothelial BMPR2 by BMP2 or BMP4 can stimulate eNOS 
phosphorylation and activation. The activation of eNOS by BMP2 and BMP4 interaction with 
BMPR2 has been shown to be largely dependent on protein kinase A (PKA) activity 
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(Gangopahyay, Oran et al. 2011).  Consistent with the hypothesized central role of this 
signaling pathway in PH, a recent study associated the loss of BMPR2 function with 
abnormal DNA repair in PH, suggesting an association between EC dysfunction and genomic 
instability (Li, Vattulainen et al. 2014).  
 
 
 
Figure 9: Schematic diagram of canonical and noncanonical BMP pathways. The dashed line separates 
canonical TGF-β signaling (on the left) from some of the noncanonical pathways activated by BMPR2. In the 
Smad-mediated pathway, the activation of the BMP receptor complex by BMP ligand interaction leads to 
phosphorylation of R-Smads 1, 5, and 8, which enables the interaction between R-Smads and Co-Smad 
proteins resulting in the nuclear transportation of the heteromeric complexes and activation of gene 
transcription. In the Smad-independent pathway, several intracellular pathways are activated, such as PKC 
(protein kinase C), MAPK pathway and AKT (protein kinase B) after phosphorylation by PI3K 
(phosphoinositide 3-kinase), resulting in gene target activation. 
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1.5.5.  Other mediators 
1.5.5.1. Hypoxia-inducible factors 
Hypoxia-inducible factors 1 have been implicated in the development of PH. The β subunit 
of HIF-1 (HIF-1β) is constitutively expressed, while the α-subunit (HIF-1α) is usually not 
detectable under normoxic conditions.  Several years after the discovery of HIF-1α, a closely 
related protein was identified based on its sequence similarity and subsequently named HIF-
2α (Shimoda and Semenza 2011). Like HIF-1α, HIF-2α dimerizes with HIF-1β; however, 
unlike HIF-1α, which is found in all nucleated cells, HIF-2α protein expression is restricted to 
the vascular endothelium and type II pneumocytes (Shimoda and Semenza 2011). HIF-1α 
and HIF-1α undergo ubiquitination (hence degradation) after hydroxylation of two proline 
residues (Semenza 2005). Under hypoxic conditions, hydroxylation becomes inadequate and 
HIF-1α or HIF-2α accumulates. Thus, HIF-1α or HIF-2α via hydroxylation controls the 
activation of the HIF-1 transcription complex.  
Several studies have documented the important role for HIF in the development of hypoxia-
induced PH (Shimoda and Semenza 2011). For example, either HIF-1α or HIF-2α 
heterozygous knockout mice show attenuated chronic hypoxia-induced increase in 
pulmonary arterial pressure and right ventricular hypertrophy (Yu, Shimoda et al. 1999; 
Brusselmans, Compernolle et al. 2003). Pharmacologic inhibitors of HIF activity reduce 
vascular remodeling in hypoxic-induced PH mice (Abud, Maylor et al. 2012).  
The mechanism by which HIF mediates vascular remodeling during chronic hypoxia needs 
further investigation, but it is likely to involve both Ca2+ and pH homeostasis (Iyer, Kotch et 
al. 1998). HIF also regulates expression of factors involved in the pathogenesis of PH, such as 
ET-1 and VEGF (Tuder, Chacon et al. 2001; Prabhakar and Semenza 2012).  
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1.5.5.2. Vascular Endothelial Growth Factor 
Vascular endothelial growth factor (VEGF) promotes proliferation, angiogenesis and survival 
of cultured vascular endothelial cells. Although endothelial cells are the primary target of 
VEGF, mitogenic effects in other, non-endothelial cell types have also been reported 
(Ferrara, Gerber et al. 2003) (Liu, Cox et al. 1995; Nor, Christensen et al. 1999).  
In vivo, VEGF induces vascular leakage and plays a central role in the regulation of 
angiogenesis and vasculogenesis (Le Cras, Markham et al. 2002).  VEGF binds to two 
tyrosine-kinase receptors, VEGFR-1 and VEGFR-2, which are expressed almost exclusively in 
endothelial cells. Normally, ECs do not secrete VEGF; however, in PH ECs have been shown 
to express VEGF as a protective response (Budhiraja, Tuder et al. 2004). Consistent with the 
postulated protective role of VEGF signaling, VEGF receptor blockade in combination with 
hypoxia, induces severe PH in rats while VEGF overexpression protects against the disease in 
rats (Le Cras, Markham et al. 2002). However, opinions regarding the role of VEGF in PH are 
divided, as it can also contribute to the pathogenesis of the disease by promoting 
plasminogen and collagenase activation, monocyte infiltration and plexiform lesion 
formation (Unemori, Ferrara et al. 1992).   
1.5.5.3.   Endothelin-1 
Endothelin-1 (ET-1) is a potent peptide vasoconstrictor secreted by ECs. There are three 
isoforms of endothelin (ET 1-3), but ET-1 is the most widely expressed and studied.  
Apart from vasoconstriction, ET-1 can induce proliferation and migration of vascular cells 
(Shao, Park et al. 2011). In PASMCs, ET-1 binds two receptor (ETA and ETB), triggering the 
signaling pathway that involves inhibition of activity of potassium channels (K+), increased 
levels of calcium (Ca2+) and activation of Rho downstream mediators, such as ROCK.  
PASMCs highly express ETA and ETB receptors that can activate contraction, proliferation 
and migration, meanwhile in PAECs only ETB receptor is expressed (Shimoda, Sham et al. 
2002).  
While the activation of ETA can cause vasoconstriction, ETB activation can mediate either 
vasoconstriction by its effects on smooth muscle cells, or vasodilation through the action on 
endothelial cells.  Interestingly, mRNA expression of both ETA and ETB is increased in 
experimental models of PH (Li, Chen et al. 1994; Frasch, Marshall et al. 1999), while in 
severe human PAH only ETB mRNA is increased (Bauer, Wilkens et al. 2002). Thus, it seems 
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that the effects of ET-1 depend on the balance of ETA and ETB receptors on endothelial and 
smooth muscle cells. Although ET receptor inhibitors are used in clinical practice (Hong, Coe 
et al. 2014), it is unclear if the improvement of survival in patients treated with ET-1 
inhibitors is due to reduced vasoconstriction or remodelling. 
1.5.5.4. Serotonin (5-HT) 
Serotonin (5-HT, 5-hydroxytryptamine) has long been recognized as one of the most potent 
naturally occurring pulmonary vasoconstrictors (Egermayer, Town et al. 1999). It is 
synthesised by tryptophan hydroxylase 1 (Tph1) in the pulmonary endothelium (Mlczoch 
1984). 5-HT was first implicated in the pathogenesis of PAH after an outbreak of the disease 
in Switzerland in the 1960’s among patients using aminorex fumarate, an appetite 
suppressant that inhibits serotonin uptake by platelets (Lepine, Mordasini et al. 1982). 
More than fifteen serotonin receptors (SERT or 5-HTT) have been identified so far, all of 
them capable of initiating signalling cascade involving generation of reactive oxygen species, 
activation of MAPKs and ROCK, and induction of genes involved in cell growth regulation 
(Maclean and Dempsie 2010). Studies have shown functional interaction between serotonin 
and BMP signalling (Long, MacLean et al. 2006).  The serotonin receptor inhibition was 
shown to block proliferative responses in cultured pulmonary vascular cells (Welsh, Harnett 
et al. 2004).  
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1.6. MicroRNAs involved in PH 
 MicroRNAs (or MiRNAs, or miR) are small non-coding RNA molecules around 22 nucleotides 
long that target the 3′-untranslated region (UTR) of mRNA to negatively regulate gene 
expression (Bartel 2004). As illustrated in figure 10, the transcription of miRNAs is started by 
RNA polymerase II, which synthesises a molecule over 1kb in size called primary miRNA (pri-
miRNA) from which several miRNAs can be produced. The pri-miRNA is then processed by 
the RNase III enzyme Drosha, forming a 50-60 nucleotides stem loop molecule called 
precursor miRNA (pre-miRNA). Afterwards, pre-miRNAs are transported out of the nucleus 
into the cytoplasm by Exportin-5 where they undergo cleavage by the endonuclease Dicer. 
The cleavage by Dicer creates a miRNA duplex and after the binding with argonaute protein 
(Ago2), the mature miRNA is formed. This mature miRNA is then incorporated into the RNA-
induced silencing complex (RISC) which can bind the 3-UTR of the target mRNA sequence 
and regulate gene expression (Bartel 2004).  
Several studies have now demonstrated an involvement of miRNAs in the pathogenesis of 
PH. The first report by Caruso et al, showed dysregulation of miRNAs (miR-22, miR-30, miR-
322,miR-451,miR-21) in monocrotaline (MCT) and chronic hypoxia models of PH (Caruso, 
MacLean et al. 2010). MiRNAs disregulation (in particular miRNA-204) was found also in 
human pulmonary arteries from PH patients (Courboulin, Paulin et al. 2011), highlighting the 
role of miRNAs in the pathophysiology of PH.   
Among all the miRNAs involved with the pathophysiology of PH, miR-21 has been 
investigated in several cell types and in vivo models (Parikh, Jin et al. 2012). Hypoxia can up-
regulate miR-21 expression in human PASMCs (Sarkar, Gou et al. 2010) and human PAECs 
(Parikh, Jin et al. 2012) and in mouse lungs exposed to hypoxia (Yang, Banerjee et al. 2012). 
In addition, BMP signaling also has a role in modulating miR-21; in particular BMP4 via 
SMAD proteins can stimulate Drosha complex and promote maturation of miR-21, which in 
turn, can downregulate expression of target genes (Davis, Hilyard et al. 2008).  However, the 
role of miR-21 in the pathogenesis of PH is not fully understood, with various laboratories 
showing conflicting data. For example, tissues from animal models of cardiac disease and 
patients with heart failure showed an up-regulation of miR-21 in cardiac fibroblasts (Thum, 
Gross et al. 2008), while another study reported that a reduction in miR-21 did not influence 
cardiac hypertrophy and fibrosis in mice (Patrick, Montgomery et al. 2010). For example, the 
50 
  
 
knock down of miR-21 in hypoxic mice reduced the right ventricular systolic pressure (RVSP) 
and a lowered muscularization of pulmonary arteries (Yang, Banerjee et al. 2012), while 
another study observed an exaggerated PH phenotype in mice lacking of miR-21 with an 
increased RVSP and increased pulmonary arterial muscularization (Parikh, Jin et al. 2012).  
The dissimilarity among these studies could be due to differences in species and/or distinct 
methods used to control miR-21 levels or even differences in gender. Although the effects of 
miRNAs are not fully understood, these findings highlight the potential role of miRNAs in the 
pathogenesis of PH. 
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Figure 10: The miRNA processing pathway. The maturation comprises the production of the 
primary miRNA transcript (pri-miRNA) by RNA polymerase II or III and the subsequent 
cleavage of the pri-miRNA by the Drosha–DGCR8 complex within the nucleus. The resulting 
pre-miRNA is afterward exported from the nucleus by Exportin-5in the cytoplasm where the 
RNase Dicer in complex with the double-stranded RNA-binding protein TRBP cleaves the pre-
miRNA to its mature length. The mature miRNA is bonded with Argonaute (Ago2) proteins 
into the RNA-induced silencing complex (RISC), where it leads RISC to silence target mRNAs 
through mRNA cleavage, translational repression or deadenylation. Adapted from (Winter, 
Jung et al. 2009). 
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1.7. Animal models of PH 
1.7.1. Chronic Hypoxia model 
Hypoxia is frequently used to induce PH in a wide variety of animal species. The most 
commonly used species are rats and mice, where this model produces predictable and 
reproducible results within a selected animal strain.  In rats, muscularization of small 
arteries starts quickly, due to medial SMCs proliferation (Meyrick and Perkett 1989). After 2-
3 weeks of hypoxia, rats and mice develop moderate PH with increased pulmonary artery 
pressure and vascular remodeling. Inflammation has been implicated in the hypoxia-induced 
remodeling process, at least in some strains of rodents. It has been reported that hypoxia 
induced an early and persistent lung-specific inflammatory response manifested by 
mononuclear cells infiltrates (Burke, Frid et al. 2009).  
Microarray analysis of the lung tissue demonstrates differences in gene expression induced 
by hypoxia between the species (Bull, Coldren et al. 2007). Chronic hypoxic exposure in the 
rat increased expression of genes involved in endothelial cell proliferation and decreased 
expression of genes associated with apoptosis. Furthermore, genes involved in proliferation 
and inflammation, such as phosphoinositide-3 kinase, were upregulated in rat lungs but not 
in mouse lungs. In chronic hypoxia-induced PH, animals develop right ventricular 
hypertrophy and show pulmonary vascular remodelling but there are no indications of 
plexogenic lesions, characteristic of severe PAH in humans (Yi, Kim et al. 2000). Although 
chronic hypoxia is not sufficient in inducing plexiform lesions, it is regarded as an important 
contributing factor. 
1.7.2. Monocrotaline injury 
Monocrotaline is a toxic pyrrolizidine alkaloid, which is activated in vivo by oxidases in the 
liver. The reactive compound MCTP leads to vascular injury, particularly in rats, after a single 
subcutaneous or intraperitoneal injection. Although monocrotaline induces PH in both rats 
and mice, rats remain the preferred species for this model.  The response to monocrotaline 
is variable among species and strains of animals because of differences in the hepatic 
metabolism of this compound by cytochrome P-450. While the exact mechanism needs to 
be clarified, it has been speculated that monocrotaline induces endothelial damage that 
triggers pulmonary vascular remodelling (Jasmin, Lucas et al. 2001). Reports have also 
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suggested that adventitial inflammation, in particular macrophage accumulation, 
contributes to the pulmonary smooth muscle hypertrophy in this model (Wilson, Segall et al. 
1989). Indeed, it has been suggested that adventitial inflammation may have more dramatic 
effects on the pathogenesis of PH than the ECs (Wilson, Segall et al. 1989). This model is 
considered to be an acute toxic model of damage to the lung vasculature and other organs 
(heart, kidney and liver). Similar to the chronic hypoxia- induced model of PH, 
monocrotaline does not induce obstructive intimal lesions in the peripheral vasculature of 
the lung.  
1.7.3. Sugen 5416 and Hypoxia 
Taraseviciene-Stewart developed a model of severe PH for a greater understanding of the 
mechanisms involved in the endothelial cell hyper-proliferation, which characterizes the 
plexogenic lesions of human PH (Taraseviciene-Stewart, Kasahara et al. 2001). The 
compound Sugen 5416 (SU-5416), a VEGF receptor inhibitor, causes mild PH and pulmonary 
vascular remodelling in normoxic rats, while in chronic hypoxic rats causes severe PH 
associated with arterial endothelial cell proliferation. The SU-5416-injected animals exhibit 
increased pulmonary vascular SMC proliferation and endothelial cells apoptosis. The authors 
speculate that the synergy between chronic hypoxia and SU-5416 vasoconstriction may 
stimulate the proliferation of apoptosis-resistant endothelial cells. In contrast to other 
animal models of the disease, in this model, PH can persist and progress besides the end of 
the hypoxic stimulus. SU-5416 injection, and concomitant exposure to hypoxia for 2 weeks, 
decrease the mRNA expression of the anti-apoptotic proteins (such as Bcl-2, Bcl-X), as 
compared with chronic hypoxic lung (Burke, Frid et al. 2009). Remarkably, in contrast to 
MCT, VEGF receptor blockade affects only the lung and no other organs. Another 
unexpected feature of this model is the absence of perivascular infiltration of 
monocytes/macrophages. This finding is somehow surprising since chronic hypoxia causes 
infiltration of mononuclear cells in the pulmonary arterial wall (Dumitrascu, Weissmann et 
al. 2006).  
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1.7.4. Additional animal models 
1.7.4.1. Genetic Model of BMPR2 mutations 
As previously mentioned, BMPR2 signaling plays a critical role in the pathogenesis of 
idiopathic PH and familial PH (Lane, Machado et al. 2000). Due the importance of BMPR2 
pathway in PH, the mouse heterozygous for the BMPR2 allele (BMPR2 +/−) model was 
studied in order to provide an insight into the disease mechanisms (Beppu, Ichinose et al. 
2004). BMPR2 +/− mice showed moderately elevated mean pulmonary artery pressure and 
pulmonary vascular resistance under basal conditions (Beppu, Ichinose et al. 2004), even 
though other reports demonstrated no significant difference in RVSP between BMPR2 +/− 
and wild type mice (Beppu, Ichinose et al. 2004). Furthermore, it has also been shown that 
mice with short hairpin RNA (shRNA)-mediated, constitutive knockdown of BMPR2, did not 
exhibit increases in PVR (Liu, Wang et al. 2007). Mice carrying a specific mutation in the 
BMPR2 tail domain developed PH with significant vascular remodeling and inflammation 
(West, Harral et al. 2008). Interestingly, only some mice with lung endothelium-specific 
deletion of the BMPR2 gene had elevated RVSP and RV hypertrophy (Hong, Lee et al. 2008). 
In spite of its limitations, the genetic model of BMPR2 mutations can be used to improve 
our understanding of the effects of gene mutations in PH. 
1.7.4.2. The S100A4-overexpressing mice 
The S100A4 protein is highly expressed in metastatic mouse mammary adenocarcinoma 
cells, conferring a metastatic phenotype that correlates with advanced stages of human 
tumors. The S100A4-overexpressing mouse, a cancer animal model (Ebralidze, Tulchinsky et 
al. 1989), has been also used to study PH (Ambartsumian, Klingelhofer et al. 1998).  
Although in the lungs of healthy individuals low levels of S100A4 expression were detected, 
a marked expression of S100A4 has been observed in plexiform lesions. These findings 
suggest that S100A4 may be not involved in the development of PH but may have a role in 
the development of severe vascular lesions in the end-stage PH.   
In addition, this model shows a marked inflammatory response, supporting the view that 
inflammation triggers the development of plexiform lesions in PH. However, increased 
S100A4 expression has also been noted in hypoxic models of PH, which do not show 
plexiform lesions (Kwapiszewska, Wilhelm et al. 2005). Hypoxic S100A4-overexpressing mice 
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show increased RV hypertrophy, but unlike in chronic hypoxia model, the RV hypertrophy 
does not regress on return to normoxic conditions (Merklinger, Wagner et al. 2005).  In 
summary, this model shows a marked inflammatory response and development of 
plexogenic arteriopathy, suggesting once again that the inflammatory insult plays a key role 
in development of PH.  
1.7.4.3. IL-6 overexpression in mice 
Studies have shown increased levels of IL-6 in serum and lungs of patients with PH.  Steiner 
et al. studied the role of IL-6 in the pathogenesis of PH using lung-specific, IL-6-
overexpressing mice under normoxic and chronic hypoxic conditions (Steiner, Syrkina et al. 
2009). These mice showed increased right ventricular systolic pressure, right ventricular 
hypertrophy and pulmonary vasculopathic changes, all exacerbated by hypoxia.  The 
occlusive vascular lesions in this model were composed of ECs and T lymphocytes, probably 
due the activation of VEGF and pro-proliferative factors, such as mitogen-activated protein 
kinase (MAPK) (Steiner, Syrkina et al. 2009). Additionally, studies have also linked IL-6 
expression to reductions in TGF-β signaling (Brock, Trenkmann et al. 2009) via inhibition of 
BMPR2/STAT3-microRNA 17/92 pathway (Brock, Trenkmann et al. 2009). The authors 
speculated that STAT3 plays an important role in the development of PH, since it has been 
shown that the activation of STAT3 can activate cell survival in PAECs from patients with PH. 
Conversely, hypoxic IL-6 −/− mice showed reduced inflammatory cell recruitment in the 
lungs compared with hypoxic wild-type mice, supporting the hypothesis that IL-6 has a 
pivotal role in hypoxia-induced pulmonary vascular remodeling (Savale, Tu et al. 2009). 
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1.8. Treatments for PH 
1.8.1. Current treatments for PH 
Patients with PH often receive diuretics, an anti-coagulant drug, Warfarin and oxygen, all 
treatments that are referred to as a conventional therapy. While diuretics provide a relief 
without affecting the course of the disease, Warfarin may improve survival, although this 
contribution is difficult to estimate. In the last 30 years, new treatments have been 
introduced in the clinical practice to directly target the pathology of PH. The three main 
categories of drugs have been approved for PH therapies are: prostanoid analogues 
(Epoprostenol, Beraprost), endothelin receptor antagonists (Bosentan, Macitentan) and 
phosphodiesterase-5 inhibitors (PDE-5) (Sildenafil, Tadalafil).  
The first prostanoid analogue used in PH was Epoprostenol. Epoprostenol was the first 
treatment targeted directly at PAH pathology, and has a proven survival advantage (Rubin, 
Mendoza et al. 1990). In fact, the intravenous (IV) injection of epoprostenol improved the 
pulmonary haemodynamic and enhanced survival (Rubin, Mendoza et al. 1990). However, it 
has short half-life (< 5 min) and the route of administration requires constant monitoring. 
The adverse effects, in common with all the prostanoids, are headache and gastrointestinal 
upset, but the main problem remains the route of delivery (Agarwal and Gomberg-Maitland 
2011). These problems have led to the development of more stable analogues with more 
favourable means of administration and pharmacokinetic profiles, iloprost, trepostinil and 
beraprost are all used in the clinical management of PH patients. For example Beraprost, an 
orally administrated prostanoid analogue, shows a modest efficacy in PH patients (Galie, 
Humbert et al. 2002). Recent studies show that orally active prostanoid analogues were 
effective as a single therapy but did not display significant benefits when used in 
combination with endothelin receptor antagonists or PDE-5 (de Jesus Perez, Rosenzweig et 
al. 2012) (Jing, Parikh et al. 2013). 
Endothelin receptor antagonists such as bosentan or ambrisentan have been shown to 
improve pulmonary haemodynamics, exercise capacity and reduce PAH symptoms 
(Williamson et al., 2000; Channick et al., 2001; Barst et al., 2004; Galie et al., 2005a); 
Although these drugs showed clinical benefit, in particular with PH associated connective 
tissue disease (Denton et al., 2008), a significant survival effect has not been observed.  
However, macitentan, a novel and highly potent antagonist of ET-A/B receptors, used during 
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the SHERAPHIN trial, showed reduced risk of morbidity/mortality event by 30% (3mg dose) 
to 45% (10mg dose) compared with placebo control (Pulido, Adzerikho et al. 2013). 
Phosphodiesterases (PDEs) are the enzymes that facilitate the breakdown of the second 
messengers, cAMP and/or cGMP (Bender and Beavo 2006). 11 PDE families have been 
characterised, with each type consisting of several isoforms and splice variants. PDE 
inhibitors have been a major focus in drug development, particularly for cardiovascular 
disease. In the vasculature, PDE inhibitors exert several favourable effects including 
vasodilatation, inhibition of smooth muscle proliferation and prevention of platelet 
aggregation (Wharton, Strange et al. 2005). In particular, the blockade of PDE5, which 
metabolizes cGMP exclusively, reduces systemic and pulmonary artery pressure under 
physiological conditions in animals and humans (Madhani, Okorie et al. 2006). 
Indeed, the first PDE-5 inhibitor approved for PH therapy was Sildenafil (Galie, Ghofrani et 
al. 2005) even though there were doubts regarding its impact on long term survival and 
haemodynamics.  Tadalafil, another PDE-5 inhibitor, has also been examined as treatment 
and received approval for use in patients with PH in 2009 (Galie, Brundage et al. 2009).  
Although PDE5 inhibitors represent a therapeutic advance, their effects on PAP are limited 
(only ~ 5 mm Hg reduction in PAP) (Baliga, MacAllister et al. 2011). A significant number of 
PH patients do not respond to sildenafil treatment. Additionally, in patients that respond 
well to sildenafil, there is often a dose-dependent systemic hypotension that can limit the 
beneficial effects of the drug. Nowadays, there is no evidence to suggest that modern PDE5 
inhibitors have a greater effect than sildenafil, or that sildenafil-resistant patients will 
respond to other PDE5 inhibitors. 
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1.8.2. Emerging Treatments for PH 
There are more than 30 drugs at different stages of development for treatment of PH. 
Although some represent variations of current drugs used in PH, the majority are novel 
drugs. These include receptor tyrosine kinase inhibitors (Imatinib, Sorafenib)(Ghofrani, 
Seeger et al. 2005; Moreno-Vinasco, Gomberg-Maitland et al. 2008), agents that enhance 
the coupling of eNOS (Cicletanine) (Waxman, Lawler et al. 2008), guanylate cyclase 
activators (Riociguat)(Ghofrani, Hoeper et al. 2010), prostacyclin receptor agonists 
(Selexipag) (Simonneau, Torbicki et al. 2012), vasoactive intestinal peptides (Petkov, 
Mosgoeller et al. 2003), serotonin inhibitors (Terguride) (Kekewska, Gornemann et al. 2012) 
and drugs targeting epigenetic activities (Zhao, Chen et al. 2012).  
In addition, augmenting cGMP levels is thought to have a therapeutic value in PH, either in 
animal models or in patients with the disease (Baliga, MacAllister et al. 2011). Soluble 
guanylate cyclise (sGC) appears a good target in PH as its expression and activity are 
increased in conditions of decreased NO bioavailability (Black, Sanchez et al. 2001) and 
genetic deletion of this enzyme results in an exaggerated response to hypoxia-induced PH 
(Vermeersch, Buys et al. 2007). 
Two different classes of sGC agonists have been developed. First class includes sGC 
‘stimulators’ which stimulate the native Fe2+-sGC and synergize with NO (Stasch, 
Dembowsky et al. 2002). Second class includes the sGC ‘activators’, which activate the Fe3+ 
or heme-free form of the enzyme and are additive with NO (Belik 2009). Both classes of 
drugs have favourable effects in experimental models of PH (Chester, Tourneux et al. 2009; 
Weissmann, Hackemack et al. 2009). 
Riociguat is the first sGC stimulator that has entered clinical development. Clinical trials 
demonstrated that it improves pulmonary vascular haemodynamics and increases exercise 
ability in PH patients. Additionally, riociguat reduces mean pulmonary arterial pressure in 
and pulmonary vascular resistance in PH patients. Overall, these promising results suggest 
that sGC stimulators are a valuable new approach for treatment of PH (Stasch and Evgenov 
2013). 
Recently, experiments using animal models demonstrated the potential of microRNA-based 
therapies in PH.  
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MicroRNAs have a critical role in regulating gene expression in the cardiovascular system 
(Small and Olson 2011) and in particular two miRNAs have been found to regulate BMPR2 
expression  (Brock, Samillan et al. 2012; Pullamsetti, Doebele et al. 2012). It has been 
demonstrated that injection of inhibitors of miRNA-17 or miRNA-20 can improve 
haemodynamics and reduce cardiovascular remodelling in both hypoxia- and MCT-induced 
PH. Other potential therapies involving stem or progenitor cells have been proposed to 
enhance endothelial repair (Zhao, Courtman et al. 2005). 
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1.9. Main Hypothesis and Project Aims  
 
Hypoxia causes pulmonary vasoconstriction and pulmonary hypertension, but the 
mechanisms involved are not well understood.  In the current study, I hypothesized that 
increased ADMA metabolism would protect against hypoxia-induced endothelial and 
smooth muscle dysfunction in vitro and in vivo and would prevent pulmonary vascular 
remodelling in chronic hypoxia-induced PH.  
 
 
The aims of the project:  
1) To study the role of ADMA/DDAH in hypoxia-induced responses in human pulmonary 
artery endothelial and smooth muscle cells and to study the effect of DDAH over expression 
on hypoxia-induced cell responses in vitro.  
2) To study the effect of increased DDAH expression on pulmonary vascular responses in 
vivo, in chronic hypoxia-induced mouse model of PH. Contributions of DDAH to hypoxia-
induced pulmonary responses and pulmonary vascular remodelling will be characterised in 
transgenic mice overexpressing DDAH1 or DDAH2.  
3) To identify mechanism responsible for the loss of DDAH activity in hypoxic pulmonary 
vasculature and to characterise main signalling mediators involved in DDAH-induced 
responses to hypoxia. 
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2. Materials and Methods 
2.1. Cell Culture 
Human Pulmonary Artery Endothelial Cells (HPAECs) and Human Pulmonary Artery Smooth 
Muscle Cells (HPASMCs) were purchased from Promo Cell (C-12241; C-12521). HPAECs were 
cultured in Endothelial Cell Basal Medium 2 (Promo Cell, C-22211) in tissue culture dishes 
coated with 10 mg/L bovine serum fibronectin (Sigma Aldrich F1141-5MG) in PBS, while 
HPASMCs were cultured in Smooth Muscle Cell Growth Medium (Promo cell, C-22062). The 
cells were purchased at passage 2 and used for experiments between passages 4-10.  
The cells were left in a humidified incubator in normoxic conditions (PO2 90-100 mmHg; 5% 
CO2, 19% O2, 37ºC) or exposed to hypoxia (PO2 14-30 mmHg, 5% CO2, 2% O2, 37ºC) for 1-48 
h.  These conditions were previously shown to affect pulmonary vascular cell phenotype, 
protein expression, and angiogenic potential in vitro (Wojciak-Stothard 2012; Tsang, Leiper 
et al. 2013). 
 Prior to hypoxic exposure, the cells were infected with adenoviruses to express mutant 
DDAH proteins. Alternatively, the cells were transfected with miR overexpression constructs 
or with miR inhibitors, locked nucleic acids (LNAs). In some experiments, the cells were 
incubated with 100 µM of ADMA, SDMA or L-257 (DDAHs inhibitor) for 0-24h. Following the 
treatment, the cells were used for studies of DDAH expression, cell proliferation, apoptosis 
or endothelial permeability. 
2.2. RNA extraction and cDNA Synthesis 
RNA was extracted using PureLink RNA Mini Kit (Invitrogen, 12183018A) according to 
manufacturers’ instructions. In order to remove possible DNA contamination, all the 
samples were treated with DNase I (Amplification grade; AMPD1, Sigma-Aldrich) and the 
amount of RNA was quantified by absorption at 260 nm using  NanoDrop® (ND-1000; 
NanoDrop Technologies, Willington, DE, USA). The first strand of complementary DNA 
(cDNA) was synthesised by reverse transcription (RT)-polymerase chain reaction (PCR). 2 µg 
of total RNA in 10 µl of diethylpyrocarbonate (DEPC)-treated RNase/DNase-free water 
(Invitrogen, 750024) were mixed with 4 µl 5x cDNA synthesis buffer, 1 µl 0.1M DTT, 1 µl 
RNase OUT™, 1 µl ThermoScript™ reverse transcriptase with 1 µl of 50 ng/µl of random 
hexamers, and 2 µl of 10 mM dNTP mix (Invitrogen ThermoScript™ RT-PCR System, 11146-
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016). The 20 µl mixture was subsequently placed into a thermal cycler (Peltier PTC-200) with 
profiles as follows: 25 ͦC for 10 min, 50  ͦC for 50 min and 85  ͦC for 5 min. 1 µl of RNA-H 
(Invitrogen ThermoScript™ RT-PCR System) was then added  and the solutions were 
incubated for 20 min at 37  ͦC in order to digest the remaining RNA. Finally, the samples 
were diluted in 100 µl of DEPC-treated RNase/DNase-free water to obtain a 20 ng/µl cDNA 
solution. As a negative control, the RNA treated with DNase I with omission of the RT step, 
was used in all experiments.  
2.3. qRT-PCR 
Following exposure to normoxia/hypoxia, quantitative real-time PCR was prepared with 100 
ng of cDNA using 10 µl of TaqMan MasterMix™ 2X (Applied Biosystems 4304437), 1 µl of 
20X primer-probe and DEPC water to reach 20 µl final volume. The qPCR was carried out 
using a HT-7500 thermo-cycler (Applied Biosystems) with the following thermal profile: 95  ͦC 
for 10 min for denaturation and 95  ͦC for 15 seconds and 60  ͦC for 1 min (the underlined 
repeated for each cycle, for 40 cycles). TaqMan Primers/probes set for DDAH1 
(Hs00201707_m1), DDAH2 (Hs00967863_g1), VEGF (Hs00900055_m1), miR21 
(Hs04231424_s1) and mir128 (Hs04231494_s1) were purchased from Applied Biosystems.  
For each sample, the level of expression of transcript was determined relative to the 
expression of the housekeeping gene (2-ΔCt) TATA box binding protein (TBP)(Applied 
Biosystems, 4351372) or GAPDH (Applied Biosystems, 4331182). 
To assess mRNA stability, RNA synthesis was terminated by the addition of 5 mg/L of 
actinomycin D.  
Actinomycin D is an antineoplastic antibiotic that inhibits blocks the movement of RNA 
polymerase interfering with RNA synthesis. The cells were harvested at various time points 
(1-4 h) after the actinomycin D addition, and the RNA was isolated using the PureLink RNA 
Mini Kit protocol (Invitrogen, 12183018A). In some experiments, the cells were incubated as 
previously published (Wojciak-Stothard, Abdul-Salam et al. 2014) with the 10µmol/L of NFκB 
inhibitor, BAY 1170-85 (Sigma Aldrich) for 24h before the measurement of miR-21 and 
DDAH1 mRNA. 
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2.4. Western Blot Analysis 
To study changes in DDAH protein expression, homogenised lung tissues, HPAECs and 
HPASMCs were lysed in RIPA lysis buffer (Sigma Aldrich, R0278) with protease inhibitor 
(1:100 in RIPA buffer; Sigma Aldrich R8346) on ice and harvested using a cell scraper. 
Samples were centrifuged at 13000 rpm at 4 ͦC for 5 minutes and protein concentration was 
measured using a Pierce BCA Protein Assay Kit (Thermo Scientific). Equal amounts of 
proteins were denatured in lithium dodecyl sulphate (LDS) loading buffer and reducing 
agent (both from Invitrogen) by heating to 70 Cͦ for 10 min. Proteins were separated by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE; 12% gel 1.5 mm) at 
120V for approximately 2 hours in migration buffer (25 mM Tris base, 190 mM glycine 0.1% 
SDS, pH 8.8). The spectra multicolor broad range protein ladder (10 to 260kDa; Thermo 
Scientific 26623) was run on each gel to show migration of marker proteins for estimation of 
protein molecular weight.  Proteins were electrophonically transferred to hydrophobic 
polyvinylidene difluoride (PVDF) membranes (GE Healthcare Amersham, RPN2020F) using 
the wet transfer method (BioRad). The gel and the PVDF membrane were sandwiched in 
between sponges and filter papers in a transfer cassette soaked with transfer buffer (20% 
methanol, in 1xTris-glycine-SDS) and was placed in a transfer tank (BioRad) filled with 
transfer buffer and run at 100V for 1 h and 30 min with an ice pack to avoid overheating. 
The membranes were then washed with phosphate buffered saline (PBS) and 0.1% Tween-
20 (Sigma Aldrich, 94158) (PBS-T) and blocked with PBS-T 5% BSA (blocking solution) (from 
Sigma Aldrich). Consequently, the membranes were either incubated for 1 h at room 
temperature (RT) or overnight (ON) at 4°C with primary antibodies in blocking solution. The 
membranes were incubated with goat anti-DDAH 1 or goat anti-DDAH 2 antibodies 
(generated in Leiper’s Laboratory, dilution 1:3000) (Leiper, Maria et al. 1999), mouse 
monoclonal anti-PCNA antibody (fl-261 Santa Cruz  Biotechnology; dilution 1:1000), rabbit 
anti-pSer188 RhoA antibody (sc-32954 Santa Cruz Biotechnology; dilution 1:1000), mouse 
monoclonal anti-RhoA (sc-418 Santa Cruz Biotechnology, dilution 1:1000) and rabbit anti-
RhoB (sc-180 Santa Cruz Biotechnology; dilution 1:1000) for 1 h 30’. Mouse monoclonal 
anti- β-Tubulin antibody (Sigma, T7816-2ML; dilution 1:5000) was used as a loading control.  
After washing 3 times with PBS-T, 10 min each, membranes were incubated for 1h at RT 
with respective, species-specific horseradish peroxidase (HRP)-conjugated secondary 
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antibodies (HRP-conjugated sheep anti-mouse IgG  Sigma Aldrich A9044, HRP-conjugated 
goat anti-rabbit IgG Sigma Aldrich A0545,  HRP-conjugated rabbit anti-goat IgG  Sigma 
Aldrich A5420) and then washed 3 times in PBS-T, 15 mins/each wash. 
Afterwards, bands were visualized using Luminata Crescendo Western HRP Substrate 
(Millipore, WBLUR) in ChemiDoc™ (BioRad, 170-8070) system.  The membranes were then 
re-probed for β-tubulin expression to confirm equal protein loading. Semi-quantitative 
analysis of protein expression was performed using densitometric measurement by 
Quantity One Software (BioRad) and proteins of interest were normalised to the loading 
control β-tubulin. The antibodies used and the optimal incubation conditions are 
summarised in Table 2. 
 
Primary 
Antibody 
Species 
of source 
Primary 
antibody dilution 
used & condition 
Secondary 
antibody dilution 
used & condition 
Optimal protein 
loading (µg) 
DDAH1 Goat  pAb 1:3000 1h 30’ RT 1:9000 1h RT 20 
DDAH2 Goat pAb 1:1000 1h 30’ RT 1:9000 1h RT 50 
PCNA Mouse mAb 1:2000 1h 30’ RT 1:10000 1h RT 20 
RhoA Mouse mAb 1:1000 ON 4°C 1:5000 1h RT 30 
RhoB Rabbit pAb 1:1000 ON 4°C 1:5000 1h RT 30 
pSer188 RhoA Rabbit pAb 1:1000 1h 30’ RT 1:10000 1h RT 20 
β-Tubulin Mouse mAb 1: 5000 1h 30’ RT 1:10000 1h RT Re-probing 
 
Table 2: Primary and secondary antibodies used in Western blotting. All the secondary antibodies were HRP-
conjugated and used for the respective species-specific primary antibodies.  
 
 
2.5. Construction and Purification of Recombinant Adenoviruses 
2.5.1. Adenoviruses construction 
Adenoviral vectors for DDAH1, DDAH2 and the inactive mutants of DDAH1 (ΔDDAH1-GFP) 
and DDAH2 (ΔDDAH2-GFP) were constructed as described in (Wojciak-Stothard, Torondel et 
al. 2007). Briefly, cDNA encoding DDAH1or DDAH2 were subcloned into the transfer vector 
pAdTrack-CMV. The transfer vector was then co-transformed with pAdEasy-1 DNA plasmid 
into E. coli BJ5183 strain. The transformed colonies were selected for kanamycin resistance, 
identified by restriction digest using Pac I (New England BioLabs R0547S), purified, linearized 
and transfected into 293 human embryonic kidney cells (Microbix Biosystems Ltd) that 
express E1 genes to allow purification of adenoviral particles.  The purification was carried 
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out using AdEasy Virus Purification™ (Agilent Technologies, 240243) kit instructions. 
Infected viral lysate was resuspended in 20ml of DMEM media containing 20µl of benzonase 
nuclease mixed and incubated at 37 ºC for 30 min. A 50ml syringe was set up in a retort 
stand above the conical flask and connected to the tube set supplied that consist of a three 
way tap attached to  a feed tube. Air was removed from the syringe and the benzonase 
nuclease-treated supernatant drawn up into the syringe through the feed tube. A 0.45 µm 
filter was attached to the syringe outlet and the volume of supernatant was filtered into a 
fresh container. The Sartobind™ filter unit (membrane absorbers) was washed by syringing 
8ml of sterile PBS through it. A 50ml syringe was filled with the prepared supernatant and 
passed through the Sartobind filter unit (10ml/min), followed by an equal volume of 1X 
washing buffer. In order to eluate the adenovirus from the Sartobind filter unit, 5ml of 
elution buffer were passed through the filter unit (1min/ml) and collected in a 15ml falcon 
tube (BD, Bioscience). The eluate was centrifuged for 15 min at 3000g and the buffer 
exchanged with 4ml of storage buffer (25mM NaCl, 20mM TrisHCl, 2.5% Glycerol). The virus 
was recovered by pipetting gently up and down and the titre determinate using the Adeno-
X- titre kit by ClonoTech. Adenoviral vectors inducing expression of green fluorescent 
protein (GFP) were taken as controls. Inactive DDAH mutants have Cys249Ser mutation in 
their active site, which completely inactivates the enzyme but does not affect the protein 
folding. DDAH1, DDAH2 and DDAH mutants (ΔDDAHs) were co-expressed with GFP, allowing 
easy identification of over expressing cells (Wojciak-Stothard, Torondel et al. 2007).  
2.5.2.  Propagation of adenoviruses  
Human embryonic kidney cells (HEK 293) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM; Gibco BRL Life Technology) supplemented with 10% Fetal Bovine Serum 
(FBS) and plated into a 6 well plate (SARSTEDT) with 5 X 105 cells/well and growth until 
~80% confluent. Cells were infected in 1ml serum-free DMEM containing viruses at the 
multiplicity of infection (MOI) 1:100.  After 4h, 1 ml of 4% FBS DMEM was added to each 
well to give a final concentration of 2% FBS DMEM. HEKs were cultured until full cytopathic 
effect (CPE) of the virus was visible. The medium containing lysed cells was harvested and 
subjected to three freeze-thaw cycles using liquid nitrogen and water bath set at 37 ºC. The 
resultant lysate was then used to infect a T75 (SARSTEDT) of 80% confluent HEK 293 cells. 
The procedure was repeated as for a 6 well plate and the resultant lysates from the T75 
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were used to infect four T175 flasks (SARSTEDT) of HEK 293. Once the cells started rounding 
up, the cells were harvested and pelleted by centrifugation at 1500rpm for 15min. The 
supernatants were discarded and the pellets resuspended in 5ml of fresh DMEM. The 
lysates were then subjected to ulterior freeze-thaw cycles and purified using the AdEasy 
Virus Purification Kit (Agilent technology UK Ltd). 
2.5.3. AdEasy virus purification 
AdEasy Virus purification was carried out following the kit instructions. Infected viral lysate 
was resuspended in 20ml of DMEM media containing 20µl of benzonase nuclease mixed and 
incubated at 37 ºC for 30 min. A 50ml syringe was set up in a retort stand above the conical 
flask and connected to the tube set supplied that consist of a three way tap attached to  a 
feed tube. Air was removed from the syringe and the benzonase nuclease-treated 
supernatant drawn up into the syringe through the feed tube. A 0.45 µm filter was attached 
to the syringe outlet and the volume of supernatant was filtered into a fresh container. The 
Sartobind™ filter unit (membrane absorbers) was washed by syringing 8ml of sterile PBS 
through it. A 50ml syringe was filled with the prepared supernatant and passed through the 
Sartobind filter unit (10ml/min), followed by an equal volume of 1X washing buffer. In order 
to eluate the adenovirus from the Sartobind filter unit, 5ml of elution buffer were passed 
through the filter unit (1min/ml) and collected in a 15ml falcon tube (BD, Bioscience). The 
eluate was centrifuged for 15 min at 3000g and the buffer exchanged with 4ml of storage 
buffer (25mM NaCl, 20mM TrisHCl, 2.5% Glycerol). The virus was recovered by pipetting 
gently up and down and the titre determinate using the Adeno-X- titre kit by ClonoTech. 
2.5.4. Adenovirus Titration  
HEK 293 cells were plated at 10 x 103 cells/well in a 96 well plate (SARSTEDT) and infected 
with serial dilutions of the adenovirus from 10-5 to 10-10 for 7 days in 100µl of DMEM 
containing 2% FBS at 37 ºC / 5%CO2. At day 8, the number of wells showing cytopathic 
effect (CPE) /fluorescent staining was counted for each dilution. The titre was calculated 
using 50% tissue culture infective dose equation:  
(TCID50) = Highest dilution giving 100% CPE + 0.5-(total wells with CPE). 
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2.6. Manipulation of DDAH gene expression and activity in cultured cells  
2.6.1. Plasmid and lock nucleic acids cell transfection 
To investigate the effect of miR-21 and miR-128 on DDAH1 expression, the cells were 
seeded into 6-well plates (500,000 cells per well) in 2 ml of growth medium and cultured to 
80-90% confluence. HPAECs and HPASMCs were transfected with pCMV-miR21 (p-
miRNA21), pCMV-miR128 (p-miR-128) and the negative control, pCMV-EGFP (p-EGFP) 
expression vectors from Origene, using electroporation system (Nucleofector I; AMAXA, 
M03). Briefly, the culture dishes were pre-incubated/equilibrated with 2ml of supplemented 
culture media in a humidified 37 ͦC/5% CO2 incubator. Trypsinised cells were centrifuged in 
culture media containing 10% serum at 100g for 10 minutes at RT. The cells were re-
suspended in 5ml of serum-free medium, counted and the required number of cells (500 
000 cells/single transfection) was centrifuged again. Following centrifugation, the resulting 
pellet was resuspended in 100µl of Nucleofector™ Solution and combined with 1-5µg of 
plasmid and 2µg of pmaxGFP™ (Amaxa) as transfection control. Consequently, the cell/DNA 
suspension was transferred into a close cap cuvette and the appropriate Nucleofector™ cell 
program was used (M03 for HPAECs and A33 for HPASMCs). Following electroporation, the 
suspension was finally added to the equilibrated media and left undisturbed for 24 h 
(Amaxa; VPI-1001, VPI-1004; Lonza). 
Has-miR-21 or Has-miR-128 lock nucleic acids (LNA21, LNA128), able to inhibit their 
respective miRNA, were purchased from Exiqon and were used at a final concentration of 
50nmol/L. After 4 h following transfection in Amaxa Nucleofector, the cells were left in 
normoxia or were exposed to hypoxia for 24 h. 
2.6.2. DDAH1 3’UTR Luciferase constructs  
The 3′ UTRs of DDAH1 gene was cloned by GenScript into the 3′ UTR of the Firefly luciferase 
gene (using XbaI sites) in the luciferase pGL3-CMV plasmid (Promega, E1741). The full-length 
DDAH1 3’UTR (~3000 nucleotides) was cut with EcoI-FseI restriction enzyme (NEB; R3101S-
R0588S) to obtain two fragments of different size,  a short fragment  of ~400 nucleotides 
and a long fragment of ~2600nt.   These two fragments were run on 0.8% gel and extracted 
using QIAquick Gel Extraction Kit (Qiagen, 28704). Successively, 100 ng of total DNA (75 ng 
insert + 25 ng empty vector) were used in a standard ligation reaction using T4 DNA Ligase 
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(NEB; M0210S). 2μl of ligation reaction were transformed in E. Coli competent cells 
DH5alpha (Invitrogen; 11319-019) and plated on ampicillin agar plates. The following day, 
10 colonies were selected and analysed by PCR using specific primers. The primer sequences 
for the short fragment and the long fragment were as follows: 400bp, forward: 
TGCCCACTCCTGTTGTTTT, reverse: AAGGAGCTGACTGGGTTGAA; 2600bp, forward: 
TCAAAGAGGCGAACTGTGTG, reverse: GGTGTTGGAGCAAGATGGAT. The PCR reaction was 
carried out on ice using for each colony: 28μl of sterile water, 5μl of 10X PCR buffer 
(Invitrogen), 3μl of 25mM MgCl2, 10mM dNTPs, 1μl of 20μM forward primers, 1μl of 20μM 
revers primer and 1μl of Taq polymerase (Invitrogen, 11306-016). To each PCR tube, a small 
amount of colony, diluted in 30μl of SOC medium (Invitrogen, 15544-034) and 5µl were 
added to the PCR reaction. The colony PCR was carried out using a Peltier PTC-200 with the 
following thermal profile: 95 ͦC for 5 min, 95  ͦC for 1 min,  54  ͦ for 3 min, 72  ͦC for 1 min and 
72  ͦC for 5 min (the underlined was repeated in 35 cycles). Thus, the PCR-positive colonies 
were first growth in 5ml of SOC medium for 4 hours at and successively in 100ml of SOC 
medium overnight in a 37 ͦC/5% CO2 incubator. The 2600 and 400bp constructs were then 
purified with the plasmid maxi kit (Qiagen, 12965) following the manufacturer's instructions. 
2.6.3. Luciferase Assay System 
Genetic reporters are used commonly in cell biology to study gene expression and other 
cellular events coupled to gene expression, such as mRNA processing. Firefly luciferase was 
used as a reporter because the reporter activity is available immediately upon translation 
and the assay is very sensitive; indeed its light production has the highest quantum 
efficiency known for any chemiluminescent reaction (Gould and Subramani 1988). 
The two luciferase constructs (2600bp and 400bp) described in 2.6.2 were separately 
transfected into cells using electroporation system as described in paragraph 2.6.1. After 24 
hours, the cells seeded in 96-well plates were exposed to normoxia/hypoxia and lysed using 
20µl of 1X lysis buffer from Promega. Cells were left for 10 minutes with lysis buffer and 
then 100µl of Luciferase Assay Reagent™ (Promega, E1500) was dispensed in each well. The 
total 120µl suspensions were transferred in a white 96-well plate (Corning™ 3912) and 
luminescence was measured in the Glomax™ luminometer (Promega, E6501). The 
luminometer was set to perform a 2-second measurement delay followed by 10-second 
measurement read for luciferase activity (peak emission wavelength 560 nm). Renilla 
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luciferase plasmid (peak emission wavelength 480 nm) (Promega, E2810) served as a 
transfection control in all the experiments. 
2.6.4. Network-Based Analysis 
The analysis of interactions between DDAH1 gene sequence and miRNAs was performed 
with the use of consolidated databases of miRNAs such as TargetScan, Diana and miRBASE. 
TargetScan 5.2 (http://www.targetscan.org/vert_50/) predicts biological targets of miRNAs 
by searching for the presence of conserved 8monomer and 7monomer (8mer, 7mer 
respectively) sites that match the seed region of each miRNA, meanwhile DIANA 
(http://diana.cslab.ece.ntua.gr/)  is specifically focused on a positive and a negative set of 
miRNA Recognition Elements (MREs) located in the 3'-UTR. MiRBASE 
(http://www.mirbase.org/) is a searchable database of published miRNA sequences and 
annotation. All the results were confirmed at least on 2 algorithms used for miRNA target 
prediction.  
2.7. Methylarginines and DDAH Assays 
2.7.1. Methylarginines and cGMP Measurement  
HPAECs, HPASMCs and plasma from mice were used for quantification of methylarginines. 
Cell media were harvested and briefly centrifuged to remove unattached cells. Following the 
addition of an internal standard 2,3,3,4,4,5,5-D7-asymmetric dimethylarginine (D7-ADMA, 
10 μmol/L; NovaChem DLM-7476-5) and methanol protein precipitation, the supernatants 
were dried for 1 hour using a vacuum centrifuge and the resultant pellets were re-
suspended in mobile phase (0.1% Formic Acid in H2O). Quantification of ADMA and L-NMMA 
was performed using a reversed-phase high-performance liquid chromatography (HPLC) 
system with an ASI-100 auto sampler, model P680 gradient pump (model RF-2000). Briefly, 
samples were cleaned-up by solid-phase extraction on polymeric cation-exchange extraction 
columns using D7-ADMA as an internal standard. After derivatisation with ortho-
phthaldialdehyde reagent containing 3-mercaptoproprionic acid, analytes were separated 
by isocratic HPLC with fluorescence detection. The chromatography was performed on a 
C18 column (3.9 X 150mm; 5µm particle size; 100Å pore size, Waters) and the mobile phase 
A consisted of 50mM potassium phosphate buffer pH 6.5, containing 8.7% acetonitrile. 
Mobile phase B was 50% acetonitrile in water. Separation was performed under isocratic 
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conditions with 100% mobile phase A at 30 ͦC. After elution, the column was flushed with 
mobile phase B for 22 min in order to remove retained compounds. An injection of 20µl was 
used for each sample and the fluorescence was measured at excitation wavelengths of 340 
nm and emission of 455 nm. Peaks were quantified on the basis of peak area Analytical 
recovery was 98–102%, and the inter-assay coefficient of variation was <3%. (Teerlink, 
Nijveldt et al. 2002).  
For cGMP measurement, at day 0 lung tissue samples were homogenised in cold 6% 
(weight/volume) trichloroacetic acid. After centrifugation, supernatants were washed four 
times with water-saturated diethyl ether. The aqueous extracts were then lyophilized and 
redissolved in the assay buffer. cGMP levels were measured with cGMP Enzyme 
immunoassay Biotrak (EIA) System (GE Healthcare, UK) according to the manufacturer's 
instructions. Briefly, frozen lungs from mice were homogenised in cold 6% trichloroacetic 
acid at 4 ◦C and centrifuged at 2000 x g for 15 minutes at 4◦C. The supernatant was 
recovered and washed 4 times with 5 volumes of water saturated diethyl ether. 
Consequently, the aqueous extract was dried under a stream of nitrogen at 60 ◦C. At day 1, 
the standard curve was prepared and 100µl of each dilute standard was added into the 
appropriate wells, at the same time 100µl of the samples were pipetted into specific wells. 
Subsequently, 100µl of diluted antibody was added into wells and incubated at 4 ◦C 
overnight. At day 2, cGMP conjugate was pipetted into wells and incubated for 3 hours at 4 
◦C.  After, wells were washed 4 times with wash buffer and 200µl of enzyme substrate were 
added into all wells. After 30 minutes incubation the blue color developed in the well was 
read at 630nm using the Glomax luminometer (Promega). The result was calculated using 
the average optical density (OD) for each set of replicate wells. 
2.7.2. DDAH Activity Assay 
After incubation in normoxic/hypoxic conditions, the cells grown in 6-well dishes were 
scraped into 0.5 ml of RIPA buffer (50 mmol/L Tris HCl pH 8, 150 mmol/L NaCl, 1% Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS) and centrifuged at 10000 rpm for 10 minutes to 
pellet cellular debris. 
Lung samples were homogenized in ice-cold sodium phosphate buffer (pH 6.5) and the 
samples were centrifuged at 10,000g for 10 minutes to obtain a supernatant. Crude lysates 
were incubated for 30 min at 37 ͦC on a rotor shaker with 500 µmol/L of DDAH substrate, 
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2,3,3,4,4,5,5-D7-asymmetric dimethylarginine (D7-ADMA). DDAH enzyme activity was 
determined by measuring the formation of D7-citrulline from D7-ADMA. Quantification of 
was performed using a HPLC system with an ASI-100 auto sampler, model P680 gradient 
pump as described in 2.7.1. 50μg of the lysates or lung homogenates were incubated at 
37°C for 1h. One unit of enzyme was determined as the amount of enzyme that catalysed 
the formation of 1 mole of D7-citrulline from D7-ADMA per hour at 37°C. In all the 
experiment the enzyme activity measured at 4°C was considered as background and 
subtracted from the final result. Data were reported as the peak area ratio of D7-ADMA 
to D7-citrulline.  
2.8. Cell Function Assays 
2.8.1. Endothelial Cell permeability 
The effects of hypoxia and DDAH over expression on transendothelial permeability were 
studied using HPAECs grown in Transwell-Clear chambers (Corning Life Sciences).  HPAECs 
were seeded in transwells (3 μm pore size; Corning Life Sciences, 3452) in complete medium 
at cell density of 100,000 cells/well and grown till confluence. HPAECs were used for 
experiments 24 h after infection with AdDDAH1 and/or ADMA addition (100 µM). 
Fluorescein isothiocyanate (FITC)-conjugated dextran (Sigma, 46947 molecular weight 40 
kDa; 1g/L) was added to the upper chamber of Transwells. Passage of FITC-dextran across 
the endothelial layer following 1 hour incubation was determined using a Glomax 
luminometer (Promega) programmed to read fluorescence at excitation wavelength of 485 
nm and emission at 510 nm. 
2.8.2. Cell proliferation  
5-bromo-2’-deoxyurine (BrdU) assay (Millipore, 2750) incorporation was used to assess DNA 
synthesis. BrdU is a thymidine analogue that is incorporated into new synthesised DNA 
during the S phase of the cell cycle.   
HPAEC and HPASMC were seeded into 96 well plates (3000 cells per well) in 100µl/well of 
appropriate cell culture media. In each experiment, some of the wells were set aside as 
controls without cells (blank) and controls without BrdU reagent. 20µl of BrdU (Millipore, 
2752a) were added into the medium 24h before the end of experiment, in order to achieve 
a better sensitivity/noise ratio. After 24 hours exposure to normoxic or hypoxic conditions, 
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cells were fixed using Millipore Fixing Solution (Millipore, 2752b) for 30 minutes and then 
washed  3 times with 1X Millipore Washing Buffer (Millipore, 2752h). Subsequently, the cells 
were incubated for 1h with 100µl/well of pre-diluted Millipore Anti-BrdU Monoclonal 
Antibody (2752c) at room temperature followed by 3 additional washings. Afterwards, cells 
were incubated with 1:2000 diluted Millipore Goat anti-mouse IgG peroxidase conjugate 
(Millipore, 2752e) for 30 minutes at room temperature, as recommended by the 
manufacturer. The cells were then washed 3 x in Millipore Washing Buffer and once with 
DEPC-water (Sigma Aldrich, 95284). After that, 100µl/well of TMB Peroxidase Substrate 
(Millipore, 2752g) were added to each well and incubated in the dark for 30 minutes, 
followed by the addition of 100µl/well of Millipore Acid Stop Solution (Millipore, 2752d). 
Finally, the colorimetric quantification was carried out using 96-well plate reader (Glomax, 
Promega) with a dual wavelength setting of 450/550nm. The level of absorbance at 450nm 
is considered directly proportional to the number of living cells in culture.  In all the 
experiments, the background and blank values were subtracted from the sample values.  
In some experiments, HPAEC were treated with protein kinase G (PKG) inhibitor Rp-8-Br-PET-cGMPS 
(R&D; 0.5 µmol/L) 24h prior to permeability measurement. 
2.8.3. Matrigel tube formation assay 
Angiogenic capacity of cultured cells was studied using the Matrigel™ tube formation assay. 
Matrigel is a solubilised preparation of extracellular matrix protein from Engelbreth-Holm-
Swarm mouse sarcoma cells and is widely used to test the in vitro angiogenic capacity of 
endothelial cells (Arnaoutova and Kleinman 2010).  
Matrigel (Corning™, 354230) was thawed on ice for 4 hours and after 25 µl of ice-cold 
Matrigel was added into each well in a 96 well plate and left at 37°C for 30 minutes to allow 
polymerization.   
Cells, less than 80% confluent, were detached with 0.05% Trypsin-EDTA and resuspended in 
Endothelial Cell Basal Medium 2 (Promo Cell, C-22211) serum-deprived after centrifugation 
at 1500 rpm for 5 min and seeded at 5000 cells/well in triplicate onto Matrigel™. Plates 
were then incubated in a humidified incubator under normoxic or hypoxic conditions. After 
24-48 hours, cells were fixed in 4% formaldehyde (Sigma Aldrich, 252549) in PBS and then 
used for microscopic examination. For each well, 3 phase-contrast images were captured 
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using Olympus IX70 with Peltier CCD camera. The total tubule length was calculated in blind 
using Image J software. 
2.8.4. Apoptosis Assay 
The analysis of cell viability was carried out using the propidium Iodide (PI) staining, 
followed by flow cytometry. PI easily penetrates membranes of non-viable cells, while live 
cells are not stained. PI binds to double stranded DNA by intercalating between base pairs 
and its fluorescence can be measured at excitation 488 nm and emission at 617 nm. 
HPAECs, HPASMCs (1X106cell/well) and the respective media (10ml) were collected in flow 
cytometric tubes (Sarstedt, 55.1578) and briefly centrifuged at 1500rpm for 10 min.  The 
resulting pellet was gently resuspended in 150µl of PBS and 150µl of 2X PI lysis buffer (0.1% 
sodium citrate, 0.1% 100 x Triton and 0.5% PI). After incubation at room temperature for 10 
minutes in the dark, the samples were analysed by flow cytometry using FACSCalibur (BD 
Biosciences) followed by data analysis with CellQuestPro software (BD Biosciences). Arsenic 
trioxide (As2O3), an apoptosis enhancer, was used as a positive control. 
2.8.5. Immunofluorescence and Confocal Microscopy 
HPAECs and HPASMCs (50,000 cells/well) were cultured on 24-well plastic coverslips (Nunc, 
174950) until confluence and subjected to normoxia/hypoxia or infected with adenoviruses. 
After 24-48 hours, cells were fixed with 4% formaldehyde solution in PBS for 20 minutes at 
room temperature and permeabilised for 3 minutes with 0.1% Triton X-100 in PBS. Cells 
were then incubated in 0.5% BSA in PBS for 45 minutes to block non-specific antibody 
binding and incubated with mouse monoclonal anti-VE-cadherin antibody (Santa Cruz 
Biotechnology) at 1:100 dilution for 1 hour. The coverslips were then washed 3 times in PBS 
and incubated with Cy5 goat anti-mouse antibody (Zymed, 81-6516) at 1 µg /ml and 1µg/ml 
TRITC-phalloidin (Sigma Aldrich, P1951) to stain actin filaments for 15 minutes. Coverslips 
were washed 3x in PBS and mounted in Vectashield mountant containing nuclear stain DAPI 
(Vector Laboratories, H-1200). Images of cells were taken under the confocal laser scanning 
fluorescence microscopy (Leica TCS SP5). 
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2.9. In Vivo Studies 
2.9.1. Chronic Hypoxia Studies In Vivo. 
All studies were conducted in accordance with UK Home Office Animals (Scientific 
Procedures) Act 1986 and institutional guidelines. Twelve- to 15-week-old C57BL male mice 
(~20 g; Charles River, Margate, UK) and DDAH1tg male mice (~20 g; Jackson Laboratory, 
Maine, USA) were either housed in normal air or placed in a specially constructed 
environmental chamber and exposed to hypoxia in a normobaric hypoxic chamber 
(FIO2 10%) for 2 weeks (n=6–8/group).  
At 2 weeks, animals were weighed and anesthetized and the development of pulmonary 
hypertension was confirmed measuring RV systolic pressure (RVSP) in the anesthetized 
animals (Hypnorm 0.25 mL/kg; Midazolam 25 mg/kg by intraperitoneal injection) via direct 
cardiac puncture using a closed-chest technique in the spontaneously breathing. The 
animals were then euthanized, the hearts were removed, and the individual ventricular 
chambers were weighed. Right ventricular hypertrophy was assessed as the ratio of right 
ventricle /septum with left ventricle + septum. The right lungs were snap-frozen in liquid 
nitrogen and stored at −80°C for biochemical measurements. The left lungs were fixed by 
inflation with 10% formalin, embedded in paraffin, and sectioned for histology. Transverse 
lung sections were stained with van Gieson’s elastic method or α smooth muscle-actin 
antibody from Sigma Aldrich. Vascular muscularization was defined as the proportion of 
fully and partially muscularised vessels (with immunoreactivity for α smooth muscle-actin as 
evidence for muscularization) on total number of vessels stained with elastin. Two separate 
lung sections from each animal were used for quantification, and counting was performed 
by two investigators blinded to genotypes. 
2.9.2. Treatment of Mice with LNA21 
In order to study the effects of miR-21 inhibition in vivo, C57BL/6 male mice (~20 g; Charles 
River, Margate, UK) were given intraperitoneal (IP) injection of  100 µl of vehicle or 100 µl 
locked nucleic acid anti-miR-21 probes (LNA21) in PBS at 10 mg/kg once every other day for 
a total of 8 times based on (Elmen, Lindow et al. 2008).  At day 1, after the first 
administration of the probes, the mice were exposed to hypoxia for two weeks (n=8/group). 
Following the hypoxic exposure, the mice were phenotyped as described in 2.9.1. In all the 
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in vivo experiments, two separate sections from each animal were quantified, with counting 
performed by two investigators blinded to genotypes. 
2.10. Human study 
Tissue samples were obtained with the informed consent of patients and the approval of 
the Brompton Harefield & NHLI and Hammersmith Hospitals Research Ethics committees. 
Surgical samples of lung tissue were acquired from treatment-naïve PAH patients at lung 
transplantation (n=12). Control tissues (n=12) comprised uninvolved regions of lobectomy 
specimens from patients undergoing surgery for bronchial carcinoma. Patient characteristics 
are shown in Table 1. Tissues were transported on ice, and samples for protein extraction 
were snap-frozen between 0.5 and 4.0 hours before being stored at −80°C until further 
analysis; transport times for both control and PAH samples were similar. Tissue samples 
(excluding large vessels and airways) suitable for RNA analysis were collected from 
peripheral regions of the lung. RNA was extracted from tissue samples using the Trizol 
method (Invitrogen). 1ml of Trizol was used to extract RNA per 100 mg tissue and 
homogenised using in-tube pestles (VWR, Leicestershire, UK). RNA was quantified by 
measurement of absorption at 260 nm in a spectrophotometer to ensure that equal 
amounts of RNA were used in each RT-PCR reaction. RNA concentration was calculated as 
Abs 260nm x dilution factor x 40 / 1000. 2 μg RNA in up to 10μl RNase/DNase-free water 
(Invitrogen) were added to 4μl 5x cDNA synthesis buffer, 1μl 0.1M DTT, 1μl RNaseOUT™, 
and 1μl ThermoScript™ reverse transcriptase (Invitrogen) with 50 ng random hexamers, and 
2μl 10 mmol/L dNTP mix. RT-PCR conditions were as follows: 25˚C for 10 min, followed by 
50 min at 50˚C, terminated at 85ºC for 5 mi 
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              Table 3: Patient characteristics 
Diagnosis Sex Age (years) Disease duration 
(months) 
mPAP 
mmHg 
Vasodilator therapy 
IPAH patients      
IPAH F 41 18 61 naive 
IPAH F 28 42 52 PGI2 tested 
IPAH M 28 14 50 naive 
IPAH F 51 96 60 naive 
IPAH M 48 N/A 70 naive 
IPAH F 10 N/A 64 naive 
IPAH M 42 40 69 naive 
IPAH F 38 N/A N/A N/A 
IPAH F 41 N/A 54 naive 
IPAH F 41 60 58 PGI2 tested 
IPAH F 25 N/A N/A N/A 
IPAH F 28 N/A N/A N/A 
Control subjects      
Ca F 50    
Ca F 61    
Ca M 63    
Ca M 56    
Ca M 59    
Ca M 52    
Ca M 27    
Ca M 67    
Ca F 79    
Ca F 78    
Ca M 55    
Ca F 45    
 
2.11. Data presentation and statistical analysis 
Results are presented in bar charts or scatter plots where appropriate, and error bars 
indicate means with standard deviation error of the mean (SEM), while “n” refers to the 
number of samples per group. All numerical data were tested for normal distribution using 
Pearson normality test (P); specifically, normally distributed data were analysed by unpaired 
t-test. One-way ANOVA was used for data of more than 2 groups, with Bonferroni post-hoc 
analysis performed if P <0.05. Two-way ANOVA was applied for comparing data of multiple 
groups with multiple experimental conditions followed by Bonferroni post-hoc analysis 
performed if P <0.05. Statistical significance was regarded as P <0.05 for all presented data. 
All graphs and calculation were performed with GraphPad Prism6 (GraphPad Software Inc). 
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Diagram: Schematic diagram of experimental design process.  
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3. The Effects of Hypoxia on DDAH Expression and ADMA Metabolism 
in Pulmonary Vascular Cells 
3.1. Introduction 
Dysregulation of ADMA metabolism has been implicated in the development and 
progression of hypoxia- associated chronic respiratory diseases (Millatt, Whitley et al. 2003). 
The effects of hypoxia on pulmonary vascular cells and the underlying molecular 
mechanisms are not completely understood. Hypoxia can be considered as a cause for 
vascular changes or as a consequence of chronic respiratory diseases, in either case hypoxia 
plays a pivotal role in the regulation of the ADMA/NO pathway. 
Elevated concentrations of intracellular ADMA may result from increased methylation of 
arginine residues in proteins or decreased metabolism of ADMA. ADMA and L-NMMA are 
actively metabolized to L-citrulline and methylamines by the action of DDAH enzymes 
(Ogawa, Kimoto et al. 1989).  
Two human DDAH isoforms (DDAH 1 and 2) have been identified (Leiper, Maria et al. 1999) 
but their individual contributions to ADMA metabolism in vascular cells are not completely 
understood. 
In this chapter we studied the effects of hypoxia on DDAH1 and DDAH2 gene and protein 
expression and DDAH activity in human pulmonary artery endothelial cells (HPAECs) and 
human pulmonary artery smooth muscle cells (HPASMCs).  
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3.2. Results 
3.2.1. Hypoxia Decreases DDAH mRNA and Protein Expression in vitro 
Chronic hypoxia reduces NO signalling and DDAH expression in the lung (Dayoub, Achan et 
al. 2003; Millatt, Whitley et al. 2003; Smith, Birdsey et al. 2003) but mechanisms are not well 
understood. The purpose of the experiments described in this section was to investigate the 
effects of hypoxia on DDAH1 and DDAH2 mRNA, protein expression and activity in cultured 
human pulmonary artery endothelial cells (HPAECs) and human pulmonary artery smooth 
muscle cells (HPASMCs).  
Hypoxia (1-48 hours) led to a 3-fold decrease in DDAH1 and DDAH2 mRNA levels in HPAECs, 
with a maximal reduction at 2 hours of hypoxic exposure (figure 11 A and B). DDAH1 mRNA 
levels were unaffected by hypoxia in HPASMCs, while DDAH2 mRNA was reduced by 2-fold 
following 4 hours hypoxia (figure 11 C, D). Consistent with  the changes in the mRNA levels, 
DDAH1 and DDAH2 protein levels were both significantly reduced by hypoxia in HPAECs 
(figure 12 A and B), whereas in HPASMCs only DDAH2 protein levels were reduced (figure 12 
C and D). 
 
In summary, these results show that hypoxia selectively downregulates DDAH1 expression 
in pulmonary endothelial cells, while DDAH2 expression is reduced in both pulmonary 
endothelial and smooth muscle cells.  
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Figure 11: The effect of hypoxia (1-48hr) on DDAH1 and DDAH2 mRNA expression in HPAECs and 
HPASMCs. (A) and (B) show gene expression of DDAH1 and DDAH2 in HPAECs while (C) and (D) show 
gene expression of DDAH1 and DDAH2 in HPASMCs, as indicated. Results are normalized to the 
expression levels of the housekeeping gene TATA Binding Protein (TBP). ***P<0.0001; *P<0.05 
(comparison with normoxic controls); n= 8. 
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Figure 12: The effects of hypoxia on DDAH1 and DDAH2 protein expression in HPAECs and 
HPASMCs. (A) DDAH1 and (B) DDAH2 protein expression in HPAECs; (C) DDAH1 and (D) DDAH2 
protein expression in HPASMCs. Representative examples of western blots are shown underneath 
the graphs. Comparison with normoxic controls; ***P<0.0001; **P<0.001; *P<0.05; n=8. 
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3.2.2. Hypoxia decreases ADMA Metabolism via inhibition of DDAH1 activity in 
HPAECs.  
Changes in DDAH activity have a major impact on ADMA metabolism and thus ADMA levels 
(Sibal, Agarwal et al. 2010). In order to study the metabolism of methylarginines during 
hypoxia, ADMA, L-NMMA and SDMA were extracted from culture media of normoxic or 
hypoxic HPAECs or HPASMCs and their levels were measured using liquid chromatography 
mass spectrometry (LC-MS), as described in materials and methods 2.7.1. The levels of 
methylarginines in the media of hypoxic cells were compared with normoxic controls.  
As shown in figure 13 A-D, L-NMMA and SDMA levels were not significantly affected by 
hypoxia in either HPAECs or HPASMCs.  
Consistent with the reduced DDAH expression in HPAECs, the concentration of ADMA in 
HPAEC culture media increased by 2 and 3-fold respectively after 24 and 48 hours of hypoxic 
exposure (figure 14 A). In contrast, ADMA levels in HPASMC culture media were unaffected 
by hypoxia (figure 14 B). Taken together, our experiments suggest that hypoxia selectively 
affects ADMA metabolism in endothelial cells.  
DDAH activity was measured directly using labelled D7 ADMA as a substrate for DDAH 
enzymes and measuring the levels of D7 L-citrulline, which is a product of ADMA 
metabolism. As can be seen in figure 14 C, DDAH activity showed a 5-fold decrease (P< 
0.0001) following hypoxic exposure in HPAECs, while DDAH activity in HPASMCs was 
unaffected (figure 14 D).  
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Figure 13: Methylarginine levels in HPAECs and HPASMCs following hypoxic exposure. L-NMMA 
and SDMA levels were measured using liquid chromatography mass spectrometry (LC-MS). L-
NMMA levels (a, b) and SDMA levels (c, d) in normoxic and hypoxic HPAECs and HPASMCs are 
shown, as indicated. Comparison with normoxic controls; n=8. 
84 
  
 
 
Figure 14: Hypoxia-induced changes in DDAH activity. ADMAs levels were measured using liquid 
chromatography mass spectrometry (LC-MS). The levels of ADMA in cell media increased 3-fold in HPAECs 
during 48 hours of hypoxic exposure (A), while no significant changes were observed in HPASCMs (B).   
DDAH activity was measured directly, by using labelled D7 ADMA as a substrate for DDAH enzymes and 
measuring the levels of D7 L-citrulline, which is a product of ADMA metabolism. A 2.5-fold decrease in DDAH 
activity was observed in hypoxic HPAECs (C), while HPASMCs did not show significant changes in DDAH 
activity (D). ***P<0.0001; *P<0.05; n=6 
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To further verify the role of DDAH expression in hypoxia-induced ADMA metabolism, 
DDAH1, DDAH2 and inactive DDAH (ΔDDAH) mutants were over expressed in HPAECs using 
adenoviral gene transfer. ΔDDAH1 and ΔDDAH2 have a Cys249Ser mutation in their active 
site, which inactivates the enzyme without affecting protein folding (Wojciak-Stothard, 
Torondel et al. 2007). DDAH overexpression was confirmed by Western blot and EGFP was 
used as adenoviral control in all the experiments. The multiplicity of infection (MOI) and 
expression time were established experimentally to induce a physiological (~3-fold) increase 
in DDAH expression (figure 15 C and D).  
DDAH1 overexpression reduced ADMA levels by 1.3-fold (P<0.001) in HPAECs exposed to 24 
hour hypoxia, while DDAH2 or inactive DDAH mutants had no effect (figure 15A, B).   
In contrast, ADMA levels in HPASMCs were not significantly affected by overexpression of 
DDAH1. Although a decreasing tendency in ADMA levels was observed, it is possible that 
due to the low basal levels of ADMA in HPASMCs, the changes induced by DDAH1 were too 
small to render significance.  
Taken together, these results may help clarify the ambiguity regarding the role DDAH 
enzymes in ADMA metabolism in pulmonary vascular cells. The fact that hypoxia-induced 
increase in ADMA levels was prevented by overexpression of DDAH1 and not DDAH2, argues 
for the predominant role of DDAH1 in ADMA metabolism.  
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Figure 15: ADMA levels in culture media of (A) HPAECs and (B) HPASMCs over expressing 
AdGFP (control), AdDDAH1, AdDDAH2, AdΔDDAH1 and AdΔDDAH2, as indicated.  The 
graphs in (C) and (D) show DDAH1 and DDAH2 expression levels following infection of 
HPAECs with AdDDAH1-2 and inactive mutants, AdΔDDAH1 and AdΔDDAH2 with a 
representative Western blot below the graph. **P<0.001, comparison with adenoviral 
controls (AdGFP); n= 6. 
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3.2.3. Hypoxia decreases DDAH mRNA stability in HPAECs  
I have established that hypoxia downregulates DDAH1 and DDAH2 mRNA and protein 
expression in HPAECs and that only DDAH1 is involved in the regulation of hypoxia-induced 
changes in ADMA metabolism in cultured pulmonary vascular cells. In the next series of 
experiments, I investigated the mechanism of hypoxia-induced downregulation of DDAH 
mRNA.   
Changes in DDAH mRNA levels may result from changes in mRNA stability; indeed hypoxia 
has been shown to affect mRNA synthesis and stability (Levy, Chung et al. 1998) (Paulding 
and Czyzyk-Krzeska 2000). 
In order to study mRNA stability, the half-life (t1/2) of DDAH1 and DDAH2 mRNA was 
measured in HPAECs and HPASMCs cultured in hypoxic and normoxic conditions. After the 
addition of mRNA synthesis inhibitor, actinomycin D to the cells, mRNA levels were studied 
by qRT-PCR, as described in material and methods 2.3.  
The half-life of DDAH1 mRNA in HPAECs was reduced during hypoxia when compared to 
normoxic conditions (figure 16 A), (N t1/2 = 1.5h ± 5 versus H t1/2= 1h ± 5 min; P < 0.001), 
while no significant reduction was observed in HPASMCs (N t1/2= 1.35h ± 4 min; H t1/2= 1.1h 
± 7 min) (figure 16 B).  Consistent with changes in mRNA levels, DDAH2 mRNA half-life was 
reduced by hypoxia in both HPAECs (N t1/2= 2h ± 7 min; H t1/2 = 0.7 h ± 5min) and HPASMCs 
(N t1/2= 0.8h ± 5 min; H t1/2= 0.2h ± 8 min) (figure 16 C, D). The half-life of VEGF mRNA 
(serving as a positive control) increased, as expected (Levy, Chung et al. 1998), from 0.4h ± 2 
min in normoxia to 2h ± 3 min in hypoxia. 
In summary, these experiments demonstrated for the first time that the decrease in DDAH 
mRNA and protein expression in hypoxic pulmonary vascular cells could be caused by a 
decrease in DDAH mRNA stability.   
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Figure 16: Hypoxia plays a key role in the regulation of DDAH mRNA stability. HPAECs and HPASMCs were 
pre-incubated with actinomycin D (5.0 mg/ml) and exposed to hypoxia (2% O2) for different time intervals 
(0 – 2.5 hours). The cells were harvested at designated time points, and total RNA was isolated and reverse 
transcribed. The fold change in DDAH mRNA expression was measured by real-time PCR and is represented 
as percentage decrease in mRNA levels compared to the untreated samples. Results are representative of 
the three independent experiments with all readings repeated in triplicate. The half-life of DDAH1 mRNA 
was reduced during hypoxia when compared to normoxic conditions in HPAECs (Figure A), (Nt1/2 = 98 ± 5 
min; H t1/2 = 60 ± 5 min) but not in HPASMCs (B) (Nt1/2 = 79 ± 4 min; H t1/2 = 65 ± 5 min).  DDAH2 half-life 
was reduced by hypoxia in both HPAECs (C) (Nt1/2 = 120 ± 7 min; H t1/2 = 60 ± 5min) and HPASMCs (D) 
(Nt1/2 = 70 ± 5 min; H t1/2 = 25 ± 8 min); (E) VEGF was used as positive control for hypoxic conditions 
(Nt1/2 = 0.4 ± 3 min; H t1/2 = 2 ± 1 min). 
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3.3. Discussion 
In this chapter we have described the effects of hypoxia on gene and protein expression of 
DDAH isoforms and ADMA metabolism in pulmonary vascular cells. The key findings are 
summarised in the following points:  
 
1. Hypoxia downregulates mRNA and protein expression of DDAH1 and DDAH2 in 
endothelial cells. 
2. In smooth muscle cells, only DDAH2 mRNA and protein expression is downregulated 
by hypoxia. 
3. Hypoxia decreases ADMA metabolism via inhibition of DDAH1 activity in endothelial 
cells. 
4. DDAH1 overexpression reduces ADMA levels in endothelial cells. 
5. Hypoxia decreases DDAH1 and DDAH2 half-life in endothelial cells but only DDAH2 
half-life is reduced by hypoxia in smooth muscle cells. 
 
Dysregulation of the ADMA/NO pathway plays a pivotal role in the development of hypoxia- 
associated respiratory diseases (Liu, Wang et al. 1998; Pullamsetti, Savai et al. 2011), but the 
underlying molecular mechanisms remain unclear. 
Both DDAH isoforms are expressed in the vasculature; early studies demonstrated that the 
pharmacological inhibition of DDAH increases cellular concentrations of ADMA, contributing 
to NO deficiency and vascular contraction (MacAllister, Parry et al. 1996).  
Contrasting findings have been reported regarding the role of DDAH1 and DDAH2 in the 
metabolism of ADMA. In fact, it has been shown that DDAH1 is required for metabolizing 
ADMA and L-NMMA in vivo, while DDAH2 had no detectable role for degrading ADMA and 
L-NMMA (Hu, Atzler et al. 2011). Genetic mutation studies showed detrimental effects of 
altered DDAH function in human diseases (Ding, Wu et al. 2010). Indeed, a loss of function 
mutation in DDAH1 gene promoter identified in the Chinese Han population is associated 
with a reduced DDAH1 mRNA expression, raised plasma ADMA and significantly increased 
risk heart disease (Ding, Wu et al. 2010). Furthermore, a study of 1300 middle-aged Finnish 
men identified a mutation in DDAH1 gene linked to elevated plasma ADMA levels, increased 
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risk of developing hypertension and coronary heart disease (5-fold and 50-fold increase, 
respectively)(Valkonen, Paiva et al. 2001).  
Han et al observed that after 48 h of hypoxia exposure (1% O2) human lung microvascular 
endothelial cells showed a decrease of DDAH1 expression that led to an increase in ADMA 
levels and consequently, a decrease in NO production, while DDAH2 was undetectable in 
the cell type used (Han, Pope et al. 2009). Moreover, in vivo experiment performed using 
hypoxic rats (1 week exposure) showed that DDAH1 protein was strongly expressed in the 
lungs of normoxia-exposed animals and that its expression was significantly decreased in 
the lungs of hypoxia-exposed animals (Millatt, Whitley et al. 2003).  
Conversely, an in vitro study by Pope et al supported the role of DDAH2 as a major enzyme 
in ADMA metabolism (Pope, Karrupiah et al. 2009). In this study performed using bovine 
aortic endothelial cells (BAECs), the authors observed that the overexpression of DDAH2 can 
improve endothelium-dependent vasorelaxation and increases NO synthesis, whereas small 
interfering RNA knockdown of DDAH2 reduces NO synthesis (Pope, Karrupiah et al. 2009).  
Additionally, it has been reported that DDAH2 overexpression can prevent endothelial 
dysfunction and cardiovascular diseases associated with hyperhomocysteinemia (Liu, Guo et 
al. 2012).   
In order to clarify the contrasting findings regarding the role of DDAH1 and DDAH2 in the 
metabolism of methylarginines, ADMA levels and DDAH activity were quantified in 
pulmonary vascular cells. We showed that hypoxia increases ADMA levels by reducing 
DDAH1 expression in human pulmonary artery endothelial cells but not in human 
pulmonary artery smooth muscle cells. In agreement with the hypothesized major role of 
DDAH1 in control of ADMA metabolism (Hu, Xu et al. 2009), overexpression of DDAH1 but 
not DDAH2 had a major impact on ADMA levels in hypoxic endothelial cells. This differential 
effect is somewhat surprising because both DDAH isoforms are capable of metabolising 
ADMA in cultured normoxic cells. It is possible that the activity of DDAH2 is suppressed in 
hypoxic conditions and the mechanism of this response will require further studies. 
To further investigate the mechanism of hypoxia-induced effects on DDAH1 and DDAH2 
expression,  the half-life (t1/2) of DDAH1 and DDAH2 mRNA was measured in normoxic and 
hypoxic cells in which transcription had been blocked by the action of actinomycin D, using 
qRT-PCR (Levy, Chung et al. 1998).  
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It is estimated that 1.5% of the human genome is transcriptionally responsive to hypoxia 
(Denko, Fontana et al. 2003). The best studied transcription factor induced in hypoxic cells is 
HIF-1, which controls more than 100 downstream genes involved in diverse cellular 
processes (Manalo, Rowan et al. 2005). Hypoxia is also able to regulate the stability of 
several mRNAs using different mechanisms. For example, it has been reported that hypoxia 
can downregulate IL-7 mRNA expression in vitro in a calcium-dependent manner (Lu, Clark 
et al. 2009), and VEGF in vitro (Shweiki, Itin et al. 1992; Goldberg and Schneider 1994; Levy, 
Levy et al. 1995; Levy, Levy et al. 1996) and in vivo (Sharma, Wunsch et al. 1992; Aiello, 
Avery et al. 1994). The key control point for the hypoxic induction of the VEGF gene is the 
regulation of the steady-state level of mRNA (Levy, Levy et al. 1995), which is determined by 
the relative rates of mRNA synthesis and decay. Post-transcriptional mechanisms of 
regulation have previously been suggested for erythropoietin mRNA (Goldberg, Gaut et al. 
1991; Rondon, MacMillan et al. 1991) and demonstrated for tyrosine hydroxylase 
(Czyzykrzeska, Dominski et al. 1994), two other hypoxia-inducible genes.  
 
In the present study we examined post-transcriptional regulation of DDAH1 and DDAH2 
mRNA expression under both normoxic and hypoxic conditions showing for the first time 
that hypoxia causes DDAH1 and DDAH2 mRNA instability in endothelial cells. The 
mechanism of this endothelium-specific regulation will be discussed in detail in the next 
chapter.  
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4. Regulation of DDAH mRNA Stability during Hypoxia  
4.1. Introduction 
Messenger RNA (mRNA) is transcribed as a complementary copy of DNA, which can 
subsequently be translated into an amino acid chain. Synthesised in the nucleus by RNA 
polymerases, the mRNA travels to the cytoplasm for translation where can eventually be 
degraded by nucleases. When these two events occur at a constant rate, they give rise to a 
steady-state mRNA population for each unique transcript (Ross 1995). Since the mRNA is 
constantly being degraded in the cytoplasm, it has to be synthesized by the cell at a much 
higher rate than is needed for the maintenance of a steady amount (Wilusz, Wormington et 
al. 2001). Messenger RNA steady amount often changes in response to a stimulus, thereby 
rapidly increasing or decreasing mRNA abundance to satisfy the cell needs for specific 
proteins. Several RNA-binding proteins and noncoding RNAs can bind to mRNA and control 
its stability (Storz, Opdyke et al. 2004; Glisovic, Bachorik et al. 2008). Three major pathways 
are involved in the regulation of mRNA stability, with the deadenylation-dependent mRNA 
decay considered the main pathway in mammalian cells (Goldstrohm and Wickens 2008).  
The process is driven by a combination of three deadenylases that perform the poly(A) tail 
removal, which results in the degradation of the mRNA. Another way of regulating mRNA 
stability involves the family AU-rich elements (AREs) located within the 3’UTR of many 
mRNAs (Shaw and Kamen 1986). AREs are sequence elements of 50–150nt that are rich in 
adenosine and uridine bases and located in the 3′-UTRs of many mRNAs that have a short 
half-life. ARE sequences have been identified by their capacity to cause mRNA degradation 
by a mechanism dependent on the shortening of the poly(A) tail (Shaw and Kamen 1986; 
Wilson and Brewer 1999). 
MicroRNAs (microRNAs) also regulate mRNA stability by interacting with their target 
consensus sequence on the 3’-UTRs.  These 21–25-nt RNAs comprise about 3% of all human 
genes and regulate gene expression by controlling translation and mRNA degradation 
(Huntzinger and Izaurralde 2011). The 3'-UTR contains microRNA response elements (MRE) 
and the binding between microRNAs and MRE sequences within the 3'-UTR, can cause 
translational repression or degradation of the mRNA transcripts (Jackson 1993).  
 
93 
  
 
Hypoxia alters the expression of numerous miRs in various cell types (Huang, Ding et al. 
2009; Ali, Mah et al. 2012; Mace, Collins et al. 2013). We have studied the DDAH 3’-UTR in 
order to identify the mechanism controlling DDAH mRNA stability under hypoxic conditions. 
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4.2. Results 
4.2.1. The DDAH1 3’ Untranslated Region Regulates DDAH1 Gene Expression in 
HPAECs 
In order to identify the mechanisms controlling the DDAH1 mRNA stability, the 3′-UTR of 
DDAH1 was sub-cloned as a whole (≈3000nts) or as two shorter fragments of ≈2600nt  and 
≈400nt  downstream the luciferase gene as described in 2.6.2 (figure 17).   
 
 
 
 
 
 
 
 
Figure 17: Luciferase Reporter Assay System with 3′UTR of DDAH1 mRNA.  Regulated by the SV40 promoter, 
the luciferase reporter vector contains the 3′UTR of DDAH1 mRNA downstream of the firefly luciferase gene 
(Luciferase in yellow) and the poly A tail. Restriction enzymes EcoRI and FseI were used to reduce the length 
of the 3’UTR from 3000 nt to approximately 400 nt and 2600 nt 
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To determine the role of the DDAH1 3’UTR in the regulation of its mRNA, HPAECs and 
HPASMCs were transfected with luciferase gene reporter constructs containing the whole 
3000nt DDAH1 3’UTR, the 2600nt and  400nt  fragments of DDAH1 3’UTR. No significant 
changes in luciferase activity were detected in hypoxic HPASMCs transfected with the whole 
DDAH1 3’-UTR (figure 18 A). By contrast, hypoxic exposure of HPAECs transfected with the 
whole DDAH1 3’-UTR construct resulted in a 2-fold reduction in luciferase activity (***P< 
0.0001) (figure 18 B), indicating that hypoxia-induced regulation of DDAH 3’UTR may be cell-
type specific. The same effect was observed when the cells were transfected with the 
reporter construct containing 400nt fragment of DDAH1 3’UTR (figure 18 C), (2-fold 
reduction in luciferase activity, ***P< 0.0001, comparison with normoxic controls), while 
the 2600nt construct luciferase activity was not affected by hypoxia. These results indicated 
that the first 400 nucleotides of the DDAH1 3’UTR are essential for the downregulation of 
DDAH1 mRNA in endothelial cells. 
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Figure 18: The DDAH1 3′-UTR is regulated by hypoxia. (A) HPASMCs and (B) HPAECs were transfected with 
Luciferase 3’UTR DDAH1 reporter plasmid. In C, HPAECs were transfected with luciferase reporter construct 
containing 3000 nt, 2600 nt and 400nt fragments of DDAH1 3’UTR. Decrease in luciferase activity in hypoxic 
HPAECs transfected with 400 nt construct indicates that the regulation occurs on the first 400nt of DDAH1 
3’UTR. Each graph represents values from 4 independent experiments performed in quadruplicates. Renilla 
Luciferase was used as control in all the experiments; ***P<0.0001 comparison with normoxic control as 
indicated; n=4 
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4.2.2. MiR-21 Directly Targets the 3’-UTR of DDAH1 and Represses its Expression 
in HPAECs 
In order to identify potential microRNA candidates (miRs) that can bind to the first 400nts 
3′-UTR of the DDAH1 sequence and downregulate DDAH1 mRNA, three commonly utilised 
algorithms (DIANA, Target Scan and microRNA) were used. A total of 13 miRs were 
predicted to target DDAH1 3’-UTR (figure 19). Among the 13 predicted miR candidates, only 
2 showed links to hypoxia signalling and pulmonary hypertension, miR-21 and miR-128 
(Yang, Banerjee et al. 2012; Rhodes, Wharton et al. 2013) and therefore were chosen for 
further analysis. 
 
 
 
Figure 19: Predicted microRNA target sites on the 400 nt fragment of 3′UTR of DDAH1 mRNA. MiR target 
sites were identified with programs MicroRNA, Target Scan and DIANA lab software. MiR-21 was aligned to 
position 344–364 on the 3′UTR of DDAH1 mRNA with a PhastCons score of 0.5085, while miR-128 was 
aligned to position 83-106 with a PhastCons score of 0.7177. The sequence is adapted from Microrna.org 
website (http://www.microrna.org/microrna/getMrna.do?gene=23576&utr =20215&organism=9606). 
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To verify the role of miR-21 and miR-128 in the regulation of DDAH1 3’UTR and DDAH1 
mRNA levels, HPAECs and HPASMCs were transfected with the microRNA precursors (~33 
nt) pre-miR-128 and pre-miR-21 expression plasmids. Subsequently, mRNA expression levels 
of DDAH1 and DDAH2 were analysed. As shown in figure 20 A, the overexpression of miR-21 
reduced DDAH1 mRNA  in HPAECs, and  HPASMCs, while miR-128 did not show any 
significant effects on DDAH1 expression in either endothelial or smooth muscle cells (figure 
20 A and C). In addition, to assure that the inhibition observed was due to site-specific 
microRNA-3’UTR interaction, DDAH2 mRNA expression was also investigated. As expected, 
due the lack of consensus sequences for these microRNAs on DDAH2 3’-UTR, the 
overexpression of miR-128 or miR-21 did not have any significant effect on mRNA levels of 
DDAH2 (figure 20 B and D).   
To further study the mechanism of endothelium-specific inhibition of DDAH1 in hypoxia, 
miR-21 expression levels were measured in normoxic and in hypoxic (24 hours) HPAECs and 
HPASMCs.  As shown in figure 20 E, a 3-fold increase in endogenous miR-21 was observed in 
hypoxic HPAECs, while in hypoxic HPASMCs the increase was too small to render 
significance.   
The endothelial-specific effects of miR-21 on DDAH1 expression were also confirmed by 
measuring DDAH1 protein levels. MiR-128 overexpression did not affect DDAH1 protein 
levels, while miR-21 overexpression significantly reduced DDAH1 protein levels in HPAECs. 
The role of miR-21 in the regulation of DDAH1 expression was further verified with the use 
of miR-21 knockdown probes.  
Locked nucleic acid (LNA, Exiqon) anti-microRNA probes bind to specific microRNAs forming 
heteroduplexes, thereby sequestering and preventing the microRNA from binding to the 3′ 
UTR of its target mRNAs (Jensen, Lamy et al. 2011). As shown in figure 21 B, co-transfection 
of  LNA21 with the 400nt DDAH1 3’UTR luciferase plasmid prevented hypoxia-induced  
degradation of DDAH1 3’-UTR, while co-transfection of LNA128 had no effect.  
Taken together, these results show that the hypoxia-induced, endothelium-specific increase 
in miR-21 is required for the downregulation of DDAH1 expression. MiR-21 inhibits DDAH1 
expression by regulating the 3'-UTR of DDAH1 mRNA and this downregulation can be 
prevented by miR-21 inhibitors.  
99 
  
 
 
Figure 20: The effect of miR-21 and miR-128 overexpression on DDAH1 and DDAH2 mRNA levels in HPAECs 
and HPASMCs. Overexpression of miR-21 inhibits DDAH1 expression in HPAECs (A), and in HPASMCs (C). (B 
and D), miR-21 and miR128 have no effect on DDAH2 expression in HPAECs or HPASMCs, respectively; (E) 
miR-21 levels are increased by hypoxia in HPAECs but not in HPASMCs. NT: untreated controls; EGFP: 
transfection control; p-miR21: cells overexpressing miR-21; p-miR128: cells overexpressing miR-128. In (A-D) 
cells were kept in normoxic conditions, in (E) cells were cultured in normoxia or were exposed to hypoxia for 
24 hours. N=5. ***P<0.0001; **P<0.001, comparison with no transfected cells or normoxic controls as 
indicated. 
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Figure 21: The role of miR21 and miR128 in the regulation of DDAH1 expression in HPAECs. (A) 
Overexpression of miR-21 mimics the effect of hypoxia on DDAH1 protein expression, while miR-128 has no 
effect. MiR-21 and miR-128 were overexpressed in normoxic HPAECs using shuttle plasmids (p-miR-21 and 
p-miR-128). (B) Lock nucleic acid (LNA) probes against miR-21 (LNA21) repress the effects of hypoxia on 
DDAH1 3’UTR, while LNA128 has no effect. The luciferase reporter vector containing 400nt fragment of 
DDAH1 3’ UTR was co-transfected into HPAECs with 10 nmol of lock nucleic acid against miR-21 or miR-128 
(LNA21 and LNA128). N=5; ***P<0.0001; **P<0.001, comparison with transfection controls or as indicated.   
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4.3. Discussion 
The results described in this chapter can be summarised as follows:  
1. Hypoxia downregulates DDAH1 expression by acting on the 3’-UTR of DDAH1 mRNA. 
2. The first 400nt of DDAH1 3’-UTR confer the effects of hypoxia on DDAH1 mRNA 
stability.  
3. MiR-21 regulates DDAH1 mRNA stability in HPAECs 
4. Hypoxia triggers the endothelial cell-specific increase of miR-21 expression  
5. The competitive inhibition of miR-21 protects against hypoxia-induced 
downregulation of DDAH1 
 
Regulation of protein expression under hypoxic conditions may involve various 
transcriptional and post-transcriptional mechanisms (Levy, Levy et al. 1996; Paulding and 
Czyzyk-Krzeska 2000; Bail, Swerdel et al. 2010). However, the absence of AREs sequences on 
the 3’-UTR of DDAH1 and the large amount of data present in the literature regarding miRs, 
led our study to focus on miR-mediated control of DDAH mRNA stability. 
The 3’ untranslated region has been shown to play a major role in the regulation of mRNA 
turnover (Benjamin and Moroni 2007; Bail, Swerdel et al. 2010; Fabian, Sonenberg et al. 
2010; Yamakuchi 2012). The mRNA turnover rate can be determined by the interaction 
between miRs and consensus sequences located within the 3’-UTR of the target mRNA. 
MiRs regulate normal cell and tissue function but their dysregulation contributes to 
development of various diseases, including cancer, diabetes, hypertension, or 
atherosclerosis (Sassen, Miska et al. 2008; Kantharidis, Wang et al. 2011; Batkai and Thum 
2012; Yamakuchi 2012). MiRs profiling and pathway analysis has led to the identification of 
disease-specific changes in single miRs or miR clusters linked to pathological changes 
observed during disease development (Ikeda, Kong et al. 2007). 
The analysis of the DDAH1 3’-UTR showed that the first 400nt confer the effects of hypoxia 
on DDAH mRNA stability. Using three algorithms (DIANA, Target Scan and microRNA), a total 
of 13 microRNAs were predicted to target DDAH1 3’-UTR within this region. We focused our 
study on 2 microRNA candidates with previously reported links to hypoxia and pulmonary 
hypertension, miR-128 and miR-21 (Rhodes, Wharton et al. 2013; Yang, Banerjee et al. 
2012). Limited studies regarding miR-128 have been shown. Indeed, it has been 
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demonstrated that miR-128 may play a critical role in human cell lung cancer 
tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular 
endothelial growth factor C (Hu, Cheng et al. 2014). In addition, miR-128 levels were found 
increased in plasma of PAH patients, but its regulatory effects have not been characterised 
(Rhodes, Wharton et al. 2013).  By contrast, miR-21 is one of the most studied microRNAs in 
cardiovascular diseases (Cheng and Zhang 2010).  In fact, it has been shown that expression 
of miR-21 in human hearts from patients with heart failure was much higher than that in 
normal human control hearts (Thum, Galuppo et al. 2007) and that miR-21 contributes to 
myocardial disease by stimulating MAP kinase signalling (Thum, Gross et al. 2008). In the 
arteries of rats with neointimal growth after angioplasty, miR-21 expression showed more 
than a fivefold increase, compared with normal control vessels (Ji, Cheng et al. 2007). 
Relevant to our investigation, Fleissner et al observed that patients with coronary disease 
show elevated levels of ADMA and miR-21. In this study miR-21 overexpression significantly 
repressed superoxide dismutase 2 (SOD2) in angiogenic progenitor cells (APCs), which 
resulted in increased intracellular reactive oxygen species concentration and impaired nitric 
oxide bioavailability. Therefore, the authors hypothesized that miR-21 inhibition can reduce 
ADMA-mediated oxidative stress and improve APCs functions (Fleissner, Jazbutyte et al. 
2010). 
Interestingly, a recent study has shown that the downregulation of DDAH1 expression 
occurs via miR-21-dependent mechanism in human umbilical venous endothelial cells 
(HUVECs)(Chen, Zhou et al. 2013). Chen et al in this study observed that 4-hydroxynonenal 
(4-HNE), a major active product formed by lipid peroxidation, can dysregulate intracellular 
ADMA through a miR-21 dependent pathway. However, the authors showed that miR-21 
inhibition only partially inhibited ADMA metabolism by DDAH1, indicating that miR-21-
independent mechanisms are also involved in the regulation of ADMA metabolism under 4-
HNE exposure (Chen, Zhou et al. 2013). Curiously, in this study the overexpression of miR-21 
also led to a decrease of DDAH2 expression despite the fact that DDAH2 3’-UTR has not miR-
21 recognition site. The downregulation of DDAH2 by miR-21 observed in this study could 
be explained by the fact that DDAH2 expression is ROS sensitive (Wang, Hu et al. 2009), 
while miR-21 can regulate ROS formation by attenuating superoxide dismutase 2 and 3 
(SOD2 and SOD3) (Fleissner, Jazbutyte et al. 2010; Zhang, Ng et al. 2012).  Although the 
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authors suggested a possible regulation of DDAH1 and DDAH2 by miR-21 and ROS-
dependent pathways, the exact mechanisms involved remain unclear.  
Another study involving a network biology approach combined with experimental data in 
cultured cells, animal models, and diseased human tissue recognised miR-21 as an 
important regulatory factor that controls the downstream development of PH (Parikh, Jin et 
al. 2012). In this bioinformatics-based study the authors showed a molecular model of the 
pulmonary vasculature where hypoxia, inflammation and BMP-dependent signalling can up-
regulate miR-21.  In response, miR-21 can downregulate other genes involved in PH, such as 
RhoB and BMPR2. RhoB has been shown to suppress angiogenesis (Sabatel, Malvaux et al. 
2011) and induce a vasoconstriction by activation of endothelin-1 (Hernandez-Perera, Perez-
Sala et al. 2000) and inhibition of eNOS (Laufs and Liao 1998). Thus, RhoB modulation may 
reflect a key function of miR-21 in PH. Regarding BMPR2 it has been observed that miR-21 
can be up-regulated by hypoxia and BMPR2 signaling, linking in this way miR-21 with two 
major pathogenic triggers of PH, hypoxia and BMPR2-dependent signaling (Parikh, Jin et al. 
2012).   
 
In summary, although the modulation of miR-21 targets may differ depending on the 
biological context, we showed that changes in ADMA metabolism induced by hypoxia can be 
mediated by the endothelium-specific downregulation of DDAH1 by miR-21. 
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5. The Role of DDAH-ADMA pathway in Hypoxia-Induced Vascular 
Dysfunction 
5.1. Introduction 
Endothelial dysfunction manifested by an imbalance in the levels of vasodilators and 
vasoconstrictors and the breakdown of endothelial barrier function is thought to play a 
critical role in the pathogenesis of PH (Budhiraja, Tuder et al. 2004).  We hypothesized that 
hypoxia-induced endothelial dysfunction may result, at least in part, from inhibition of 
DDAH expression and activity.  
We have established so far that hypoxia induces endothelium-specific downregulation of 
DDAH1 expression via miR-21 overexpression, resulting in an inhibition of ADMA 
metabolism and increase in ADMA levels. In order to investigate functional implications of 
hypoxia-induced decrease in ADMA metabolism, we studied cell death, proliferation, 
endothelial junctional organization, permeability and angiogenesis in pulmonary endothelial 
cells overexpressing DDAH1, DDAH2 and their inactive DDAH mutants. Pharmacological 
inhibition of DDAH1 activity was achieved by treating the cells with the DDAH 1 inhibitor, L-
257 (Rossiter, Smith et al. 2005). 
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5.2. Results 
5.2.1. Hypoxia Does Not Induce Cell Death in Pulmonary Vascular Cells 
The Propidium Iodide (PI) assay combined with flow cytometry was used to evaluate the 
effect of hypoxia (1-48 hours) on cell death in HPAECs and HPASMCs.  PI assay is based on 
the principle that apoptotic cells are characterized by DNA fragmentation and loss of 
nuclear DNA content. PI is capable of binding and labelling DNA, allowing a precise 
evaluation of cellular DNA content by flow cytometric analysis, followed by identification of 
apoptotic cells (Riccardi and Nicoletti 2006). 
As shown in figure 22 A and B, hypoxia did not induce any significant changes in cell survival 
in either HPAECs or in HPASMCs. A positive control, arsenic trioxide (As2O3) induced a >4-
fold increase in cell death. 
 
 
 
 
 
Figure 22: The effects of hypoxia (1-48 hr) on HPAECs and HPASMCs cell death. Hypoxia did not affect cell 
death in pulmonary vascular cells. Cell cell death was measured by PI staining and As2O3 was used as 
positive control. n= 6 
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5.2.2. HPASMCs Proliferation is controlled by endothelial DDAH1 expression 
BrdU incorporation assay was used to measure changes in cell proliferation in endothelial 
and smooth muscle cells cultured under normoxic or hypoxic conditions.  
Hypoxia (24h) increased smooth muscle cell proliferation by 2-fold, while endothelial cell 
proliferation was unaffected (figure 23 A, B). In order to verify the role of ADMA-DDAH1 
pathway, HPAECs and HPASMCs were infected with adenoviruses to induce overexpression 
of DDAH1 (Ad-DDAH1) or DDAH1 inactive mutant (Ad-ΔDDAH1). Overexpression of DDAH1 
or ΔDDAH1 did not affect HPAEC or HPASMC proliferation in normoxic or in hypoxic 
conditions (figure 23 C, D). In addition, incubation of both cell types with ADMA (100 µM) or 
DDAH inhibitor L-257 (100 µM) did not considerably affect cell proliferation in either 
normoxic or hypoxic conditions (figure 23 E-F), demonstrating that vascular cell proliferation 
may not be directly regulated by the ADMA-DDAH pathway.  
The endothelium-derived NO inhibits smooth muscle cells proliferation in vitro and in vivo 
(Ambalavanan, Mariani et al. 1999). We hypothesized that this NO-dependent effect may be 
attenuated in hypoxia as a result of DDAH downregulation.  
In order to study the effect of endothelium on smooth muscle cell proliferation in vitro, 
HPAECs and HPASMCs were co-cultured in Transwell chambers (details in material and 
methods 2.8.1).  Briefly, HPASMCs were cultured in the bottom chambers of Transwell 
dishes, while HPAECs were seeded in the top chambers. The cells were separated by porous 
membrane (3µm pore size), allowing diffusion of soluble mediators between the two cell 
layers (figure 24 A). To manipulate DDAH expression, the endothelial cells were infected 
with AdDDAH1, AdDDAH2 or inactive DDAH mutants.  On the following day, HPAECs and 
HPASMCs were co-cultured for 24 hours before the measurement of BrdU incorporation. As 
can be seen in figure 24 B, HPAECs had an inhibitory effect on HPASMC proliferation in 
normoxic conditions, while in hypoxic conditions this inhibitory effect was significantly 
attenuated. Overexpression of DDAH1, but not DDAH2 or DDAH mutants, in hypoxic HPAECs 
restored the endothelium-dependent inhibition of HPASMC proliferation (figure 24 B). 
Furthermore, the protective effects of endothelial DDAH1 overexpression were attenuated 
in the presence of protein kinase G (PKG) inhibitor, phosphodiesterase-resistant cGMP 
antagonist, Rp-8-cGMP (figure 24 C), suggesting the involvement of the NO/cGMP pathway.  
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Taken together, the results demonstrate that hypoxia-induced changes in DDAH1 expression 
have a critical impact on endothelium-dependent modulation of HPASMC proliferation.  
 
 
Figure 23: The effects of hypoxia and DDAH on cell proliferation. Proliferation (BrDU incorporation) in 
HPAECs (A) and HPASMCs (B) in normoxia or after 24 hours of hypoxia, as indicated. (C) Overexpression of 
DDAH1 and ΔDDAH1 had no effects on HPAECs and (D) HPASMCs proliferation. (E-F) Addition of ADMA 
(100µM) or inhibition of DDAH using L-257 (100µM) did not show any significant change on either HPAECs or 
HPASMCs proliferation. N= 6; *P<0.05, **P<0.01 comparison with the normoxic control. 
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Figure 24: DDAH1 endothelium-dependent modulation of HPASMC proliferation. In (A) illustration of non-
contact co-culture using Transwell system: HPAECs and HPAECs cells were co-cultured in two different 
compartments of Transwell dishes allowing exchange of  soluble signalling mediators through the pores in 
the Transwell membrane (3µm) (green). (B) HPASMCs proliferation was inhibited in the presence of HPAECs 
in normoxia, while this inhibitory effect was attenuated in hypoxia. DDAH1 overexpression in HPAECs 
restored the endothelium-dependent inhibition of HPASMC proliferation in hypoxia. In (C) PKG inhibitor Rp-
8-Br-PET-cGMPS (PKGi), attenuates the effects of endothelial DDAH1 overexpression on HPASMC 
proliferation  HPAECs were left untreated or were over expressing GFP (adenoviral control) or AdDDAH1. 
PKGi (0.5 µM) was added to the cells 24h before the end of experiment. S: HPASMCs; E: HPAECs. AdEGFP 
(EGFP) was used in all the experiments as adenoviral control. *P<0.05; **P<0.01, comparisons with 
normoxic control; &&P<0.01 comparison, as indicated; n=6. 
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5.2.3. DDAH1 Regulates Endothelial Barrier Function 
Endothelial barrier disruption is thought to occur early during PH development (Predescu, 
Predescu et al. 2005). Endothelial barrier function depends on the integrity of endothelial 
cell-cell contacts, in particular adherens and tight junctions (Wojciak-Stothard and Ridley 
2002; Brunner, Cockcroft et al. 2005).   
In order to investigate the effects of hypoxia on the organization of intercellular junctions, 
confluent HPAECs overexpressing DDAH1, DDAH2 (AdDDAH1-2) or their inactive mutants 
(ΔDDAH1-2), were exposed to normoxic or hypoxic conditions for 24h. The cells were then 
fixed and stained for adherens junctions protein, vascular endothelial (VE)-cadherin and 
filamentous (F) actin and examined under the confocal microscope.  
Normoxic HPAECs showed cobblestone morphology with a predominant localization of F-
actin and VE-cadherin at the cell periphery (figure 25). Hypoxia (24h) induced a loss of 
peripheral F-actin, dispersion of VE-cadherin from the inter-cellular junctions and the 
formation of central stress fibres (figure 25). Interestingly, DDAH1 prevented stress fibre 
formation in HPAECs, restored cortical localization of F-actin and junctional localization of 
VE-cadherin, while overexpression of DDAH2 had a lesser effect.  
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Figure 25: DDAH1 prevents hypoxia-induced dispersion of inter-cellular adherens 
junctions in HPAECs. HPAECs were infected with AdDDAH1, AdDDAH2, AdΔDDAH1 or 
AdΔDDAH2 and exposed to normoxia or to hypoxia (24h), as indicated. The columns 
of images from the left show localization of F-actin, VE-cadherin and GFP staining in 
cells, as indicated.  Corresponding merged images are shown on the right (F-actin-red, 
VE-cadherin-blue and GFP-green). Bar=10 µm 
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In order to measure changes in endothelial barrier function, HPAECs were plated in the top 
chamber of Transwell dishes (3 μm pore size) and grown until confluence. Passage of FITC-
dextran across the confluent endothelial layer was quantified after 1 hour incubation in 
normoxic or in hypoxic conditions (figure 26 A). 
Consistent with the observed dispersion of endothelial adherens junctions, HPAECs showed 
a 1.5-fold increase in endothelial permeability following hypoxic exposure (figure 26 B). 
DDAH1 overexpression significantly attenuated the effect of hypoxia, while the 
overexpression of DDAH2 or inactive DDAH mutants did not have a significant effect on 
endothelial barrier function. The protective effects of endothelial DDAH1 overexpression 
were attenuated in the presence of protein kinase G inhibitor (PKGi), phosphodiesterase-
resistant cGMP antagonist (figure 26 C), indicating that NO/cGMP/PKG signaling  is required 
for the maintenance of endothelial barrier function. 
 
In summary, these results demonstrate that the hypoxic insult compromises endothelial 
barrier integrity and that the effects of hypoxia are attenuated by endothelial 
overexpression of DDAH1 via the increase of NO/cGMP bioavailability.  
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Figure 26: The effects of hypoxia and DDAH on endothelial barrier function. In (A) Transwell permeability 
assay in vitro measuring passage of FITC-dextran (yellow dots) across the endothelial cell layer). In (B) over 
expression of DDAH1 (AdDDAH1) but not DDAH2 (AdDDAH2) or inactive DDAH mutants (AdΔDDAH) 
attenuates hypoxia-induced increase in endothelial permeability; NT-untreated cells. (C) PKG inhibitor Rp-8-
Br-PET-GMPS (PKGi) attenuates the effects of endothelial DDAH1 overexpression on endothelial 
permeability. HPAECs were left untreated, were over expressing EGFP (adenoviral control), AdDDAH1 or 
were treated with PKGi (0.5 µM). PKGi was added to the cells 24h before the end of experiment. **P<0.01, 
comparisons with normoxic control; #P<0.05, &&P<0.01 comparison as indicated; n=5. 
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5.2.4. DDAH1-ADMA Pathway Can Regulate In Vitro Angiogenesis 
Abnormal endothelial angiogenic responses are thought to play a role in plexiform lesion 
formation in human PAH (Tuder, Chacon et al. 2001). Hypoxia is a contributing factor in PAH 
(Stenmark, Fagan et al. 2006) and therefore we studied the role of DDAH in hypoxia-induced 
changes in pulmonary endothelial angiogenesis in vitro.  
The effects of hypoxia on angiogenesis were studied using the Matrigel tube formation 
assay, as described in materials and methods chapter 2.8.4.  
24h after plating on Matrigel, endothelial cells showed formation of tubular structures 
(figure 27 C). There were no significant differences in tube formation between the cells 
cultured under normoxic or hypoxic conditions (24 hours). However, while the untreated 
cells showed a well-formed tubular network (figure 27 C), the addition of ADMA (100 
μmol/L) or the DDAH inhibitor L-257 (100μmol/L) markedly reduced the endothelial tube 
formation (30% reduction for ADMA- and 50% reduction for L-257-treated cells in both, 
normoxic and hypoxic conditions) (figure 27 A). 
To further investigate the role of DDAH enzymes in endothelial tube formation, both DDAH 
enzymes and their corresponding inactive mutants were overexpressed in HPAECs prior to 
the tube formation assay. As can be seen in figure 27 B, DDAH1 was able to increase the 
tubulogenesis under normoxic and hypoxic conditions, while either DDAH2 or the inactive 
mutants did not showed any noticeable effects,  compared to the non-treated (NT) cells.  
These results indicate that ADMA inhibits pulmonary endothelial angiogenesis in vitro, while 
DDAH1 has a stimulatory effect.  
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Figure 27: DDAH1 activity regulates angiogenesis in HPAECs. The cells were left untreated (NT) or were 
treated with ADMA (100µM, 24hr), L-257 (100µM, 24hr), or were over expressing AdEGFP, AdDDAH1, 
AdDDAH2 or inactive AdΔDDAH1/DDAH2 mutants (24 hr overexpression), under normoxic or hypoxic 
conditions, as indicated. Tube formation was measured in Matrigel assay. Representative images in (C) show 
tube formation in normoxic untreated, AdDDAH1 or L-257-treated cells, as indicated. N=6; **P<0.001; 
***P<0.0001, comparison with normoxic control 
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5.2.5. NF-kB inhibition prevents hypoxia-induced changes in miR-21 and DDAH1  
Inflammation plays an important role in the pathogenesis of PH (Dorfmuller, Perros et al. 
2003; Selimovic, Sakiniene et al. 2008; Hall, Brogan et al. 2009; Crosswhite and Sun 2010; 
Price, Wort et al. 2012; Hassoun 2014). Recent studies demonstrated that inflammation is a 
characteristic feature of many forms of PH in both humans and animals, including chronic 
hypoxia-induced PH (Lu and He 2009; Price, Wort et al. 2012). Among several pro-
inflammatory mediators, the transcriptional factor NF-κB (Sawada, Mitani et al. 2007) has 
been implicated in the progression of pulmonary hypertension.   
Recently, it has been reported that NFkB is activated by hypoxia (Culver, Sundqvist et al. 
2010) and that it can regulate miR-21 expression in cancer cells (Shin, Jin et al. 2011).  In 
order to verify the potential role of NF-KB in the regulation of miR-21/DDAH pathway, 
hypoxic HPAECs were treated with the NF-KB inhibitor BAY-117085 (Sigma Aldrich) and 
DDAH1/miR-21 mRNA expression levels were quantified.   
This experiment showed that BAY-117085 had an inhibitory effect on hypoxia-induced 
increase in mir-21 levels and downregulation of DDAH1 expression (figure 28 A, B). This 
preliminary observation might indicate a potential role of NFκB as an upstream activator of 
miR-21 signaling in hypoxic endothelial cells (figure 28 C). 
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Figure 28: NF-κB inhibitor, BAY117085 prevents hypoxia-induced changes in miR-21 and DDAH1 mRNA levels 
in HPAECs. HPAECs were incubated with BAY 117085 (10 µmol/L) for 24h in normoxic or in hypoxic 
conditions, before the measurement of DDAH1 mRNA levels (A) and miR-21 (B).  In (C) proposed mechanism 
of NF-kB in the regulation of DDAH1 signaling. ***P<0.001, comparison with normoxic controls; n=4. 
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5.3. Discussion  
Hypoxia-induced endothelial dysfunction plays a role in pulmonary vascular remodeling. 
Hypoxia causes endothelial dysfunction, at least in part, via decreased bioavailability of 
nitric oxide. 
In this chapter, we studied the role of ADMA metabolism in the regulation of hypoxia-
induced changes in pulmonary vascular endothelial and smooth muscle cell death, 
proliferation, endothelial barrier function and angiogenesis. The results show that:  
 
1. Hypoxia (2% O2, 2-24h) does not induce apoptosis in pulmonary vascular cells. 
2. Endothelium-dependent inhibition of HPASMC proliferation in vitro is lost in 
hypoxia and is restored by endothelial overexpression of  DDAH1 
3. DDAH1/NO signaling is important for the maintenance of endothelial barrier 
function. 
4. DDAH1-ADMA pathway regulates HPAEC angiogenesis in vitro. 
5. NFkB inhibition prevents hypoxia-induced increase in miR-21 expression in 
HPAECs. 
 
Endothelial cell death is regarded as an important contributory factor in the pathogenesis of 
PH (Jurasz, Courtman et al. 2010). Extensive endothelial damage and a subsequent 
inflammatory response contribute to pulmonary vascular remodelling in the rat 
monocrotaline model of PH (Arcot, Lipke et al. 1993; Schultze and Roth 1998) . Combination 
of the VEGFR2 inhibitor Sugen and hypoxia, in rats and mice induce endothelial apoptosis 
followed by the formation of occlusive plexiform lesions, resulting from a local expansion of 
apoptosis-resistant endothelial cells (Taraseviciene-Stewart, Kasahara et al. 2001). It has 
been reported that hypoxia can trigger apoptosis in several ways. In fact, hypoxia can induce 
apoptosis by causing hyper-permeability of the inner mitochondrial membrane that leads to 
the release of cytochrome C, an essential component of the mitochondrial electron 
transport chain (Saikumar, Dong et al. 1998; de Moissac, Gurevich et al. 2000) or via 
activation of the caspase 9 pathway. In this mechanism, in response to hypoxia inactive 
caspase 9 is cleaved and activated by caspases 3 and 12, without the involvement of 
cytochrome C (Morishima, Nakanishi et al. 2002). Another mechanism by which hypoxia can 
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induce apoptosis has been reported in melanoma cells, where hypoxia can activate c-Jun 
NH2-terminal kinase (JNK) and induce apoptosis (Basu and Kolesnick 1998). Hypoxia-
induced apoptosis has been reported in solid tumors (Graeber, Osmanian et al. 1996) and 
cardiovascular diseases (Mehta, Kang et al. 2002; Zhang, Li et al. 2004). Matsushita et al 
demonstrated that activation of NF-κβ by hypoxia induced human aortic endothelial cell 
(HAEC) apoptosis through the suppression of an anti-apoptotic molecule, bcl-2 (Matsushita, 
Morishita et al. 2000).  
In this chapter, we have shown that hypoxia had no effect on pulmonary endothelial or 
smooth muscle cells apoptosis in vitro. The discrepancies in hypoxia-induced effects 
reported in different studies may result from differences in the experimental design:  the 
cell type used (HPAECs versus HAECs) or the level of hypoxia (2% O2 in our study versus 
near-anoxia, undetectable O2 level in the study of Matsushita), (Matsushita, Morishita et al. 
2000).  
Endothelial NO can act as a vasorelaxant and an inhibitor of VSMC proliferation in vitro and 
in vivo (Dzau and Gibbons 1991; Peiro, Redondo et al. 1995; Ambalavanan, Mariani et al. 
1999). Our results indicate that functional endothelial DDAH1 is indispensable for the 
endothelial control of SMC proliferation. In fact, we observed that hypoxia stimulated the 
growth of smooth muscle cells co-cultured with endothelial cells, but the effect was 
inhibited in the presence of endothelial cells overexpressing DDAH1, while DDAH2 or DDAH 
mutants had no effect. We used a Transwell co-culture system to study the effect of 
endothelium-derived diffusible factors on HPASMC proliferation. The distance separating 
the two cell layers was <1mm, a distance sufficiently small to ensure free diffusion of NO 
between the cell layers (Lancaster 1996; Lancaster 1997). However, the possibility that 
DDAH1 may affect the release of other factors involved in the regulation of SMC growth 
cannot be excluded. Indeed, hypoxic endothelial cells can exhibit chemoattractant and 
mitogenic activity towards smooth muscle cells and fibroblasts as a result of increased 
production of ET-1, VEGF and PDGF (Dawes, Peacock et al. 1994). 
ADMA compromises endothelial barrier function in vitro and in vivo (Mundy and Dorrington 
2000; Predescu, Predescu et al. 2005; Wojciak-Stothard, Torondel et al. 2009). Here, we 
showed that hypoxia-induced breakdown of pulmonary endothelial function in vitro was 
attenuated by the overexpression of DDAH1. The breakdown of endothelial barrier function 
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by hypoxia can lead to leukocyte adhesion, platelet activation, SMC proliferation, migration 
and ECM deposition (Garg and Hassid 1989; Garg and Hassid 1990; Scottburden, Schini et al. 
1992; Sarkar, Webb et al. 1995; Lau and Ma 1996), contributing to pulmonary vascular 
remodelling.  
Hypoxia induces endothelial angiogenesis by activating HIF and increasing VEGF release 
(Forsythe, Jiang et al. 1996), an essential mechanism in tumour growth (Forsythe, Jiang et al. 
1996). HIF activation and increased endothelial production of VEGF are also features of cells 
in plexiform lesions in human PAH (Hirose, Hosoda et al. 2000; Humbert, Morrell et al. 
2004). However, exposure to chronic hypoxia alone does not induce plexiform lesion 
formation, suggesting that hypoxia acts only as a contributory factor in this process. We 
observed that hypoxia did not significantly affect pulmonary endothelial angiogenesis in 
vitro. However, exogenous ADMA and DDAH1 inhibitor, L-257 inhibited pulmonary 
endothelial angiogenesis in vitro, while DDAH1 overexpression had a stimulatory effect, 
suggesting that intact ADMA metabolism is required for the maintenance of correct 
angiogenic responses. 
NFkB is activated by hypoxia (Culver, Sundqvist et al. 2010) and has been shown to regulate 
miR-21 expression in cancer cells (Shin, Jin et al. 2011).  Recently, Hosokawa et al 
demonstrated the pathophysiological role of NFkB in pulmonary hypertension (Hosokawa, 
Haraguchi et al. 2013). In this study, the authors observed that the use of a synthetic 
selective NF-kB inhibitor, N-(3,5-Bis-trifluoromethyl-phenyl)-5-chloro-2-hydroxy-benzamide 
(IMD-0354) can reduce RV pressure  in MCT animal model and  inhibit PASMCs proliferation. 
Accordingly, our in vitro experiments showed that NFkB inhibition can prevent hypoxia-
induced increase in miR-21 expression in HPAECs and therefore protect DDAH1 protein from 
downregulation. 
 
In summary, these results demonstrate the importance of DDAH1 in hypoxia-induced 
changes in ADMA levels, endothelial barrier function, angiogenesis and endothelium-
dependent proliferative responses in pulmonary vascular cells. Furthermore, we also show 
that NFkB activity is required for the hypoxia-induced upregulation of miR-21 levels, 
suggesting a plausible mechanism of action of hypoxia-induced changes in DDAH1 levels.   
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6. Chronic Hypoxia-Induced Pulmonary Hypertension 
6.1. Introduction 
Hypoxia is frequently used to induce PH in a wide variety of animal species. This model is 
useful since it is very predictable and reproducible within the selected animal strain. 
Following 2-3 weeks of hypoxic exposure, mice and rats develop pulmonary hypertension 
characterised by remodelling, increased right ventricular systolic pressure and right 
ventricular hypertrophy (Stenmark, Meyrick et al. 2009). 
Overexpression of the human DDAH1 (hDDAH1) gene was reported to have beneficial 
cardiovascular effects in mice (Schwedhelm, von Leitner et al. 2009). Indeed, the DDAH1 
transgenic mice (DDAH1tg) show reduced systolic blood pressure and systemic vascular 
resistance (Dayoub, Achan et al. 2003). Furthermore, DDAH1tg mice exhibit a reduction of 
the myocardial reperfusion injury (Stuhlinger, Conci et al. 2007).  
These beneficial effects may be related to an improved metabolic clearance of ADMA by 
kidney and liver tissues or an increased DDAH1 expression in cardiovascular tissues. 
Our experiments in vitro suggest that DDAH1 plays an important regulatory role in 
pulmonary vascular responses to hypoxia. In the next series of experiments we verified the 
role of DDAH1 in mouse model of chronic hypoxia-induced pulmonary hypertension. We 
also investigated potential suitability of miR-21 targeting in treatment of PH induced by 
chronic hypoxia. 
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6.2. Results 
6.2.1. Increased Expression of DDAH1 Attenuates Development of Chronic 
Hypoxia-Induced Pulmonary Hypertension 
In order to study the effects of hDDAH1 overexpression on hypoxia-induced PH, the 
wildtype and the transgenic DDAH1- overexpressing mice (DDAH1tg) were exposed to 
hypoxia for 2 weeks. Development of pulmonary hypertension was confirmed by the 
measurement of right ventricular pressure and pulmonary vascular remodelling, as 
described in material and methods 2.9.1.  
No significant differences in the right ventricular hypertrophy (RVH, 0.79±0.15 versus 
0.82±0.19) or systolic pressure (RVSP, 15.7±0.12 versus 16.3±0.23) were observed between 
the wild type and the DDAH1tg mice kept in normal air (figure 29 A and B), consistent with 
previous reports (Bakr, Pak et al. 2013).  Hypoxia increased RVH in the wild type mice, while 
in DDAH1tg mice the response was comparable to normoxic wildtype controls (1.09±0.35 
versus 0.84±0.39) (figure 29 A). Consistently, RVSP was raised in both the wildtype mice and 
the DDAHtg mice, but DDAH1tg mice showed a significantly attenuated response (30.68 ± 
0.82 mmHg in wildtype mice versus 26.93 ± 0.86 mmHg in DDAH1tg mice) (figure 29 B). In 
addition, an increase in pulmonary vascular muscularization was observed  in both 
genotypes but the number of fully and partially muscularised vessels in DDAHtg mice was 
significantly reduced (P< 0.05), when compared with wildtype controls (79% SD 2.4 in 
wildtype mice versus 65% SD 1.04 in DDAH1tg mice)(figure 29 C, E). As expected, chronic 
hypoxia enhanced the expression of PCNA, a nuclear protein that participates in active cell 
proliferation (Takahashi, Strutton et al. 1991), in wild-type mice, whereas in DDAH1tg 
animals the expression levels of PCNA were reduced (figure 29 D).   
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Figure 29: Increased expression of DDAH1 attenuates development of chronic hypoxia-induced pulmonary 
hypertension. (A) Right ventricular hypertrophy (RVH) and (B) right ventricular systolic pressure (RVSP) were 
measured in wild type control mice (WT; grey bars) and DDAH1 transgenic mice (DDAHtg; black bars) 
following 2-week exposure to normoxia or hypoxia. (C) Percentage of muscularized vessels diameter <50 µm 
in lung sections in the wildtype (WT) or DDAHtg mice. *P<0.05, comparison with hypoxic controls; n=8. (D) 
PCNA levels in normoxic and hypoxic WT (grey bars) and DDAHtg mice (black bars) in normoxia and hypoxia, 
as indicated. (E) Representative images of lung sections showing αSM actin staining in normoxic or the 
hypoxic wild type (WT) or DDAHtg mice. The arrowhead points to the fully muscularized artery in hypoxic 
WT mice. Bar=50 μm. 
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Consistent with the effects of hypoxia on DDAH expression observed in vitro, DDAH1 protein 
expression was reduced 5-fold in the lungs of pulmonary hypertensive mice (figure 30 A) 
and although DDAH2 protein expression was also reduced, the change was less pronounced 
(figure 30 B). By contrast, the lungs of DDAH1tg mice showed elevated DDAH1 expression 
which was reduced to normoxic control levels following exposure to chronic hypoxia (figure 
30 A). Hypoxic wildtype mice showed a significant reduction in cGMP lung content (2-fold 
decrease), compared with wildtype normoxic controls, while DDAH1tg mice showed 
elevated levels of cGMP in the lung in both normoxic and in hypoxic conditions (figure 30 D).  
Protein expression levels of Rho GTPase RhoA, known to promote vasoconstriction and 
pulmonary vascular remodelling (Wojciak-Stothard, Torondel et al. 2009; Nossaman, 
Nossaman et al. 2010) were elevated in both the wild type and DDAH1tg mice (figure 30 C). 
NO/PKG-mediated phosphorylation of RhoA on Ser188 inhibits RhoA activity and reduces 
actomyosin contractility in pulmonary vascular smooth muscle and endothelial cells 
(Sauzeau, Le Jeune et al. 2000; Wojciak-Stothard, Torondel et al. 2007). Consistent with 
changes in lung DDAH expression and cGMP levels, pSer188RhoA levels were reduced in 
hypoxic wild type mice, while in hypoxic DDAHtg mice, the pSer188RhoA levels were 
comparable to normoxic controls (figure 30 E).   
DDAHtg mice did not show any changes in DDAH2 expression under basal conditions or 
following hypoxic exposure (Schwedhelm, von Leitner et al. 2009).   
In summary, we observed that the overexpression of DDAH1 in vivo attenuated 
development of pulmonary hypertension in chronically hypoxic mice, suggested a protective 
function of DDAH/NO/cGMP in PH.   
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Figure 30: Expression of DDAH1, DDAH2, RhoA, pSer188RhoA in the wildtype (WT) and DDAH1 
overexpressing transgenic mice (DDAH1tg) kept for 2 weeks in normoxia (grey bars) or in hypoxia (black 
bars). (D) cGMP levels in lungs of normoxic and hypoxic mice. *P<0.05; **P<0.001, ***P<0.0001 comparison 
with normoxic controls; representative examples of western blots are shown in (F). #P<0.05, ##P<0.01, 
comparisons with hypoxic control, &P<0.05 comparisons as indicated. N= 8, in (A-E); N=4 in (F). 
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6.2.2. MiR-21 Inhibition Moderates Development of Chronic Hypoxia-Induced 
Pulmonary Hypertension 
MiR-21 levels are increased in hypoxic mice and in hypoxic human lung (Parikh, Jin et al. 
2012; Pullamsetti, Doebele et al. 2012) and in HPAECs cultured under hypoxic conditions (as 
showed in results 4.2.2 figure 20E).  I hypothesized that inhibition of miR-21 in hypoxic mice 
may result in an increase in DDAH1 expression and may have a protective effect in 
development PH. C57BL/6 male mice were given intraperitoneal (IP) injection of 100 µl of 
vehicle or 100 µl locked nucleic acid anti-miR-21 probes (LNA21) in PBS at 10 mg/kg once 
every other day for a total of 8 times during the 2 weeks of hypoxia exposure. Following 
hypoxic exposure, the mice were phenotyped as described in 2.9.1. The in vivo inhibition of 
miR-21 with specific LNA probes, reduced chronic hypoxia-induced increase in RVSP (figure 
31 A), RVH (figure 31 B), and muscularization of small intrapulmonary arteries (figure 31 C 
and D). 
  
 
Figure 31: Treatment with LNA21 reduces (a) right ventricular systolic pressure (RVSP), (b) right ventricular 
hypertrophy (RVH), (c) muscularisation of intrapulmonary arteries in hypoxic pulmonary hypertensive 
wildtype (WT) mice. *P<0.05, ***P<0.001, comparison with untreated normoxic controls; #P<0.05 and 
##P<0.01, ###P<0.001, comparisons with untreated hypoxic controls, as indicated. n=6-8. (d) Representative 
images of lung sections showing αSM actin staining in normoxic or the hypoxic wild type (WT) untreated or 
LNA21-treated mice. The arrowhead points to the fully muscularized artery in hypoxic WT mice. Bar=50 μm. 
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DDAH1 protein expression was reduced 5-fold in the lungs of pulmonary hypertensive mice 
and was restored to control levels upon treatment with LNA-21 (figure 32 A). Consistent 
with the observed reduction in pulmonary vascular remodelling, LNA-21 treatment also 
reduced protein expression levels of PCNA (figure 32 E). LNA21-treated hypoxic mice 
showed significantly elevated pSer188RhoA, indicative of improved nitric oxide signalling 
(Sauzeau, Le Jeune et al. 2000), (figure 32 B). Protein expression of RhoA was elevated in 
hypoxic lung and was not affected by LNA-21 treatment (Figure 32 C).  RhoB, a protein 
homologous to RhoA, has been implicated in the pathogenesis of PH and is a predicted 
target of miR-21 (Sabatel, Malvaux et al. 2011; Parikh, Jin et al. 2012; Wojciak-Stothard and 
Wilkins 2012).  However, we did not observe any significant changes in RhoB expression 
levels upon treatment with LNA-21 (figure 32 D), which suggests that this protein is unlikely 
to mediate the protective effects of LNA-21.  
In order to understand the role of miR-21 in the regulation of NO/cGMP signaling, LNA21-
treated mice exposed to hypoxia and subsequently cGMP was quantified.  
As showed in figure 33 F, a significant increase in cGMP levels was noted in lungs of hypoxia 
LNA21-treated mice, compared with untreated hypoxic controls (figure 33 F). Oddly, this 
result is in contrast with the postulated role of ANP during hypoxia (Chen, Feng et al. 2006). 
In fact, ANP synthesis and secretion are enhanced during hypoxia (Raffestin, Levame et al. 
1992), increasing the synthesis of cGMP and protecting against the development of 
pulmonary hypertension (Sciarretta, Marchitti et al. 2013).  
Both the hypoxic LNA21-treated and DDAH1tg mice showed a significant reduction in ADMA 
levels in the lung, compared with hypoxic controls (figure 33 A). Interestingly, the effects of 
hypoxia on miR-21/DDAH1 expression appeared to be lung-specific, as hypoxia increased 
miR-21 mRNA levels and decreased DDAH1 protein levels by 3-fold in lung tissues, while 
miR-21/DDAH1 levels in kidney and liver remained unaffected (figure 33 B and C).  
In summary, these results show that the inhibition of miR-21 can prevent hypoxia-induced 
reduction in DDAH1 expression in the lung and attenuate the development of chronic 
hypoxia-induced PH. 
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Figure 32: LNA21 treatment increased expression of DDAH1 and attenuates development of chronic 
hypoxia-induced PH in mice. Protein expression levels of (A) DDAH1, (B) RhoA phosphorylated on 
Ser 188 (pRhoA); (C) RhoA; (D) RhoB and (E) representative Western blots corresponding to (A-D). 
(F) cGMP levels in lungs of normoxic and hypoxic mice. *P<0.05; **P<0.001, ***P<0.0001 
comparison with normoxic controls; #P<0.05, ##P<0.01, ###P<0.001comparisons with hypoxic 
control, &P<0.05 comparisons as indicated; n= 8, in (A-E); n=4 in (F). 
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Figure 33: ADMA, miR-21 and DDAH1 levels in normoxic or hypoxic (2 weeks hypoxia) 
wild type (WT), LNA21-treated or DDAHtg mice, as indicated. (b) Hypoxia-induced 
changes in miR-21 mRNA levels and in DDAH1 protein levels in mouse lung, liver and 
kidney tissues. (c) ***P<0.001, **P<0.01, comparison with normoxic WT controls; n=8. 
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6.2.3. DDAH1 is Reduced and MiR-21 is Increased in Human Pulmonary Arterial 
Hypertensive (PAH) Lungs. 
Data from the in vivo experiments suggest that microRNA21-mediated downregulation of 
DDAH1 might play a role in human PH. MiR-21 and DDAH1 mRNA levels were measured in 
lung tissues from patients with IPAH and compared with healthy controls. 
Since pulmonary hypertension is a disease of the lung vasculature with secondary effects on 
the heart, investigations of this pathology require samples of lung tissue from patients with 
PH. As shown in table 3 in the material and methods chapter, the samples used were 
obtained from end-stage IPAH patients (n=12, 9 female patients) unresponsive to available 
PH therapies that underwent lung transplantation. The lung tissues from treatment-naïve 
patients we used were obtained in the early 1990s, before epoprostenol (Flolan) was 
approved for clinical use in PAH and several years before the introduction of endothelin 
receptor antagonists and phosphodiesterase inhibitors as therapies for PAH. As control 
tissues, we used samples from healthy sections of lung from patients undergoing a 
lobectomy (n=12, 5 female patients) usually with lung cancer.  
Lung tissues from treatment-naïve patients with IPAH patients showed significantly reduced 
levels of DDAH1 mRNA (1.1 ± 0.4 in PAH and 2.1 ± 0.8 in healthy control group; P<0.001) and 
elevated levels of miR-21, (23.5 ± 5 in IPAH and 7 ± 5.3 in healthy control group; P<0.001), 
while DDAH2 mRNA levels remained unchanged (figure 34 A-C).   
Together, these results suggest that dysregulation of the miR-21/DDAH1 pathway may be 
common to different forms of pulmonary hypertension.  
 
Figure 34: DDAH1, DDAH2 and miR-21 levels in IPAH patients.  DDAH1 mRNA (a), DDAH2 mRNA (b) and 
miR-21 (c) levels were measured in lung surgical samples from IPAH patients and control subjects, as 
indicated.  ***P<0.001, comparison with control subjects. N=12. 
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6.3. Discussion 
The experiments in this chapter demonstrated the following findings: 
1. DDAH1 overexpression and inhibition of miR-21 attenuate the development of 
chronic hypoxia-induced PH. 
2. Hypoxia-induced, miR-21-mediated reduction in DDAH1 expression is lung-specific. 
3. DDAH1 is reduced and miR-21 is increased in human PAH lungs, suggesting a 
possible role of miR-21/DDAH1 signaling in human pathology. 
 
Overexpression of the human DDAH1 (hDDAH1) gene was reported to have beneficial 
cardiovascular effects in mice (Schwedhelm, von Leitner et al. 2009).   
The authors observed that DDAH1tg mice did not show an improved DDAH-metabolic 
capacity of kidney and liver under normoxic conditions (Schwedhelm, von Leitner et al. 
2009). However, they demonstrated that the decrease in circulating ADMA levels was due 
to a decreased release of ADMA from aorta and heart. The authors postulated that the 
protective cardiovascular effects observed in DDAH1tg mice may therefore result from 
improved activity of the DDAH enzyme in the cardiovascular system and not from improved 
renal or hepatic clearance of ADMA and L-NMMA. 
Accordingly, in our study DDAH1tg mice showed attenuated pulmonary hypoxic phenotype 
when compared with the wild type controls, suggesting a protective role for DDAH1 in 
pulmonary hypertension.  Furthermore, our results indicate that the protective effects of 
miR-21/DDAH1 may be mediated by NO/cGMP/PKG pathway, consistent with the increase 
in lung cGMP levels and increased phosphorylation of RhoA on Ser188.  
However, further experiments will be required in order to understand the role of ANP 
signaling in hypoxic mice treated with LNA21.  In fact, studies have shown that mice 
exposed to chronic hypoxia exhibit increased pulmonary arterial pressure and RV 
hypertrophy associated with increasing levels of plasma ANP (Preston, Hill et al. 2004). Thus, 
it has been postulated that increased secretion of ANP may provide a compensatory 
mechanism to modulate the development of hypoxia-induced pulmonary hypertension and 
vascular remodeling (Hirata, Suzuki et al. 1992). 
 
 
131 
  
 
Relevant to the postulated protective role of DDAH1, Bakr et al. (Bakr, Pak et al. 2013) have 
recently demonstrated that DDAH1tg mice show attenuated acute and sustained hypoxic 
pulmonary arterial vasoconstriction. Interestingly, exposure of these mice to 4 weeks 
(instead of 2 weeks used in our study) of hypoxia did not prevent pulmonary vascular 
remodelling (Bakr, Pak et al. 2013). The loss of a protective effect of DDAH1 after a more 
prolonged exposure to hypoxia might be associated with the gradual, hypoxia-induced 
decrease in β-actin promoter-driven expression (Brown and Davis 2005) of the DDAH1 
transgene, noted in both studies (Bakr, Pak et al. 2013). 
MiR-21 has been implicated in the pathogenesis of several diseases, including pancreatic 
and lung cancer (Mace, Collins et al. 2013; Haigl, Vanas et al. 2014), kidney fibrosis 
(Glowacki, Savary et al. 2013) and diabetic cardiomyopathy associated with cardiac fibrosis 
(Kumar, Raut et al. 2011). However the role of miR-21 in pulmonary hypertension remains 
controversial.  
Liu et al found elevated levels of miR-21 in the lungs of mice with experimental pulmonary 
fibrosis and in the lungs of patients with idiopathic pulmonary fibrosis (Liu, Friggeri et al. 
2010). Accordingly, Yang et al showed that miR-21 overexpression enhanced the expression 
of cell proliferation- associated proteins such as PCNA and cyclin D1, suggesting that miR-21 
may play an important role in the pathogenesis of chronic hypoxia-induced pulmonary 
vascular remodeling (Yang, Banerjee et al. 2012).  Mir-21 has been linked with several target 
proteins involved in pulmonary vascular remodelling and vascular smooth muscle 
proliferation, such as RhoB, BMPR2 (bone morphogenetic protein receptor type II), PDCD4 
(programmed cell death 4) or SPRY2 (Sarkar, Gou et al. 2010) 
Interestingly, Parikh et al presented a molecular model in which hypoxia, inflammation, and 
BMP-dependent signaling up-regulate miR-21 in the pulmonary vasculature (Parikh, Jin et al. 
2012).  The authors observed that miR-21 expression was increased in various in vivo 
models of pulmonary hypertension. Indeed, it has been shown that miR-21 expression was 
increased in lungs of IL-6-overexpressing mice and in chronic hypoxia mice treated with 
SU5416.  Furthermore, miR-21–null mice used in the study exhibited exaggerated 
manifestations of PH. Parikh and colleagues suggested that  the absence of miR-21 can  
enhance Rho-kinase activation, and probably other pathways exacerbating  the PH 
phenotype in vivo (Parikh, Jin et al. 2012).  
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By contrast, Caruso et al observed differences in miR-21 regulation between monocrotaline 
and chronic hypoxia models, where miR-21 was downregulated in monocrotaline-induced 
PH (Caruso, MacLean et al. 2010). In addition, the authors reported a downregulation of 
miR-21 in lung homogenates of idiopathic PAH patients (Caruso, MacLean et al. 2010). 
However, in our study we observed that both, DDAH1 overexpression and the inhibition of 
miR-21, attenuate the development of chronic hypoxia-induced PH.  These discrepancies 
may result from different experimental approach and in vivo conditions used in other 
studies. Moreover, the global miR-21 knockout, used by Parikh and colleagues, is expected 
to have a persistent effect on multiple targets in several tissues, while in our approach the 
intravenous injection of LNA-21 would predominantly affect the vasculature within a chosen 
timeframe. Although miR-21 is expressed in multiple tissues in adult mice (Syed 2014), our 
experiments showed a lung- specific increase of miR-21 in response to hypoxia. Our results 
suggest that the regulation of miR-21 expression may be tissue-dependent. The precise 
mechanism of differential hypoxia-induced regulation of miR-21 expression in various 
tissues and organs will require further investigation. 
We observed increased levels of miR-21 and decreased levels of DDAH1 in lung tissues of 
IPAH patients, a pattern similar to the one observed in hypoxic mouse lungs. However, the 
roles of miR-21 and DDAH1 may be different in these two forms of pulmonary hypertension. 
In contrast to its protective role in chronic hypoxia-induced PH, increased NO signalling may 
have a detrimental effect on the development of plexiform lesions in human PAH, by 
promoting angiogenesis and iNOS-induced tissue damage associated with increased protein 
nitrosylation, metabolic stress and formation of reactive oxygen species (Hampl and Herget 
2000). 
 
In summary, we show that hypoxia induces pulmonary vascular dysfunction by selective 
miR-21-mediated inhibition of DDAH1 expression in vivo and that the overexpression of 
DDAH1 and/or the inhibition of miR-21 attenuate chronic hypoxia-induced PH in mice. 
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7. Conclusions  
This study addresses for the first time the mechanism of hypoxia-induced regulation of 
DDAH expression and function in pulmonary vasculature in vitro and in vivo.  Hypoxia 
inhibited the expression of DDAH1, at both the mRNA and protein level, and increased 
ADMA levels in pulmonary endothelial but not vascular smooth muscle cells, while DDAH2 
expression was inhibited in both cell types. The selective change in endothelial DDAH1 
abundance accounted for the increase in ADMA levels, led to HPAEC dysfunction and 
modulated HPASMC proliferation in vitro, whereas DDAH2 had little effect. The selective 
reduction of DDAH1 expression in hypoxic endothelial cells resulted from miR-21-induced 
degradation of DDAH1 mRNA and was prevented by inhibition of miR-21. We further show 
that reduced DDAH expression in the chronic hypoxic mouse lung is associated with 
elevated miR-21 levels and decreased NO signaling. DDAH1 overexpression or treatment of 
mice with the miR-21 inhibitor, LNA-21 attenuated the development of chronic hypoxia-
induced pulmonary hypertension. Evidence that these observations might have translational 
significance is provided by the demonstration that miR-21 levels are also increased and 
DDAH1 levels decreased in IPAH lung tissues. Hypoxia-induced increases in ADMA levels 
have been attributed to increased protein arginine methylation and decreased DDAH 
activity but the mechanisms are not well understood (Yildirim, Bulau et al. 2006). Our data 
show that both DDAH1 and DDAH2 are reduced in hypoxic lung, but only pulmonary 
endothelial DDAH1 contributes to hypoxia-induced changes in ADMA metabolism.  
The development of pulmonary arterial vasculopathy in animals and humans with 
pulmonary hypertension has been linked to dysregulation of microRNA (Grant, White et al. 
2013). We identified 13 candidate miRs that can bind to the 3’UTR region of DDAH1, and 
two of these, miR-21 (Parikh, Jin et al. 2012; Chen, Zhou et al. 2013) and miR-128 (Rhodes, 
Wharton et al. 2013), have been implicated in the pathogenesis of pulmonary hypertension. 
Our data show that miR-21 but not miR-128 contributes to the hypoxia-induced degradation 
of DDAH1 mRNA in pulmonary endothelial cells. MiR-21 expression was elevated while 
DDAH1 expression was reduced in the cultured HPAECs and in the lungs of chronically 
hypoxic pulmonary hypertensive mice. Importantly, similar differences were observed in 
lung tissues of treatment-naïve IPAH patients, suggesting that dysregulation of the miR-
21/DDAH1 pathway may be common to different forms of pulmonary hypertension.  In 
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support of the postulated role of miR-21, other studies have documented a progressive 
increase in miR-21 in chronic hypoxia-induced pulmonary hypertensive mice and localization 
of miR-21 to distal small arteries in the animal and human hypoxic lung (Parikh, Jin et al. 
2012; Pullamsetti, Doebele et al. 2012; Wojciak-Stothard and Wilkins 2012). Of interest, 
published data from our laboratory have shown that blood-derived endothelial-like cells 
from idiopathic PAH patients display a distinct disease-related phenotype characterised by 
reduced DDAH1 expression, increased ADMA production and abnormal angiogenesis and 
that this phenotype is ameliorated by over expression of DDAH1 or stimulation of NO/cGMP 
pathway (Tsang, Leiper et al. 2013). 
While overexpression of miR-21 has been implicated in the hypoxia-induced proliferation 
and migration of cultured PASMCs (Sarkar, Gou et al. 2010), we found that the manipulation 
of miR-21/DDAH1 expression had no direct effect on the hypoxia-induced proliferative 
responses of HPASMCs. Exposure to hypoxia induced a relatively small increase in miR-21 
levels in HPASMCs compared to HPAECs (1.5 and 4-fold increase, respectively) and, 
consistent with this, no significant changes in DDAH1 expression were observed in 
HPASMCs.  Furthermore, neither DDAH enzymes nor their inactive mutants affected PASMC 
growth in vitro. In agreement with the postulated role of endothelial DDAH1 in pulmonary 
vascular homeostasis, hypoxia-induced stimulation of HPASMC proliferation was also 
significantly reduced in cells co-cultured with DDAH1-overexpressing HPAECs. In vivo studies 
in DDAHtg mice demonstrated that overexpression of DDAH1 was accompanied by reduced 
levels of the cell proliferation marker, PCNA, in the lung and reduced pulmonary artery 
muscularization, without compensatory changes in DDAH2 expression. Reduced PASMC 
proliferation in DDAHtg mice might result from increased bioavailability of the endothelium-
derived NO, which is known to have an inhibitory effect on vascular smooth muscle growth 
in vitro (Peiro, Redondo et al. 1995).  In addition, we also observed an inhibitory effect of 
ADMA on endothelial angiogenesis in normoxia and in hypoxia, rescued by over expression 
of DDAH1. However, the rationale of performing this assay in future studies needs to be 
considered. There is no evidence of increased angiogenesis in chronic hypoxia-induced PH, 
although hypoxia may be a contributory factor in plexiform lesion formation in human PAH.   
DDAH1tg mice exhibit greater tissue DDAH activity, reduced plasma ADMA levels, increased 
NOS activity and reduced systemic vascular resistance (Schwedhelm, von Leitner et al. 
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2009). These mice are also more resistant to the inhibitory effect of ADMA on 
angioadaptation after hindlimb ischemia, show increased blood vessel formation in the 
fibrovascular disc system and improved endothelial regeneration after femoral artery injury 
(Jacobi, Sydow et al. 2005). Bakr et al (Bakr, Pak et al. 2013) have recently shown that 
sustained hypoxic pulmonary vasoconstriction was attenuated in DDAH1tg mice, but 
pulmonary vascular remodelling was unaffected following 4 weeks of hypoxia. At 4 weeks, 
there were no significant differences in DDAH1 activity, ADMA levels, NO or cGMP between 
the two groups of mice. In contrast, we observed a protective effect from DDAH1 
overexpression at an earlier time point, before the disease was well established (2 week 
hypoxia). While DDAH1 expression decreased overtime in both WT and DDAH1tg mice, the 
levels in hypoxic DDAH1tg mice were still significantly higher compared to hypoxic WT 
controls, likely to warrant sufficient level of DDAH1 activity and NO signalling. The loss of a 
protective effect observed in mice exposed to hypoxia for 4 weeks, it is probably associated 
with the hypoxia-induced decrease in β-actin promoter-driven expression (Brown and Davis 
2005) of the DDAH1 transgene, noted in both studies (Bakr, Pak et al. 2013). 
Consistent with this, at 2 weeks of hypoxia ADMA levels were reduced and the levels of 
cGMP target, pSer188RhoA, were increased in hypoxic DDAHtg mice compared to hypoxic 
WT controls. Furthermore, treatment of mice with LNA21 prior to and during exposure to 2 
weeks hypoxia increased DDAH1 expression, reduced ADMA levels and attenuated 
development of pulmonary hypertension, while previously reported treatment of mice with 
established disease (2 -4 weeks after hypoxic exposure) had little effect on hemodynamic 
performance or pulmonary vascular remodelling (Pullamsetti, Doebele et al. 2012).  
Interestingly, both the hypoxic LNA21-treated and DDAH1tg mice showed a significant 
reduction in ADMA levels in the lung, compared with hypoxic controls. 
Altogether, these observations show that DDAH1 overexpression attenuates early 
development of chronic hypoxia-induced PH but continuous supplementation of miR-21 
inhibitors may be required to retain DDAH/NO signalling. 
The finding that DDAH2 expression was unaffected by miR-21 in hypoxic HPAECs, is 
consistent with the fact that the human DDAH2 mRNA does not have a miR-21 recognition 
sequence in the 3’UTR region.  Although the DDAH2 mRNA and protein levels were reduced 
in hypoxia, these changes had no apparent effect on ADMA levels, cell proliferation or 
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endothelial permeability. On the other hand, it is possible that DDAH2 has a role in cardiac 
response to chronic hypoxia, as DDAH2 transgenic mice show increased cardiac NO 
production, attenuated inflammatory responses and reduced Ang II –induced perivascular 
fibrosis in coronary micro-vasculature (Hasegawa, Wakino et al. 2007). In support of our 
observations of a predominant role for DDAH1 in pulmonary hypertension, genetic deletion 
of DDAH2 had no impact on basal or hypoxic pulmonary haemodynamics (Wang, Caplin et 
al. 2013). 
The identification of additional factors that functionally integrate the miR-21/DDAH 
pathway in the development of pulmonary hypertension constitutes a longer-term 
challenge. Nonetheless, inflammation is a common feature in experimental and human 
pulmonary hypertension (Hassoun, Mouthon et al. 2009) and our observations suggest that 
pro-inflammatory transcription factor, NFκB may have a role in mediating hypoxia-induced 
changes in miR-21 and DDAH1 expression in HPAECs. This observation is also consistent with 
the reported role of NFkB as an upstream activator of miR-21 in cancer (Shin, Jin et al. 
2011). 
In addition to DDAH1, miR-21 may also affect other target proteins implicated in the 
pathogenesis of pulmonary hypertension, such as BMPR2 or RhoB (Parikh, Jin et al. 2012; 
Mehta, Parthasarathy et al. 2013). Our data indicate that RhoB is an unlikely target of miR-
21 in hypoxia, as the total RhoB expression levels in the hypoxic lung remained elevated in 
spite of  high miR-21 expression and were unaffected by LNA21. Instead, we show that the 
miR-21/DDAH pathway may affect RhoA signaling. Activation of RhoA contributes to hypoxic 
pulmonary vasoconstriction and pulmonary vascular remodelling (Connolly and Aaronson 
2011). In contrast to untreated hypoxic controls, DDAHtg and LNA-treated hypoxic mice 
showed elevated Ser188 phosphorylation of RhoA, indicative of increased NO signalling. 
NO/PKG-mediated Ser188 phosphorylation inhibits RhoA activity by enhancing its 
interaction with Rho guanine-dissociation inhibitor, mechanism implicated in the protective 
effects of sildenafil (Guilluy, Sauzeau et al. 2005).  ADMA has also been shown to induce 
endothelial dysfunction by reducing RhoASer188 levels and activating RhoA in cultured 
HPAECs (Wojciak-Stothard and Wilkins 2012).  
In summary, we show that selective NFκB-dependent miR-21-mediated inhibition of DDAH1 
expression in pulmonary endothelial cells plays an important role in hypoxia-induced 
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pulmonary hypertension. Preventing the miR-21-mediated degradation of DDAH1 mRNA 
reduces ADMA levels and attenuates development of chronic hypoxia-induced pulmonary 
hypertension. This protective effect is likely to result from increased NO bioavailability. The 
endothelial regulation of DDAH1 expression by miR-21 may have broader significance in the 
development of pulmonary hypertension. 
7.1. Study Limitations 
We have shown that hypoxia regulates DDAH1 expression, at least in part, via the miR-21-
mediated degradation of DDAH1mRNA in cultured endothelial cells. The significance of this 
pathway in chronic hypoxia-induced effects in vivo will require further analysis.  Apart from 
the DDAH1-NO pathway, miR-21 has been linked to BMP and inflammatory signaling 
(Ahmed, Mardaryev et al. 2011) and therefore it is likely that miR-21 effects are complex 
and will depend on the cell/tissue type and the stage of the disease. It has been shown that 
activation of miR-21 leads to the activation of mir-181b-1 in epithelial cells (Iliopoulos, 
Jaeger et al. 2010), suggesting that the analysis of miR clusters rather than single miRs 
would be more appropriate in future studies.  
We have identified 13 miRs potentially targeting 3’UTR of DDAH1 and selected two miRs 
implicated in the pathogenesis of PAH, miR-21 and miR-128, for further analysis. While 
manipulation of miR-21 levels was sufficient to convey the effects of hypoxia on DDAH1 
expression, other miRs may also play a role and their potential involvement will need to be 
verified experimentally. 
Our in vitro model involved exposure of cells to 1h-48h hypoxia (PO2 14-30 mmHg, 2% O2). 
Longer exposure times were not feasible in our conditions because of the re-oxygenation 
accompanying changes of culture medium. A plausible solution to this problem would be 
the use of chambers allowing manipulation of cells in a continuous hypoxic environment. 
The effects induced by 48h hypoxia (2% O2) may differ from the effects of chronic hypoxia 
(2 weeks at 10% O2).  
In order to better understand the role of miR-21/DDAH1 in human PAH, other animal 
models, such as MCT and Sugen/hypoxia should be used. Hypoxic model does not show a 
strong inflammatory response or plexiform lesion formation, a key characteristic of severe 
human PAH. 
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7.2. Future Work  
The mechanism behind hypoxia-induced DDAH2 downregulation in pulmonary vascular cells 
will require further studies.  Apart from competing with L-arginine, the hypoxia-induced 
increase in ADMA, it has been suggested that ADMA can also “uncouple” NOS, leading to 
Reactive Oxygen Species (ROS) generation, implicated in the pathogenesis of PH (Wilcox 
2012). ROS can, in turn, decrease the expression and activity of DDAH2, as shown in cancer 
cells (Wang, Hu et al. 2009). Additionally, it is possible that DDAH2 might play a role in the 
cardiac response to hypoxia, since DDAH2 transgenic mice show increased cardiac NO 
production (Hasegawa, Wakino et al. 2007). Therefore, the potential role of DDAH2 in the 
pulmonary and cardiac responses to chronic hypoxia will require further investigation. 
It has been reported that pathophysiological concentrations of ADMA can regulate gene 
expression in human endothelial cells by what appears to be an NO-independent 
mechanism (Smith, Anthony et al. 2005). Further studies will be needed to clarify the NO-
independent effects of ADMA in pulmonary vascular cells.  
Furthermore, miR cluster analysis and network-based bioinformatic approach combined 
with experimental studies in vitro and in vivo will be needed to delineate the role for miR-21 
in the pathogenesis of PAH. Potential role of NFkB in the regulation of miR-21 expression 
and DDAH pathway will also require further studies. Our preliminary data shows that the 
NFkB inhibitor, BAY-117085 attenuates hypoxia-induced increase in miR-21 expression in 
HPAECs. It will need to be established whether NFkB affects miR-21 expression directly, by 
binding to consensus sequences in the miR-21 promoter, or indirectly, via the changes in the 
levels of pro-inflammatory cytokines or growth factors. MiR-21 expression changes in the 
lung/lung vasculature will also need to be investigated in inflammatory models of PH, such 
as MCT. 
 
Finally, regarding the human data presented in this study, we observed a similar pattern of 
changes in miR-21/DDAH1 levels in lung tissues from chronically hypoxic PH mice and lung 
tissues from treatment-naïve IPAH patients.  A more detailed miR-21/DDAH1 pathway 
analysis using a larger number of human samples will be needed to draw conclusions 
regarding the importance of miR-21/DDAH1/NO signalling in human PH.   
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8. Therapeutic perspectives 
8.1. Activation of DDAH as a Therapeutic Target   
Our study, along with others, demonstrated that a reduction of DDAH1 expression or 
activity and an increase in ADMA levels occur in animal model of PH. In fact, the deficiency 
of DDAH1 or its pharmacological inhibition can raise the right ventricular pressure in animal 
models, demonstrating a strong relationship between DDAH1, ADMA and pulmonary 
vascular dysfunction (Leiper, Nandi et al. 2007). These data collectively demonstrate that 
the DDAH-ADMA pathway can have a central role in the development of PH (Millatt, Whitley 
et al. 2003; Sasaki, Doi et al. 2007). 
The modulation of DDAH expression or activity may be beneficial in diseases where there is 
an altered ADMA metabolism that consequently deregulates NO signalling. 
Potentially, there are several way of increasing DDAH activity such as, gene delivery, 
increasing transcription, attenuation of redox inactivation and allosteric activation (Leiper 
and Nandi 2011). In vitro studies, including the results presented in this thesis, 
demonstrated that the overexpression of DDAH1 is sufficient to reduce ADMA levels and 
increase NO production (Torondel, Nandi et al. 2010; Iannone, Zhao et al. 2014). 
Furthermore, studies using adenoviral-mediated delivery of DDAH1 restore vascular 
function in vivo (Shibata, Ueda et al. 2009; Ueda, Yamagishi et al. 2009). In fact, the 
overexpression of DDAH1 resulted in restoration of physiological ADMA concentrations and 
significantly attenuated systemic hypertension. Although these studies indicate that DDAH 
gene delivery may have therapeutic utility, this approach could have complications due to 
the fact that DDAH may have additional ADMA-independent related activities that could be 
mediated via protein–protein interactions (Tokuo, Yunoue et al. 2001; Hasegawa, Wakino et 
al. 2006). 
The Increased transcription of DDAH can result in reduced ADMA concentrations and 
increased NO production from cells in culture. For example, functional farnesoid X receptor 
(FXR) agonists have been shown to increase DDAH1 expression and reduce ADMA 
concentrations by acting on the FXR response element within the intron 1 of the DDAH1 
gene (Hu, Chouinard et al. 2006). Similarly, IL-1β induces expression of DDAH1 with an 
associated reduction in ADMA levels in vascular smooth muscle cells (Ueda, Kato et al. 
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2003). However, selective activators of DDAH1 transcription have not been identified and 
therefore this approach has not been tested experimentally.  
Both DDAH enzymes activities can be regulated by oxidative and nitrosative modification on 
the cysteine residue (Leiper, Murray-Rust et al. 2002; Knipp, Braun et al. 2003).  In vitro 
studies showed that antioxidant treatment of cells can attenuate DDAH inhibition that is 
induced by oxidized low-density lipoprotein (Lin, Ito et al. 2002), and similar observations 
have been made in an in vivo model of hypercholesterolemia, suggesting that the redox 
inactivation of DDAH may be an important mechanism of vascular dysfunction (Tan, Jiang et 
al. 2007).  These results indicate that antioxidant therapies might have beneficial effects on 
vasculature preserving DDAH activity. 
Another potential way to protect DDAH activity could be the inhibition of specific miRNA 
acting on the 3’-UTR of DDAH. 
Once the role of a specific miRNA in pathology is established, selecting specific anti-miRNA 
inhibitors combined with delivery strategies could be straightforward. Nevertheless, 
effective and safe delivery of anti-miRNA drugs can be difficult for many cell types.  
Although individual miRNAs are often produced only in specific cell types or developmental 
stages, the human genome contains more than 500 miRNAs, and each miRNA can 
potentially repress hundreds of genes (Bartel 2009; Chiang, Schoenfeld et al. 2010). 
Thus, treating diseases with anti-miRNA oligonucleotides will require the development of 
novel modification or formulation strategies able to increase tissue-specific modulation of 
the targeted miRNA. However, since miRNAs constitute a class of drug targets unrelated to 
any others, new additional technologies and methods are also required.  
Ideally, small molecules able to activate DDAH1 will be able to lower ADMA levels and 
restore NO signalling in disease states. Although several compounds have been clinically 
tested (as described in the next paragraph) in order to increase DDAH activity, a more 
comprehensive understanding of the role and regulation of DDAH enzymes is necessary for 
determining whether or not DDAH modulation has therapeutic potential. 
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8.2. Clinically utilized compounds and DDAH 
Several compounds have been clinically used in order to alter the activity of DDAH and thus 
the effects on ADMA and NO in various disease models (Wadham and Mangoni 2009; Leiper 
and Nandi 2011). For example, vitamin A (retinol) is known to regulate cell proliferation, 
differentiation and apoptosis (Pan and Baker 2007). Although all trans-retinoic acid can 
prevent cardiovascular remodelling in animal models of hypertension by increasing DDAH2 
expression (Achan, Tran et al. 2000), recently Bjelakovic et al failed to demonstrate any 
significant benefit of vitamin A on mortality prevention in healthy individuals (Bjelakovic, 
Nikolova et al. 2012). 
Vitamin E has also been implicated in the progression of atherosclerosis by modulation of 
angiogenesis and inhibition of vascular smooth muscle cell proliferation (Munteanu and 
Zingg 2007). Although a pilot study suggested that an antioxidant therapy with vitamin E 
could potentially lower ADMA levels, another study filed to show a significant reduction in 
plasma ADMA concentration in vivo (Tan, Jiang et al. 2007; Onozato, Tojo et al. 2008). 
In addition, it has been demonstrated that the amino acid taurine can lower blood pressure 
through effects mediated by the central nervous system (Militante and Lombardini 2002).  
Tan et al showed protective effects of taurine on the endothelium related to a decrease in 
ADMA level by an increased DDAH activity (Tan, Jiang et al. 2007). Although the effects of 
taurine on DDAH activity might provide further beneficial effects in the peripheral 
circulation, nowadays there are no clinical data on the effects of taurine supplementation 
on cardiovascular outcomes.  
The antiplatelet drug aspirin, extensively used in secondary cardiovascular prevention, has 
been reported to upregulate DDAH activity, providing new insights on its antioxidant and 
vasculoprotective effects (Deng, Deng et al. 2004). Interestingly, the effects of aspirin on 
DDAH activity were only observed at low doses (Deng, Deng et al. 2004). Furthermore, 
statins such as atorvastatin, probucol and pravastatin, which exert beneficial effects on 
endothelial function and vascular remodelling, have been reported to enhance DDAH and 
eNOS activity (Yang, Chen et al. 2005; Yin and Xiong 2005; Jiang, Zhang et al. 2006). Despite 
the fact that no significant reduction of ADMA plasma level were observed  in patients with 
chronic heart failure and diabetes, it has been shown that atorvastatin can reduce plasma 
ADMA concentration in animal models (Valkonen, Laakso et al. 2003; Tanaka, Katayama et 
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al. 2007; Young, Strey et al. 2008). Interestingly, a statin with powerful antioxidant effects 
such as fluvastatin (Yamaguchi, Matsuno et al. 2002) showed a significant reduction of 
ADMA plasma levels in patients with metabolic syndrome (Oguz and Uzunlulu 2008).  
Although the antioxidant effects of fluvastatin need to be confirmed in human (Nagase, 
Hirayama et al. 2005), this effect could explain its efficacy in lowering plasma ADMA 
concentration compared with other statins. 
The angiotensin receptor blockers exert several protective effects on vascular homeostasis 
independently of angiotensin receptor 1 blockade (Ando, Ushijima et al. 2013). In fact, it has 
been demonstrated that angiotensin blocker such as losartan and telemistran can 
upregulate DDAH activity and expression (Wakino, Hayashi et al. 2005). Clinical trials have 
demonstrated the effectiveness of angiotensin receptor blockers in reducing cardiovascular 
morbidity and mortality in several patient groups (Kjeldsen, Dahlof et al. 2002; Yusuf, Teo et 
al. 2008) 
In summary, several compounds used to treat cardiovascular risk factors showed to have 
little effect on circulating ADMA levels, suggesting that the relationship between plasma 
ADMA levels and common cardiovascular risk factors can be complex. While drugs such as 
aspirin telemistran and losartan showed a good correlation between basic studies on DDAH 
and cardiovascular outcomes, other compounds such as vitamin A, vitamin E and probucol 
have not been translated into cardiovascular protection. Plausible reasons for the lack of 
clinical beneficial effects could be due to variability of the targeted population or incorrect 
dosing. At the present, there are no current drugs that have specific effects on the 
DDAH/ADMA pathway and therefore it is not currently possible to understand the likely 
effect of DDAH activation in humans.  
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